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ABSTRACT
Background
Medically unexplained physical symptoms (MUPS) are physical symptoms for which no adequate medical explanation can be found after
proper examination. The presence of MUPS is the key feature of conditions known as 'somatoform disorders'. Various psychological
and physical therapies have been developed to treat somatoform disorders and MUPS. Although there are several reviews on nonpharmacological interventions for somatoform disorders and MUPS, a complete overview of the whole spectrum is missing.
Objectives
To assess the effects of non-pharmacological interventions for somatoform disorders (specifically somatisation disorder, undifferentiated
somatoform disorder, somatoform disorders unspecified, somatoform autonomic dysfunction, pain disorder, and alternative somatoform
diagnoses proposed in the literature) and MUPS in adults, in comparison with treatment as usual, waiting list controls, attention placebo,
psychological placebo, enhanced or structured care, and other psychological or physical therapies.
Search methods
We searched the Cochrane Depression, Anxiety and Neurosis Review Group's Specialised Register (CCDANCTR) to November 2013. This
register includes relevant randomised controlled trials (RCTs) from The Cochrane Library, EMBASE, MEDLINE, and PsycINFO. We ran an
additional search on the Cochrane Central Register of Controlled Trials and a cited reference search on the Web of Science. We also searched
grey literature, conference proceedings, international trial registers, and relevant systematic reviews.
Selection criteria
We included RCTs and cluster randomised controlled trials which involved adults primarily diagnosed with a somatoform disorder or an
alternative diagnostic concept of MUPS, who were assigned to a non-pharmacological intervention compared with usual care, waiting
list controls, attention or psychological placebo, enhanced care, or another psychological or physical therapy intervention, alone or in
combination.
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Data collection and analysis
Four review authors, working in pairs, conducted data extraction and assessment of risk of bias. We resolved disagreements through
discussion or consultation with another review author. We pooled data from studies addressing the same comparison using standardised
mean differences (SMD) or risk ratios (RR) and a random-effects model. Primary outcomes were severity of somatic symptoms and
acceptability of treatment.
Main results
We included 21 studies with 2658 randomised participants. All studies assessed the effectiveness of some form of psychological therapy.
We found no studies that included physical therapy.
Fourteen studies evaluated forms of cognitive behavioural therapy (CBT); the remainder evaluated behaviour therapies, third-wave CBT
(mindfulness), psychodynamic therapies, and integrative therapy. Fifteen included studies compared the studied psychological therapy
with usual care or a waiting list. Five studies compared the intervention to enhanced or structured care. Only one study compared cognitive
behavioural therapy with behaviour therapy.
Across the 21 studies, the mean number of sessions ranged from one to 13, over a period of one day to nine months. Duration of follow-up
varied between two weeks and 24 months. Participants were recruited from various healthcare settings and the open population. Duration
of symptoms, reported by nine studies, was at least several years, suggesting most participants had chronic symptoms at baseline.
Due to the nature of the intervention, lack of blinding of participants, therapists, and outcome assessors resulted in a high risk of bias on
these items for most studies. Eleven studies (52% of studies) reported a loss to follow-up of more than 20%. For other items, most studies
were at low risk of bias. Adverse events were seldom reported.
For all studies comparing some form of psychological therapy with usual care or a waiting list that could be included in the meta-analysis,
the psychological therapy resulted in less severe symptoms at end of treatment (SMD -0.34; 95% confidence interval (CI) -0.53 to -0.16; 10
studies, 1081 analysed participants). This effect was considered small to medium; heterogeneity was moderate and overall quality of the
evidence was low. Compared with usual care, psychological therapies resulted in a 7% higher proportion of drop-outs during treatment
(RR acceptability 0.93; 95% CI 0.88 to 0.99; 14 studies, 1644 participants; moderate-quality evidence). Removing one outlier study reduced
the difference to 5%. Results for the subgroup of studies comparing CBT with usual care were similar to those in the whole group.
Five studies (624 analysed participants) assessed symptom severity comparing some psychological therapy with enhanced care, and found
no clear evidence of a difference at end of treatment (pooled SMD -0.19; 95% CI -0.43 to 0.04; considerable heterogeneity; low-quality
evidence). Five studies (679 participants) showed that psychological therapies were somewhat less acceptable in terms of drop-outs than
enhanced care (RR 0.93; 95% CI 0.87 to 1.00; moderate-quality evidence).
Authors' conclusions
When all psychological therapies included this review were combined they were superior to usual care or waiting list in terms of reduction
of symptom severity, but effect sizes were small. As a single treatment, only CBT has been adequately studied to allow tentative conclusions
for practice to be drawn. Compared with usual care or waiting list conditions, CBT reduced somatic symptoms, with a small effect
and substantial differences in effects between CBT studies. The effects were durable within and after one year of follow-up. Compared
with enhanced or structured care, psychological therapies generally were not more effective for most of the outcomes. Compared with
enhanced care, CBT was not more effective. The overall quality of evidence contributing to this review was rated low to moderate.
The intervention groups reported no major harms. However, as most studies did not describe adverse events as an explicit outcome
measure, this result has to be interpreted with caution.
An important issue was that all studies in this review included participants who were willing to receive psychological treatment. In daily
practice, there is also a substantial proportion of participants not willing to accept psychological treatments for somatoform disorders or
MUPS. It is unclear how large this group is and how this influences the relevance of CBT in clinical practice.
The number of studies investigating various treatment modalities (other than CBT) needs to be increased; this is especially relevant for
studies concerning physical therapies. Future studies should include participants from a variety of age groups; they should also make
efforts to blind outcome assessors and to conduct follow-up assessments until at least one year after the end of treatment.

PLAIN LANGUAGE SUMMARY
Talking therapies and physical therapies for medically unexplained physical symptoms: a review of the evidence
Who may be interested in this review?
People with unexplained physical symptoms (somatoform disorders) and their family and friends.
Professionals working with people with somatoform disorders or working in chronic pain services.
Non-pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults (Review)
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General practitioners.
Why is this review important?
Up to one in three people consulting their doctor about physical symptoms have medically unexplained physical symptoms (MUPS) that
have no clear cause. MUPS are a key feature of health problems called somatoform disorders. MUPS and somatoform disorders often cause
significant distress and cause people spending a lot of time consulting doctors and health professionals to try to find the cause of their
symptoms and the correct treatment.
Talking therapies for MUPS are recommended to help with mental health problems that exist alongside the physical symptoms, and to help
people change the way they think about their physical symptoms. Physical therapies for MUPS aim to help people improve their physical
functioning through various types of exercise. This review aimed to examine the evidence for talking therapies and physical therapies for
MUPS and somatoform disorders.
What questions does this review aim to answer?
What is the quality of current research on talking therapies and physical therapies for MUPS?
Are talking therapies an effective treatment for MUPS compared with usual treatment or waiting list?
Which types of talking therapies are most effective?
Are physical therapies an effective treatment for MUPS?
How acceptable are talking therapies and physical therapies to people with MUPS?
Which studies were included in the review?
We used search databases to find all studies of talking therapies and physical therapies for people with somatoform disorders published to
November 2013. To be included in the review, studies had to compare talking therapies or physical therapies with either usual treatment,
waiting list, enhanced or structured care (where a doctor offered structured appointments to the person but no specific therapy for MUPS),
or other talking or physical therapies. We included studies if they had adults aged over 18 years with a clear diagnosis of somatoform
disorders or main presenting problem of MUPS.
We included 21 studies in the review with 2658 participants.
What does the evidence from the review tell us?
We rated the quality of current research as low to moderate. Fourteen out of the 21 studies focused on cognitive behavioural therapy, which
is a specific form of talking therapy based on the idea that thoughts and thinking can influence emotions and behaviours.
Cognitive behavioural therapy was more effective than usual care in reducing the severity of MUPS. For other types of therapy, we found
only one or two studies giving insufficient evidence for conclusions.
Cognitive behavioural therapy was no more effective than enhanced care provided by the person's doctor.
No studies of physical therapy met the criteria to be included in the review.
Talking therapies were acceptable to people and few people dropped out of the trials; however, this may not reflect real clinical practice
as the study participants were people with somatoform disorders or MUPS who were willing to try talking therapies. In clinical practice, a
high proportion of people may not be willing to accept these treatments.
What should happen next?
The review authors suggest that future high-quality trials should be carried out to find out more about which groups of people benefit
most from cognitive behavioural therapy and how it can be most effectively delivered. They also suggest that more studies are needed of
other talking therapies, and a particular focus should be on high-quality studies of physical therapies.
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Psychological therapy compared with usual care for somatoform disorders and medically unexplained physical symptoms

Outcomes

Illustrative comparative risks* (95% CI)

Relative
effect
(95%
CI)

No of
participants
(studies)

Quality of
the evidence
(GRADE)

Comments

Corresponding risk

Usual care

Psychological therapy

Severity of somatic symptoms at
end of treatment
Various instruments

The mean severity of
somatic symptoms
at end of treatment
ranged across control groups from
0.5 to 48.71 using
varying scales 1

The mean severity of somatic symptoms at end
of treatment in the intervention groups was
0.34 standard deviations lower
(0.53 to 0.16 lower)

-

1081
(10
studies2)

⊕⊕⊝⊝
low 3,4,5

A difference of 0.34
SMD was considered to be 'small to
medium'

Acceptability
1 - proportion of participants withdrawing during treatment

896 per 1000

833 per 1000
(788 to 887)

RR 0.93
(0.88 to
0.99)

1644
(14
studies6)

⊕⊕⊕⊝
moderate 7,8

Excluding the outlier (see footnote)
(70 participants)
reduced I2 statistic
from 70% to 33%

Dysfunctional cognitions, emotions, or behaviours (participant
rated) at end of treatment
Whitely Index

The mean dysfunctional cognitions,
emotions, or behaviours (participant rated) at end of
treatment in the control groups was
7.3 on the Whitely
Index

The mean dysfunctional cognitions, emotions,
or behaviours (participant rated) at end of
treatment in the intervention groups was
0.11 standard deviations lower
(0.37 lower to 0.16 higher)

-

440
(3 studies9)

⊕⊕⊕⊝
moderate 10

A difference of 0.11
SMD was considered to be 'small'

Treatment response at end of
treatment

157 per 1000

517 per 1000
(326 to 816)

RR 3.30

391

⊕⊕⊝⊝

-
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Patient or population: people with somatoform disorders and medically unexplained physical symptoms
Settings: all settings
Intervention: psychological therapy
Comparison: usual care

Cochrane

Summary of findings for the main comparison. Psychological therapy compared with usual care or waiting list for somatoform disorders and
medically unexplained physical symptoms
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(2.08 to
5.21)

(4 studies11)

low
12,13

-

The mean functional disability/quality of life
at end of treatment in the intervention groups
was
0.17 standard deviations higher
(0.03 to 0.32 higher)

-

730
(7 studies14)

⊕⊕⊝⊝
low 3,13

A difference of 0.17
SMD was considered to be small

Healthcare use
Various measures, participant or
physician assessed < 1 year after end
of treatment
Follow-up: 6-11 months

-

The mean healthcare use in the intervention
groups was
0.09 standard deviations lower
(0.31 lower to 0.12 higher)

-

532
(4 studies15)

⊕⊕⊕⊝
moderate 12

Difference small
and not statistically significant

Trusted evidence.
Informed decisions.
Better health.

Cochrane

Functional disability/quality of life
at end of treatment
Various instruments
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CGI: Clinical Global Impression; CI: confidence interval; RR: risk ratio; SMD: standardised mean difference
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Measured with different instruments using different scales.
2 Analysis 1.1.
3 Quality of evidence downgraded one point for each of the following study limitations (present in most studies): lack of blinding and incomplete outcome data (loss to follow up)
4 I2 = 49%.
5 95% CI crossed effect size of 0.5.
6 Analysis 1.4.
7 Quality downgraded by one point as studies not blinded. As acceptability and loss to follow-up are interrelated, we decided not to downgrade the evidence for loss to follow-up.
8 I2 = 70%. One outlier explained most of the heterogeneity (Kashner 1995).
9 Analysis 1.15.
10 Due to lack of blinding in all studies and loss to follow-up in one study.
11 Analysis 1.18.
12 Due to lack of blinding in all studies and loss to follow-up > 20% in 2 studies.
13 < 300 events.
14 Analysis 1.21.
15 Analysis 1.25.
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Patient or population: somatoform disorders and medically unexplained physical symptoms
Settings: all settings
Intervention: psychological therapies
Comparison: enhanced or structured care
Outcomes

Illustrative comparative risks* (95% CI)

Relative
effect
(95%
CI)

No of
participants
(studies)

Quality of
the evidence
(GRADE)

Comments

Corresponding risk

Enhanced
or structured
care

Psychological therapies

Severity of somatic symptoms at
end of treatment

-

The mean severity of somatic symptoms at end of treatment in the
intervention groups was
0.19 standard deviations lower
(0.43 lower to 0.04 higher)

-

624
(5 studies1)

⊕⊕⊕⊝
low 2, 11

95% CI excluded large
effect (> 0.5
SMD)

Acceptability
1 - proportion of participants withdrawing during treatment

904 per
1000

841 per 1000
(787 to 904)

RR 0.93
(0.87 to
1)

679
(5 studies3)

⊕⊕⊕⊝
moderate 4

-

Dysfunctional cognitions, emotions, or behaviours at end of
treatment
Whitely Index (different forms)

-

The mean dysfunctional cognitions, emotions, or behaviours at
end of treatment in the intervention groups was
0.09 standard deviations lower
(0.29 lower to 0.1 higher)

-

499
(4 studies5)

⊕⊕⊕⊝
moderate 6

95% CI excluded clinically relevant
effect

Treatment response at end of
treatment

Study population

Not estimable

0
(0)

See
comment

No studies reported on this
outcome (see
text)

See
comment
Moderate

See comment
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Summary of findings 2. Psychological therapy compared with enhanced or structured care for somatoform disorders and medically unexplained
physical symptoms

-

The mean functional disability/quality of life at end of treatment in
the intervention groups was
0.13 standard deviations higher
(0.05 lower to 0.3 higher)

-

497
(4 studies7)

⊕⊕⊕⊝
moderate 6

95% CI excluded clinically relevant
effect

Healthcare use within 1 year after treatment

-

The mean healthcare use within 1 year after treatment in the intervention groups was
0.24 standard deviations lower
(0.46 to 0.01 lower)

-

319
(2 studies8)

⊕⊕⊝⊝
low 9,10

-

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; SMD: standardised mean difference.

Cochrane

Functional disability/quality of
life at end of treatment
Various instruments

Trusted evidence.
Informed decisions.
Better health.

-

Library

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Analysis 2.1.
2 I2 = 53%
3 Analysis 2.4.
4 Quality of evidence downgraded by one point as studies not blinded. As acceptability and loss to follow-up are interrelated, we decided not to downgrade the evidence for

loss to follow-up.
5 Analysis 2.8.
6 Assessment of quality of evidence downgraded by one point as studies were not blinded.
7 Analysis 2.11.
8 Analysis 2.15.
9 In addition to both studies not being blinded, high loss to follow-up in one study. We therefore downgraded our assessment of the quality of the evidence by two points.
10 Only 2 studies with < 400 analysed participants.
11 No blinding (all studies) and >20% loss to follow up (2 studies)
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BACKGROUND
Description of the condition
Medically unexplained physical symptoms (MUPS) are physical
symptoms for which adequate evidence of an underlying
pathophysiological process cannot be identified after appropriate
examination and investigation. MUPS are common in all healthcare
settings. Up to one-third of all people presenting with physical
symptoms have MUPS (Kirmayer 2004). The presence of MUPS is
the key feature of conditions known as somatoform disorders.
The Diagnostic and Statistical Manual of Mental Disorders (DSM;
APA 2000) and International Classification of Diseases (ICD; WHO
2004) describe four somatoform diagnostic categories that include
MUPS as their main indication. These categories are: somatisation
disorder, (persistent somatoform) pain disorder, undifferentiated
somatoform disorder, and unspecified somatoform disorder. The
ICD also describes a fifth category: somatoform autonomic
dysfunction disorder. All these disorders are established through
a validated psychiatric diagnostic interview. Many different
diagnostic revisions of somatoform disorders have been suggested
and used in research since the early 2000s. Examples of proposed
revised diagnoses include abridged somatisation disorder (Escobar
1998), multisomatoform disorder (Kroenke 1997), bodily distress
disorder (Fink 2007), and complex somatic symptom disorder
(Dimsdale 2009). These alternative diagnoses have their own
diagnostic criteria, mainly based on symptom counts. Finally, in
some fields, MUPS are not described as a feature of a specific
disorder, but as a health problem in their own right. As a result,
the treatment of MUPS in general is also described in literature,
for example, in primary care research. Assessing the presence of
MUPS is usually based on the combination of a validated somatic
symptom scale, the duration of symptoms, and clinical judgement
by the physician.
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antidepressants, antiepileptic drugs are also commonly used for
somatoform disorders (Moore 2014; Silberstein 2002), although
they are not advised in guidelines. Pharmacological interventions
will be described in a separate forthcoming Cochrane review
(published protocol: Kleinstäuber 2013) and this review only
focuses on non-pharmacological interventions.
Most non-pharmacological interventions for MUPS focus on
addressing cognitions, behaviour, coping styles, and functional
consequences of symptoms. These interventions include
psychological therapies as well as physical therapies. Psychological
therapies are mostly used to tackle underlying psychological
disorders and problems, and aim to change the way that people
perceive their symptoms in order to help them to manage their
symptoms. Cognitive behavioural therapy (CBT) appears to be
a promising treatment in this category, if people accept the
treatment (Kroenke 2000). Physical therapies usually concern
physical activity treatments, which aim to improve physical
function by expanding physical activity and thereby reducing
symptoms. In the paragraph below, we described examples of
several frequently studied forms of psychological and physical
therapies.

How the intervention might work
Psychological therapies - cognitive behavioural therapy

In some health care settings the term 'somatoform' is falling out of
favour, as people can find this term offensive. In these settings the
term is being replaced with other terms such as 'functional'.

The first and most commonly used and investigated psychological
therapy for MUPS is CBT, which is based on the cognitive
behavioural model (Deary 2007). This model proposes that
MUPS are caused by a self perpetuating multi-factorial cycle,
based on the interaction of different factors in several domains,
including somatic (physical) aspects, cognitions (thoughts),
behaviour, emotions, and environment (Sharpe 1992). This
model provides a framework to incorporate people's personal
predisposing, precipitating, and perpetuating factors according to
their symptoms. CBT, as a consequence, focuses on addressing or
changing cognitions and behaviours that people have in interaction
with their symptoms.

Somatoform disorders and MUPS may lead to functional
impairment, high levels of psychological distress, a reduced quality
of life, and a troubled doctor-patient relationship (Escobar 1987;
Gureje 1997; Ring 2004; Zoccolillo 1986). Furthermore, chronic
MUPS may lead to absence from work, fragmented and high
utilisation of health care, and the associated high costs for society
(Konnopka 2012; Kroenke 1989; Smith 1986).

Reattribution is a specific form of CBT (Goldberg 1989). This method
aims to encourage people to reattribute their MUPS to physiological
or psychosocial causes rather than to somatic causes. Reattribution
consists of three stages: 1. making the person feel understood;
2. changing the agenda of the person, and the doctor, and their
mutual agenda during the consultations; and 3. making the link
between physical symptoms and psychosocial problems.

DSM 5 describes the 'somatic symptom disorder' (SSD),
which requires explicit cognitive criteria (e.g. excessive and
disproportionate thoughts, feelings, and behaviours regarding
symptoms) (APA 2013). The diagnosis does not require the somatic
symptoms to be medically unexplained.

This self propagating disadvantageous situation is illustrated by the
case of a person with low back pain who moves less freely and
more stiffly because of the pain; this, in turn, causes the low back
pain to continue and possibly worsen, and creates more stress.
Reattribution might focus on making the person realise that stress
caused by work may be responsible for causing or perpetuating the
low back pain.

Description of the intervention
In previous decades, many pharmacological and nonpharmacological interventions for somatoform disorders and
MUPS were developed. The use of antidepressants, in particular,
as pharmacological agents for syndromes of MUPS (Ford 2009; Pae
2009), or chronic pain (Saarto 2007), was tested. The most relevant
groups of antidepressants are the tricyclic antidepressants,
selective serotonin reuptake inhibitors, and selective serotonin and
noradrenaline (norepinephrine) reuptake inhibitors. In addition to

Problem-solving treatment is another form of CBT that has been
used for people with MUPS and somatoform disorders. The aim is
to reduce complaints associated with unresolved problems in daily
life by enhancing a person's problem-solving capacities in a stepby-step manner. This therapy has a positive effect on mental and
physical health problems in general (Malouff 2007).

Non-pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults (Review)
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Psychological therapies - behavioural therapy
Behavioural therapy, the second group, aims to constructively
change a person's behaviour towards their symptoms using
operant conditioning - also known as instrumental conditioning in which a response in a certain context is followed by a reinforcing
stimulus or consequence, thereby increasing the likelihood that
the same response will follow in future. Biofeedback therapy is an
important behavioural intervention relevant to this review. In this
therapy, one or more physiological measures (such as heart rate,
respiratory rate, or muscle tension) are thought to relate to the
person's physical symptoms, and people are taught to control these
measures voluntarily. As a result, they develop a personal strategy
for controlling them (Nanke 2003b; Schwartz 2003). Other forms of
behavioural therapy include relaxation therapy (Loew 2000), and
psycho-education (Guerney 1971).
Other psychological therapies
A third group of psychological therapies, more aimed at increasing
insight, such as:
1. third-wave cognitive behavioural therapy (i.e. the development
of a new attitude towards symptoms, based on self regulation of
attention and acceptance) (van Ravensteijn 2013);
2. psychodynamic therapies, a form of depth psychology, which
focusses on revealing the unconscious content of a person's
psyche in order to alleviate psychological of physical tension
(Noyes 2008). This might include group therapy, in which people
regularly come together to discuss their symptoms, supervised
by a trained group leader. The therapy aims to stimulate an
active search for causes and perpetuating factors of symptoms,
and to treat them by remedial education aiming at insight;
3. humanistic therapies, focusing on self development, growth,
and responsibilities. Treatment aims to help individuals
recognise their strengths, creativity, and choices in the 'here and
now'. An example is person-centred therapy, which specifically
focusses on an individual's self esteem and values; and
4. integrative therapies, which integrate components from several
theoretical schools, e.g. cognitive analytical therapy, which aims
to work with the person to identify procedural sequences,
chains of events, thoughts and emotions that explain how a
target problem (e.g. a physical symptom) is established and
maintained, and other psychodynamic therapies (Noyes 2008).
Enhanced care
Another group of therapies offered to people with MUPS is
enhanced care. Within these therapies people receive care as usual
(mostly by their general practitioners (GP)), enhanced with, for
example, participant education, structured counselling moments,
a psychiatric interview, or a reattribution training of the doctor
(Rosendal 2013). Within these therapies, there is no specific
treatment agenda or structure, the aim is to offer the person
some tools to assist in the recovery process, stimulating self
management. This category of treatment was not mentioned in the
protocol for this current review, but added post-hoc when we found
that it had been used as a comparator in several studies.
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training is an operant-conditioning behavioural approach in
which physical activity is expanded step by step, based on
a predetermined time schedule. It focusses on changing the
fear-avoidance behaviour that people with MUPS may have for
particular physical activities (Lindström 1992). Supervised aerobic
exercise training has beneficial effects on the physical capacity
and symptoms of people with fibromyalgia (Busch 2007). A similar
effect was found for graded activity training in people with chronic
fatigue syndrome (Edmonds 2004; Yancey 2012). In non-specific low
back pain, exercise appeared to be slightly effective at decreasing
pain and improving function (Hayden 2005). However, for graded
activity the evidence is lacking (Van der Giessen 2012).
Other physical therapies
Other examples of physical therapies for somatoform disorders and
MUPS include activation therapy, where physical and behavioural
activation is increased in a step-wise fashion, and running therapy,
where running is used therapeutically, mainly to influence the level
of stress.

Why it is important to do this review
Although there are several reviews on non-pharmacological
interventions for somatoform disorders and MUPS, a complete
overview of the whole spectrum is missing. Some reviews did not
include a meta-analysis (Edwards 2010; Sumathipala 2007), while
other reviews included only specific treatment types (Kroenke
2000; Nezu 2001), or applied restrictions on diagnostic types
of MUPS or on treatment setting (Allen 2002; Edwards 2010;
Kleinstäuber 2011; Rosendal 2013). Furthermore, currently there
are no reviews that evaluate variations in treatment effects on the
basis of diagnosis and severity of symptoms at baseline, setting, or
healthcare provider.
In this review, we aimed to give an overview of the evidence
for non-pharmacological interventions for somatoform disorders
and MUPS. This will help healthcare providers and patients to
make optimal treatment decisions. In addition, the results of
this review will provide insight into gaps in the evidence that
merit future research. This review will complement the existing
portfolio of four Cochrane reviews covering somatoform disorders
(Hoedeman 2010; Ipser 2009; Ruddy 2005; Thompson 2007), and
also the Cochrane review on pharmacological interventions for
somatoform disorders, which is currently being developed (see
Kleinstäuber 2013 for protocol).

OBJECTIVES
To assess the effects of non-pharmacological interventions
for somatoform disorders (specifically somatisation disorder,
undifferentiated somatoform disorder, somatoform disorder
unspecified, somatoform autonomic dysfunction, pain disorder,
and alternative somatoform diagnoses proposed in the literature)
and MUPS in adults in comparison with treatment as usual, waiting
list controls, attention placebo, psychological placebo, enhanced
or structured care, and other psychological or physical therapies.

Physical therapies - physical activity training
Several studies have indicated that mental health, including
mood, pain thresholds, and sleep, can be improved by lowor moderate-intensity activity (Weyerer 1994). Graded activity
Non-pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults (Review)
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METHODS
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) and cluster
randomised controlled trials (CRCTs). We also planned to include
data from the first phase of cross-over trials, but we identified no
such trials that met our inclusion criteria.
We excluded quasi-randomised trials (e.g. allocation to the study
group by day of the week).
Types of participants
Participant characteristics
Participants had to be at least 18 years old. We applied no maximum
age, as the condition can be present at any age. We placed no
restriction on gender or culture.
Diagnosis

1. Participants had to meet the criteria for a somatoform disorder
according to DSM III (APA 1980), DSM IV-TR (APA 2000), ICD-9
(WHO 1975), or ICD-10 (WHO 2004), or the criteria for one
of the alternative somatoform diagnoses proposed in the
literature. The primary diagnosis (a somatoform disorder) had
to be made on the basis of a structured clinical interview
such as the Structured Clinical Interview for Mental Disorders
(SCID; First 2002; Spitzer 1990), the World Health Organization
(WHO) Composite International Diagnostic Interview (CIDI; WHO
1990), the MINI International Neuropsychiatric Interview Plus
(Mini-Plus; Sheehan 1998), or diagnostic checklists such as
the International Diagnostic Checklists (IDCL; Janca 1996). The
secondary diagnosis of an alternative somatoform diagnosis
needed to be based on the criteria that characterise that specific
disorder, for example, abridged somatisation disorder needed
to be established through use of the Somatic Symptom Index
(SSI; Escobar 1998).
2. Participants were characterised with MUPS as their primary
problem, on the basis of a validated scale for the assessment
of MUPS, such as the Screening for Somatoform Disorders
(Screening für Somatoforme Störungen) (SOMS; Rief 1997), the
Bradford Somatic Inventory (Mumford 1991), or component
subscales of validated standardised instruments for the
assessment of general psychopathology or general health
status, such as the Patient Health Questionnaire-15 (PHQ-15;
Kroenke 2002), the subscale 'Somatisation' of the Four
Dimensional Symptom Questionnaire (4DSQ; Terluin 2006),
the subscale 'Somatisation' of the Symptom Checklist-90-R
(SCL-90R; Derogatis 1986), or the Brief Symptom Inventory (BSI;
Derogatis 1983).
As the subdivision of these two diagnostic concepts (somatoform
disorders and MUPS) is based on differences in selection methods
used in different research settings rather than on differences
between individual people, it is possible that the nature and
severity of symptoms may show a certain overlap between the two
groups.
We disregarded the DSM-5 criteria for somatoform disorders
for this version of the review. In the DSM-5, one category, the
SSD, replaced the four diagnostic categories of the somatoform
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disorders (APA 2013). This disorder was diagnosed on the basis of
explicit psychological criteria (e.g. excessive and disproportionate
thoughts, feelings, and behaviours regarding symptoms), and
diagnosis did not require the somatic symptoms to be medically
unexplained. However, as the publication of the DSM-5 was recent,
there are currently no instruments available to establish the
diagnosis. As a result, to our knowledge, no trials have been
performed that use these criteria. We will add the SSD diagnosis
to the list of conditions in future updates of the review, if more
information about diagnostic instruments becomes available and
once studies that use these criteria have been performed.
See Table 1 for an overview of all diagnostic categories of
somatoform disorders and MUPS, and a clear indication of whether
or not they were eligible for the current review.
Co-morbidities

As we aimed to summarise interventions for multiple symptoms,
we excluded studies that examined participants diagnosed
with only one specific functional syndrome or symptom (e.g.
fibromyalgia or fatigue). Moreover, existing Cochrane reviews
address specific syndromes and complaints (Bernardy 2013; Price
2008; Zijdenbos 2009).
Setting

We place no restrictions on the type of setting.
Subsets of participants

Some studies could include 'eligible' participants as well as
'ineligible' participants for this review, for example when an age
cut-off was used that was different to the cut-off of this review.
When no detailed information was available about these subsets
of participants, we requested the data from the trial authors. If
this did not yield any further information, we included the study
only if at least 80% of the sample population had the characteristic
of interest (e.g. aged 18 years or over). The Characteristics of
included studies and Characteristics of excluded studies tables
document the decisions about the eligibility of these subsets of
participants. We assessed the impact of these decisions using
sensitivity analysis.
Types of interventions
Experimental interventions
Eligible studies included one or more of the following experimental
interventions.
1. Psychological therapies:
i. CBT (e.g. reattribution therapy and problem-solving
therapy);
ii. behavioural therapy (e.g. classical CBT, biofeedback
therapy, relaxation therapy, and psycho-education);
iii. third-wave CBT (e.g. mindfulness);
iv. psychodynamic therapies (e.g. group therapy);
v. humanistic therapies (e.g. person-centred therapy);
vi. integrative therapies (e.g. cognitive analytical therapy).
2. Physical therapies:
i. physical activity training (e.g. graded activity training);
ii. other physical therapies (e.g. activation therapy or
running therapy).

Non-pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults (Review)
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We excluded interventions based on complementary medicine
from this review. In addition, pharmacological interventions and
consultation letter interventions were beyond the scope of this
review; they were evaluated in other Cochrane reviews (Hoedeman
2010; Kleinstäuber 2013).
However, in several of the studies, in both study arms a
consultation letter was sent to the primary care physician after
baseline assessment, in addition to the planned psychological
therapy or comparison condition. Post-hoc, we decided that this
was not a reason for exclusion, and we categorised these studies
according to the main comparison (We conducted a sensitivity
analysis to explore this decision).
Comparator interventions
We accepted the following comparator interventions.
1. Normal/usual treatment (e.g. treatment according to
(multidisciplinary) guidelines or common practice in primary or
secondary care) or waiting list procedures.
2. Attention or psychological placebo (an attention placebo was
regarded as being inactive by both participants and researchers
in a trial, while a psychological placebo was regarded as active
by participants but inactive by researchers).
3. Enhanced or structured care (e.g. care as usual by physician
trained in reattribution, or structured appointments with a
physician without a specific treatment being performed). This
comparator was not foreseen at the protocol stage, but added
afterwards (see Differences between protocol and review).
4. Other psychological therapies (as per the list of experimental
interventions above).
5. Other physical therapies (as per the list of experimental
interventions above).
Types of outcome measures
We included studies that met the inclusion criteria described above
regardless of whether they reported on the following outcomes.
Primary outcomes
(Outcomes marked with an asterisk were included in the 'Summary
of findings' tables).
1. Severity/intensity of somatic symptoms*

If a validated self report scale was used for symptom severity,
we extracted the results for this instrument for the meta-analysis.
Validated scales for the assessment of MUPS considered for this
review were already described in Criteria for considering studies
for this review above. Where multiple visual analogue self report
scales or unvalidated scales were used, the first two review authors
(NvD, MdB) decided which scale most closely approximates MUPS.
This was supervised by two other review authors (HvdH, BT),
who were experts on somatoform disorders, MUPS, and clinical
diagnostics, but who were not directly involved in the process of
study selection or data extraction and management, so that they
were blinded to the results. We examined clinician-rated severity
of MUPS separately and it was not combined with self report
outcomes into one effect-size index.
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2. Acceptability*

We measured acceptability by the complement of the proportion of
trial participants who dropped out during the trial from either the
experimental or the comparator intervention.
Secondary outcomes
3. Depression and anxiety

We distinguished between validated clinician-rated instruments
(e.g. the Hamilton Depression Rating Scale (HDRS) (Hamilton 1960),
the Hamilton Anxiety Rating Scale (HARS) (Hamilton 1959)), and
participant self report instruments (e.g. BDI (Beck 1961), and the
Beck Anxiety Inventory (BAI) (Beck 1988)).
4. Dysfunctional cognitions, emotions, or behaviours (participantrated)*

We measured dysfunctional cognitions, emotions, or behaviours by
validated self report scales (e.g. the Whitely Index (WI) (Pilowsky
1967), Illness Attitude Scales (IAS) (Kellner 1986), and the Scale for
the Assessment of Illness Behavior (SAIB (Rief 2003)).
5. Adverse events

We expected that the frequency of adverse events of
non-pharmacological interventions would be low, but not
absent. Forms of psychotherapy may lead to psychological
decompensation, while an intervention such as running therapy
may lead to certain injuries. When possible, we described the
most common adverse effects for the included studies narratively
(defined as effects that occur in at least 10% of participants
receiving the specific therapy), as well as significant differences in
the rate of occurrence of adverse events between intervention and
control groups. However, it must be noted that RCTs and CRCTs
are not the optimal study design for obtaining information about
rare or long-term adverse outcomes, limiting our interpretation of
adverse effect data.
6. Treatment response (responder versus non-responder)*

We measured treatment response using the clinician-rated Clinical
Global Impression Scale (CGI) - Improvement item (Guy 1976); this
scale defined responders as those with a score of "1 = very much
improved" or "2 = much improved". Alternatively, we used the
number of participants who responded to the treatment according
to the author's definition. We calculated response rates out of the
total number of randomised participants.
7. Functional disability and quality of life*

We assessed functional disability and quality of life through
validated clinician-rated scales (e.g. the Global Assessment of
Functioning (GAF) (Hall 1995)) or validated self report instruments
(e.g. the 36-item Short Form Questionnaire (SF-36) (Ware 1992); or
the Sheehan Disability Scale (SDS) (Sheehan 1983)).
8. Healthcare use*

We assessed healthcare use as measured by direct
measurements (e.g. consultation counts), or through participantrated measurements (e.g. healthcare use diary or Trimbos/iMTA
questionnaire for Costs associated with Psychiatric Illness (TiC-P;
Hakkaart-van Roijen 2002).
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Hierarchy of outcome measures

If there were multiple instruments measuring the same outcome,
we preferred whichever instrument was most commonly used
from those listed above. Several studies used both the Physical
Component Scale (PCS) and the Mental Component Scale (MCS) of
the SF-36, and sometimes also the subdomains. In these cases, we
restricted ourselves to the main domains and combined PCS and
MCS into one outcome.
Timing of outcome assessment

We analysed primary and secondary outcomes at the following
time points, if available:
1. immediately post treatment;
2. within 12 months after treatment ending; and
3. more than 12 months after treatment ended.

• Cochrane Central Register of Controlled Trials (CENTRAL) (all
years) (Appendix 1);
• Web of Science (from 1945 onwards, cited references search only
(April 2014)).
3. To identify ongoing trials, we searched the ClinicalTrials.gov
register (clinicaltrials.gov/), the Current Controlled Trials
metaRegister of Controlled Trials - active registers (mRCT;
www.controlled-trials.com/mrct/), and the WHO International
Clinical Trials Registry Platform Search Portal (www.who.int/
trialsearch).
We applied no restrictions regarding date, language, or publication
status to the searches. We will revise the search strategies for future
updates, as these will include studies that use DSM-5 criteria.

Search methods for identification of studies

Searching other resources

Electronic searches

Grey literature

The Cochrane Depression, Anxiety and Neurosis Review Group's
Specialized Register (CCDANCTR)
The Cochrane Depression, Anxiety and Neurosis Group (CCDAN)
maintains two clinical trials registers at the editorial base in
Bristol, UK: a references register and a studies-based register.
The CCDANCTR-References Register contains over 36,000 reports
of RCTs in depression, anxiety and neurosis. Approximately 60%
of these references have been tagged to individual, coded trials.
The coded trials are held in the CCDANCTR-Studies Register and
records are linked between the two registers through the use of
unique Study ID tags. Coding of trials is based on the EU-Psi
coding manual, using a controlled vocabulary. Reports of trials
for inclusion in the Group's registers are collated from routine
(weekly), generic searches of MEDLINE (1950 to date), EMBASE
(1974 to date), and PsycINFO (1967 to date); quarterly searches
of the Cochrane Central Register of Controlled Trials (CENTRAL),
and review-specific searches of additional databases. Reports
of trials are also sourced from international trials registers c/o
the WHO trials portal (the International Clinical Trials Registry
Platform (ICTRP)), pharmaceutical companies, and handsearching
of key journals, conference proceedings, and other (non-Cochrane)
systematic reviews and meta-analyses.
Details of CCDAN's generic search strategies (used to identify RCTs)
can be found on the Group's website.
1. We searched the CCDANCTR (Studies and References Registers)
on 29 November 2013 using the following free-text terms:
(somatization or somatisation or somatoform or hysteri* or
briquet or polysymptom* or multisomatoform or somatizer* or
(somatic NEAR symptom*) or (MUPS or “medical* unexplained”
or "unexplained medical*" or (unexplained NEAR (symptom* or
syndrom*)) or "frequent attend*" or (multiple NEAR (“physical
symptom*” or “symptom diagnos*”)) OR neurastheni*)
We screened the records retrieved
pharmacological interventions.

(controlled vocabularies) and search syntax, appropriate to each
resource:

manually

for

non-

2. We conducted complementary searches on the following
bibliographic databases using relevant subject headings

We searched the ProQuest Dissertation & Theses Database
(www.proquest.com), National Guideline Clearing House
(guideline.gov/) and Open Grey (www.opengrey.eu/) for grey
literature.
Handsearching
We searched the conference proceedings for the following
associations from 2009 if available (for titles not already indexed
in EMBASE or PsycINFO, or already handsearched within The
Cochrane Collaboration).
1.
2.
3.
4.

Annual meeting of the American Psychiatric Association (APA);
International Congress of Behavioral Medicine (ICBM);
European Conference on Psychosomatic Research (ECPR);
Annual Meeting of the European Association for ConsultationLiaison Psychiatry and Psychosomatics (EACLPP);
5. Annual congress of the Dutch Network on Unexplained Physical
Symptoms (NOLK).
Reference lists
We checked the reference lists of all included studies and relevant
systematic reviews to identify additional studies that might have
been missed from the original electronic searches (e.g. references
that were unpublished or in press). We also conducted a cited
reference search on the Web of Science (15 April 2014) for citations
to primary reports of included studies.
Correspondence
We contacted researchers and subject experts for information on
unpublished or ongoing studies or to request additional trial data.

Data collection and analysis
Selection of studies
In the first step, two review authors (NvD, MdB) independently
screened the titles and abstracts of reports identified from the
literature search. We discarded studies that obviously did not
fulfil the inclusion criteria at this stage of the screening process.
Two review authors (NvD, MdB) retrieved eligible or potentially
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eligible articles for full-text assessment. We identified and excluded
duplicate records and we collated multiple reports that related to
the same study so that each study - rather than each report - was the
unit of interest in the review. After full-text assessment, the review
authors identified studies for inclusion and exclusion. We recorded
reasons for exclusion of studies, and resolved disagreements by
consensus - if necessary with the involvement of a third review
author (JvdW). We listed studies for which additional information
was required in order to determine their suitability for inclusion
in the review as 'Studies awaiting assessment'. We recorded the
selection process in sufficient detail to complete a PRISMA flow
diagram (Moher 2009), and Characteristics of included studies and
Characteristics of excluded studies tables.
Data extraction and management
We used a data collection form, piloted on one study in
the review, to extract study characteristics and outcome data.
Independently, four review authors (NvD, MdB, HvdW, HvM)
extracted study characteristics and outcome data from included
studies. If necessary, we contacted the authors of trial reports for
clarification or for additional information. We organised data using
the most recent version of Review Manager 5 software (RevMan
2012). We negotiated disagreements with another review author.
We extracted data on the following study characteristics.
1. Trial characteristics: first author, publication year, status of
publication, language of publication.
2. Details of methodology: study design, study setting, total
duration of study, details of any 'run-in' period, number of study
centres and location, withdrawals, lost to follow-ups.
3. Participants' characteristics: source of sample, size of sample,
mean age, age range, gender, severity and duration of MUPS
at baseline, diagnostic criteria, inclusion and exclusion criteria,
selection instrument (e.g. interview), presence of a somatoform
diagnosis, co-morbidity, and previous treatments for MUPS.
4. Intervention characteristics: intervention, category of nonpharmacological intervention, healthcare provider performing
the intervention, intervention frequency and duration,
comparison, concomitant MUPS-related interventions (e.g.
pharmacotherapy) and number of drop-outs due to adverse
effects or inefficacy of treatment.
5. Outcome measures: primary and secondary outcome measures
(as specified in Primary outcomes; Secondary outcomes),
summary statistics of continuous data (mean, standard
deviation (SD)) and dichotomous data (number of responders),
timing of outcome assessments, intention-to-treat (ITT) analysis
(with last observation carried forward (LOCF)) or observed
cases/completer analysis and other methods of estimating the
outcome for participants who dropped out (e.g. mixed-effect
analyses).
6. Notes: source of funding for trial and any notable conflicts of
interest for trial authors.
We noted in the Characteristics of included studies table whether
outcome data were reported in a usable way. We resolved
disagreements by consensus. Two review author (NvD, HvdW)
entered data into Review Manager 5 for analysis (RevMan 2012). We
double-checked that data had been entered correctly by comparing
the data presented in the systematic review with the data in the
study reports. A third review author (MdB) spot-checked study
characteristics for accuracy against the trial reports.
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Main comparisons
We aimed to stratify comparisons according to treatment classes
as described in Types of interventions when the available data
allowed. For physical therapies, we planned to perform a specific
analysis for physical activity training, all other therapies would
be combined into one group. We planned the following main
comparisons for each class of non-pharmacological treatment.
1. Treatment versus care as usual or waiting list procedures.
2. Treatment versus attention or psychological placebo.
3. Treatment versus another non-pharmacological treatment.
After inclusion of eligible articles, we concluded that all studies
addressed some form of psychological therapy; no studies
addressed 'treatment versus attention or psychological placebo';
and no studies addressed any form of physical therapy. In addition,
as mentioned above (How the intervention might work), we found
several studies comparing a psychological therapy to a form of
enhanced or structured care. As a result of these findings, we
decided to add the comparison 'psychological therapy versus
enhanced care'. So the final categorisation of comparisons was as
follows:
1. psychological therapy versus usual care (or waiting list
procedures);
2. psychological therapy versus enhanced (or structured) care;
3. psychological therapy versus another psychological therapy.
If in future updates of this review we find new studies not fitting
into this categorisation (e.g. comparing some physical therapy with
psychological therapy), we will update the categorisations.
Assessment of risk of bias in included studies
Independently, two review authors (NvD, MdB) assessed the risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved any disagreements by discussion or by involving
another review author (HvM, HvdW). We assessed the risk of bias for
the following domains.
1. Random sequence generation: was the method used to generate
the sequence of randomised allocation adequate for the
production of comparable groups?
2. Allocation concealment: was the allocation adequately
concealed so that intervention allocations could not have been
foreseen in advance of, or during, enrolment?
3. Blinding:
a. was knowledge of the allocation of treatment by the
participants and study personnel adequately prevented
during the study?
b. was knowledge of the allocation of treatment by the outcome
assessor(s) adequately prevented during the study?
4. Incomplete outcome data: were incomplete outcome data
adequately addressed? Was the completeness of outcome data
described, including attrition and exclusions from analyses? If
there were attritions and exclusions in the treatment and control
groups, they were reported, along with the underlying reasons?
We also reported whether the review authors conducted any reinclusions in their analyses.
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5. Selective outcome reporting: were reports of the study free of
suggestion of selective outcome reporting?
6. Other sources of bias: was the study apparently free of other
sources that could produce risk of bias?
7. Treatment fidelity: were therapies based on protocols or
manuals? Were therapy sessions adequately monitored to
assess whether they adhered to treatment protocols and
manuals?
8. Researcher allegiance: could researchers be expected to have a
preference for one of the treatment modalities?
9. Therapist qualifications: were the therapists qualified to
perform the interventions?
In order to assess risk of bias in the following specific types of study
design, we made additional judgements.
1. Multiple-intervention studies: were data presented for each of
the groups to which participants were randomised?
2. Cross-over trials:
a. was it clear that the order of receiving a treatment was
randomised?
b. were unbiased data from the first treatment period available?
3. CRCTs:
a. were individuals recruited to the trial after the clusters had
been randomised?
b. were methods of stratified or pair-matched randomisations
of clusters used?
c. were adequate statistical analyses (taking clustering into
account) used?
We judged each potential source of bias as to be of high, low, or
unclear risk and provided a supporting quotation from the study
as justification for our judgement in the 'Risk of bias' table. We
summarised the risk of bias judgements across different studies
for each of the domains by means of a 'Risk of bias' figure.
Where information on risk of bias related to unpublished data or
correspondence with researchers, we noted this in the 'Risk of bias'
table. When considering treatment effects, we took into account the
risk of bias for the studies that contributed to each outcome.
Measures of treatment effect
Dichotomous data
For dichotomous outcomes, we used risk ratio (RR) as the summary
statistic, together with 95% confidence intervals (CI). If relevant, we
calculated the number needed to treat for an additional beneficial
outcome (NNTB) for every class of non-pharmacological treatment
for which we found a statistically significant treatment effect. We
used the RR estimate and the control risk from the pooled control
groups for this calculation.
Continuous data
As different measures were used to assess the same outcome, we
pooled data using the standardised mean difference (SMD); we
calculated 95% CI. Specific attention was paid to the secondary
outcome 'functional disability and quality of life', as the direction
of scales for these outcomes can differ. An increase on a scale
of functional disability usually indicates deterioration, while an
increase on a scale for quality of life often indicates improvement.
We ensured that it was appropriate to pool the data (e.g. different
instruments measuring the same underlying concept). Using the
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SMD does not correct for such differences in the direction of scales.
In this case, we multiplied the mean values from the smaller set
of studies by -1 to ensure that all the scales pointed in the same
direction.
Unit of analysis issues
Cluster-randomised controlled trials
In order to avoid unit-of-analysis errors for trials in which incorrect
statistical analyses were conducted, we performed approximate
analyses for continuous outcomes based on inflating standard
errors. Before we entered data into Review Manager 5 for metaanalytic calculations (RevMan 2012), we multiplied the standard
error of the effect estimate (from an analysis that did not take
clustering into account) by the square root of the design effect.
The design effect was 1+ ((M-1)* ICC), where M was the mean
cluster size and ICC was the intracluster correlation coefficient. We
assumed a common design effect across intervention groups. If the
ICC was not available in the published report, we used an external
estimate (0.03) obtained from Campbell 2005. We meta-analysed
these inflated variances using Review Manager 5 (RevMan 2012),
and the generic inverse-variance method. For dichotomous data,
we divided both the number of events and the group sizes by the
design effect (Higgins 2011, Chapter 16.3).
Studies with multiple treatment groups
In trials with more than two relevant non-pharmacological
treatment arms, we managed data as follows.
If the different experimental treatments were of the same class of
treatments (e.g. psychotherapy), we summarised them into a single
group and compared it with the control group. For continuous data,
we pooled means and SDs across all of the treatment arms as a
function of the number of participants in each arm (Higgins 2011,
Table 7.7.a). For dichotomous outcomes, we summed both the
sample sizes and the numbers of participants with events across
groups.
If the different treatments were of different classes (e.g. a form of
psychotherapy versus a physical activity intervention), we included
each pair-wise comparison separately, but divided the 'shared
control-group' into two or more smaller groups (according to
the number of intervention groups). For dichotomous outcomes,
we divided both the number of events and the total number
of participants over these groups. For continuous outcomes, we
divided only the total number of participants over these groups
and left the means and SDs unchanged. Although this method only
partially overcomes the unit-of-analysis error, the advantage of this
approach is that it permits investigation of heterogeneity across
intervention arms.
Cross-over trials
We found no cross-over trials. For future updates of our review, we
will only include cross-over trials for meta-analysis if relevant data
are available, or can be obtained, from the first treatment period for
both the treatment and control group(s).
Dealing with missing data
We attempted to contact trial authors in order to verify key study
characteristics and obtain outcome data that were not reported in
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the articles. When we could not retrieve missing data, we managed
the data as follows.
Dichotomous data
We managed missing dichotomous data through ITT analysis,
in which we assumed that participants who dropped out after
randomisation had a negative outcome. We conducted sensitivity
analyses for dichotomous data according to Gamble and Hollis
(Gamble 2005): we calculated best-case/worst-case scenarios for
the clinical response outcome, in which we assumed, for the bestcase scenario, that drop-outs in the active treatment group had
positive outcomes and those in the control group had negative
outcomes; and, for the worst-case scenario, that drop-outs in
the active treatment group had negative outcomes and those in
the control group had positive outcomes. This method provided
boundaries for the observed treatment effect.
Continuous data
Where continuous data were missing, we performed analysis on an
endpoint basis, including only participants with a final assessment,
or by using LOCF to the final assessment where reported by the trial
authors. If necessary, we performed sensitivity analyses where we
compared outcomes with the observed case data versus the LOCF
data. When using LOCF data, we used the baseline SD as a more
conservative approach. If SDs were missing, we calculated them
from t-, F-, P, or CI values (Higgins 2011), or standard errors (Altman
1996).
Assessment of heterogeneity
We assessed the groups for clinical similarities including elements
such as age, gender, and setting.
First, we assessed statistical heterogeneity visually by inspecting
forest plots of standardised mean effect sizes and of relative risks.
We used the I2 statistic as a second test: I2 describes the percentage
of variability in effect estimates that is due to heterogeneity rather
than chance.
We used conventions of interpretation defined by Higgins (Higgins
2011). In the case of substantial levels (i.e. where I2 = 50% to
90%) and considerable levels (I2 = 75% to 100%) of heterogeneity,
we explored data further by means of subgroup and sensitivity
analyses (see below). However, these were not clear-cut criteria,
as the importance of the observed I2 also depends on the
magnitude and direction of treatment effects and the strength
of evidence for heterogeneity (Deeks 2008; Higgins 2003); for
example: if the I2 value fell slightly below 50% (e.g. 45%) and the
direction and magnitude of treatment effects suggested important
heterogeneity, we investigated the data further.
Assessment of reporting biases
We created funnel plots (treatment effect versus standard error of
the effect size), if we included at least 10 trials in a meta-analysis,
according to the recommendations of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011; Sterne 2011).
When analysing and interpreting a funnel plot, we considered
all potential reasons for asymmetry, not just publication bias
(e.g. differences in methodological quality, true heterogeneity in
intervention effects).
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Data synthesis
If we found two or more included studies in a comparison
category (see Data extraction and management) that used the same
outcome construct, we performed a meta-analysis of the results.
Two authors (NvD, JvdW) entered data into Review Manager 5
software (RevMan 2012). We expected to find high heterogeneity
in non-pharmacological therapy approaches and in symptom
severity, duration of symptoms and co-morbidities among the
various study populations. Therefore, we analysed dichotomous
and continuous treatment effects using a random-effects model.
For studies of which data could not be combined, we summarised
the results narratively.
Subgroup analysis and investigation of heterogeneity
If analysis of heterogeneity indicated significant heterogeneity,
we performed subgroup analysis in order to explore whether
methodological and clinical differences between the trials had
produced systematic differences observed in the treatment
outcomes. If we found statistically significant differences between
subgroups, we reported the results of the corresponding subgroup
meta-analysis. If subgroup analysis provided no explanation for
heterogeneity, we did not report the results of meta-analysis.
When available data allowed (at least 10 studies), we performed
subgroup analyses based on the following factors (only for the
primary outcomes).
1. Severity, based on symptom count, and duration of MUPS at
baseline.
2. Diagnosis at baseline.
3. Somatoform disorders versus alternative somatoform
diagnoses versus MUPS.
4. Psychiatric and somatic co-morbidity: as known from various
mental disorders, co-morbid psychological and somatic
problems can modify the efficacy of an intervention. Therefore,
we compared the effects of non-pharmacological interventions
for people with somatoform disorders or MUPS with or without
co-morbid mental or somatic disorders.
5. Primary care versus secondary care and tertiary care, including
healthcare provider performing the intervention.
6. Treatment as usual versus a waiting list procedure as a control
intervention.
Sensitivity analysis
We planned sensitivity analyses to evaluate the robustness of the
conclusions in conjunction with decisions made during the review
process. Sensitivity analyses would inform that the results of the
review did not depend on specific decisions that were made during
the review process. In case of sufficient data (i.e. at least 10 studies),
we planned these analyses to examine the effects of the following
options, restricted to the primary outcome.
1. Exclusion of CRCTs.
2. Exclusion of studies with unclear allocation concealment, or
only a subset of relevant participants.
3. Exclusion of studies with unclear methods of sequence
generation.
4. Exclusion of trials where missing data have been imputed.
5. Exclusion of studies with a drop-out rate higher than 20%.
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'Summary of findings' tables
We added 'Summary of main results' tables for the two main
comparisons to create a structured overview of the main review
results for the two subgroup comparisons with the largest number
of studies: CBT versus usual care and CBT versus enhanced care.
The table only includes information about the outcome measures
marked with an asterisk (see Primary outcomes; Secondary
outcomes), as these were considered the most important for the
current review. For the same reason, the selected time point was
end of therapy, except for healthcare use, where we thought the
period within one year after end of treatment was more meaningful.
For dichotomous outcomes (acceptability, treatment response),
we reported an assumed and corresponding absolute risk with
95% CI as well as a relative risk - corresponding to the RR with
95% CI obtained from meta-analysis. For continuous outcomes,
in the column of assumed and corresponding risk, we presented
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a difference in means or SMD with 95% CI. We used footnotes
in order to specify the source or rationale for each assumed
and corresponding risk. In order to assess the quality of body
of evidence for each outcome, we used the GRADE approach
(GRADEpro software; Schünemann 2008), classifying the quality of
evidence for each study as 'high', 'moderate', 'low', or 'very low'. We
explained judgements other than 'high' quality in footnotes or the
Comments column in the 'Summary of main results' table.

RESULTS
Description of studies
Results of the search
Searches were conducted up to November 2013 (CCDAN registers)
and April 2014 (cited reference searches). Figure 1 shows the
PRISMA flow diagram of the study selection.
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Figure 1. 6 Study flow diagram.

Literature database searches
In the search of the CDANCTR-Studies and CCDANCTR-Reference
Register (from now on referred to as CCDAN database), we found
929 abstracts after de-duplication. We excluded 842 records, based
on the title and abstract, leaving 82 references (65 studies) selected

for full-text retrieval. After reading the full-text, we judged 27 studies
(49 articles) eligible for inclusion in this review. We excluded 35
studies (38 articles) and six articles are still awaiting assessment,
for example, due to unavailability of a full-text article or difficulties
in contacting authors.
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The search of CENTRAL database found 995 records. After removing
duplicates from the CCDAN search, there were 568 new references.
After title and abstract screening, we excluded 560 references, and
selected eight articles for full-text reading. After full-text reading,
we excluded five articles, and judged three articles eligible for
inclusion; however, all three articles described studies already
included in the review (e.g. long-term follow-up results) (Gili
2014; Schröder 2013; Zonneveld 2012). As the Schröder article
reported a more detailed trial methodology and higher number of
participants, we decided to use this article as the main reference
of this study (Schröder 2013) instead of Zaby 2008, which was
retrieved from the CCDAN search.
We performed a cited reference search on the Web of Science,
for citations to primary reports of all studies expected to be
included in this review. When handsearching the retrieved articles,
we identified three additional relevant references. After full-text
reading, we included one new study (Burton 2012), and excluded
one article due to randomisation method (Rembold 2011). One
article (Chernyak 2014) described an already included study (Sattel
2012).
Grey literature
We performed searches for grey literature in the databases of
www.guideline.gov (36 results), www.opengrey.eu (eight results),
and www.proquest.com (no results). We found no new articles.
We screened the conference proceedings of the International
Congress of Behavioral Medicine (ICBM, 2010 and 2012), the Annual
Meeting of the European Association for Consultation-Liaison
Psychiatry and Psychosomatics and the European Conference on
Psychosomatic Research (EACLPP/ECPR, 2009, 2010, 2011, 2012),
the Annual Meeting of the American Psychiatric Association (APA,
abstracts and syllabus of 2009-2013), and the Annual congress of
the Dutch Network on Unexplained Physical Symptoms (NOLK,
2013) and found no new articles.
Systematic reviews
We found 14 reviews about (specific) non-pharmacological
interventions for somatoform disorders or MUPS. After title
screening in the reference lists of the reviews, we selected seven
additional articles for screening of abstract. After abstract reading,
we excluded four articles, and selected three articles for fulltext reading. However, none of these three articles were eligible
due to lack of randomisation or inappropriate selection method
(Hellmann 1990; Lupke 1996; Tschuschke 2007).
Trial registers
We performed ongoing trial searches in the databases
of www.clinicaltrials.gov, www.controlled-trials.com, and
www.who.int/trialsearch. We found six potentially eligible ongoing
trials. As full details of the design and study results were not
available, we could not included these studies in the review (see
Characteristics of ongoing studies table).
Contacting authors
We tried to contact 10 trial authors for missing information
regarding the eligibility of studies; four responded and provided
the desired information (Lidbeck 1997; Gottschalk 2011; Pols 2008;
Steel 2011). The other six trials are listed in the Studies awaiting
classification table.
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We contacted authors of 20 of the included studies for additional
information regarding study design and outcomes, of which 10
provided requested data.
Included studies
We included 21 studies, reported in 43 publications, in this review
(see Characteristics of included studies table). All included studies
concerned psychological interventions.
Design
Twenty of the included 21 studies had a parallel-group, individually
randomised design (RCT). One study had a cluster-randomised
design (Schaefert 2013). We found not trials with a cross-over
design.
Sample size
The total number of randomised participants was 2658, a mean
number of 127 per study (range 32 to 328). Two studies included
fewer than 25 participants per arm (Burton 2012; Katsamanis 2011).
Most studies reported 25 to 75 participants per arm. Three studies
included 75 to 100 participants per arm (Escobar 2007; Schilte
2001; Sumathipala 2008), and two studies included more than 100
participants per arm (Sattel 2012; Schaefert 2013). The largest study
was Schaefert 2013, with 328 randomised participants.
Setting
Eight studies recruited participants in primary care only (Burton
2012; Escobar 2007; Moreno 2013; Schaefert 2013; Schilte 2001;
Sumathipala 2000; Sumathipala 2008; Van Ravesteijn 2013). Only
two studies recruited in secondary care (e.g. outpatient clinics)
(Sattel 2012; Speckens 1995), and one study recruited inpatients
in hospitals (Schweickhardt 2007). Seven studies recruited via
medical settings as well as the open population (e.g. through
advertisements) (Allen 2006; Kashner 1995; Katsamanis 2011; Kolk
2004; Martin 2007; Schröder 2013; Zonneveld 2012). Three studies
recruited via primary care as well as secondary care (Fjorback 2013;
Lidbeck 1997; Schröder 2012).
In one study, treatment was performed in group sessions by GPs
in primary care who were trained in the specific psychological
technique, combined with a psychosomatic specialist (Schaefert
2013). In six other studies, treatment took place at a department
of psychiatry or psychology (Allen 2006; Escobar 2007; Fjorback
2013; Katsamanis 2011; Kolk 2004; Van Ravesteijn 2013).
Another six studies treated participants in other outpatient
clinics (Kashner 1995; Lidbeck 1997; Schröder 2012; Sumathipala
2000; Sumathipala 2008; Zonneveld 2012). Five studies treated
participants in specific outpatient symptom clinics or outpatient
clinics for psychosomatics (Burton 2012; Martin 2007; Sattel 2012;
Schröder 2013; Speckens 1995). One study treated participants as
inpatients (they were admitted to a ward) (Schweickhardt 2007).
One study treated participants at home (Schilte 2001). Finally, in
one study the treatment setting was unknown (Moreno 2013).
Five of 21 studies were carried out in the Netherlands (Kolk 2004;
Schilte 2001; Speckens 1995; Van Ravesteijn 2013; Zonneveld 2012).
Five studies were carried out in Germany (Martin 2007; Sattel 2012;
Schaefert 2013; Schröder 2013; Schweickhardt 2007). Other studies
were carried out in the USA (Allen 2006; Escobar 2007; Kashner
1995; Katsamanis 2011), Denmark (Fjorback 2013; Schröder 2012),
Spain (Moreno 2013), Sri Lanka (Sumathipala 2000; Sumathipala
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2008), Scotland (Burton 2012), and Sweden (Lidbeck 1997). Only
two studies were carried out in a developing country (Sri Lanka)
(Sumathipala 2000; Sumathipala 2008).
Several of the included studies were performed by the same
research groups, or at least had an overlap of authors. This was the
case for the studies of Allen 2006, Escobar 2007, and Katsamanis
2011, for the studies of Fjorback 2013 and Schröder 2012, for the
studies of Sumathipala (Sumathipala 2000; Sumathipala 2008), and
for the studies of Speckens 1995 and Van Ravesteijn 2013.
Participants
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Seven studies reported on psychiatric co-morbidity in general,
percentages of participants with a current co-morbid axis 1
disorder varied between 41% (Zonneveld 2012) and 92% (Escobar
2007). Depression and anxiety were the co-morbidities reported
most often. Twelve studies reported symptoms or disorders
of depression and anxiety, methods of establishment and
percentages varied widely. Only two studies reported physical comorbidities such as hypertension, arthrosis, or asthma (Schaefert
2013; Van Ravesteijn 2013). Four studies did not report any
co-morbidities (Kashner 1995; Sattel 2012; Sumathipala 2000;
Sumathipala 2008).

Proportion of women

Interventions

Most studies recruited women than men, as found in
epidemiological studies (Fink 1999; Fink 2004). Only one study
reported more men in the intervention group (56%, Speckens
1995). The proportion of women among all participants in all
treatment groups ranged between 66% (Burton 2012) and 89%
(Allen 2006; Escobar 2007).

As described in the Types of interventions section, we aimed
to select studies investigating psychological therapies, as well
as studies on physical therapies. However, we found no studies
on physical therapies that were eligible for inclusion. All 21
included studies evaluated a form of psychological therapy.
We classified psychological therapies into six subcategories, as
pre-defined by the Cochrane Depression, Anxiety and Neurosis
Review Group: CBT, behaviour therapy, or other therapies such as
third-wave CBT, psychodynamic therapy, humanistic therapy, or
integrative therapies. Fourteen studies described certain forms of
CBT. Two studies evaluated behaviour therapies (Katsamanis 2011;
Schilte 2001). Two studies described third-wave CBT (mindfulness)
(Fjorback 2013; Van Ravesteijn 2013), and two studies described
psychodynamic therapies (Sattel 2012; Schaefert 2013). In the
study of Kolk et al., participants received CBT, client-centred or
eclectic therapy, depending on the therapist the participant was
assigned to (Kolk 2004); we classified this as integrative therapy.
None of the included studies described humanistic therapies.

Age

The mean age was 43 years in all included studies, ranging from
35 years (Kolk 2004; Sumathipala 2008) to 49 years (Martin 2007;
Schaefert 2013). One study did not provide the mean age of
participants (Katsamanis 2011), but only provided data about the
proportion of participants under and over 40 years old.
Diagnosis

Diagnostic criteria and inclusion criteria varied widely between
studies. Fourteen studies used standardised diagnostic interviews
(such as CIDI or SCID) to establish the diagnosis, the other
seven studies used standardised questionnaires (such as SOMS or
PHQ-15). In nine studies, symptoms were referred to as medically
unexplained symptoms or unexplained physical symptoms.
Three studies used the diagnoses of somatisation disorder and
somatoform disorder to describe the symptoms (Allen 2006;
Kashner 1995; Lidbeck 1997). Two studies used only the term
somatisation (Schilte 2001; Schweickhardt 2007). One study
spoke of abridged somatisation disorder (Moreno 2013), and two
other studies spoke of multiple somatoform symptoms (Martin
2007; Schröder 2013). The other four studies used individual
terminologies such as bodily distress syndrome (Fjorback 2013;
Katsamanis 2011; Sattel 2012; Schröder 2012).
Exclusion criteria varied between studies, but often included
dementia, severe psychopathology such as psychosis, active
suicidal thoughts, alcohol dependence, pregnancy, and current
psychological therapy.
Eleven studies reported severity of symptoms at baseline in terms
of number of symptoms. This number varied widely, ranging from
a lifetime number of seven symptoms (Martin 2007), to a current
number of 32 symptoms (Schröder 2012). Other studies used
somatic symptom scales or did not report baseline severity at all.
Only nine studies reported exact duration of symptoms, all of them
reported a duration of at least several years, ranging from 3.5 years
(Sumathipala 2008) to 25 years (Allen 2006). Four additional studies
reported a minimal duration of symptoms, the other eight did not
report on symptom duration at baseline.

Table 2 provides a summary overview of the main characteristics
of the interventions of the included studies. In eight studies,
the participants received group therapy, and in 11 studies they
received individual therapy. In one study, participants received
both (Schröder 2012), and in one study there were two intervention
groups of which one group received group CBT, and one group
received personal CBT (Moreno 2013).
The duration of treatment ranged from one day (one single session)
(Martin 2007) to nine months (Schaefert 2013), most often between
one and three months.
The mean number of sessions varied among studies and ranged
from one session (Martin 2007) to 13 sessions (Zonneveld 2012).
Thirteen studies used five to 10 sessions. Four studies used
one to five sessions (Burton 2012; Martin 2007; Schilte 2001;
Schweickhardt 2007). Four studies used more than 10 sessions
(Sattel 2012; Schaefert 2013; Speckens 1995; Zonneveld 2012).
All studies performed follow-up assessment, but one did not report
the outcomes of all follow-ups (Schilte 2001). Reported duration of
follow-up varied between two weeks (Schweickhardt 2007) and 24
months (Schilte 2001).
Comparisons
As described in the Types of interventions section, we aimed to
select the following comparator interventions: usual treatment
or waiting list, attention or psychological placebo, and other
psychological/physical therapies. Fifteen studies compared an
intervention to usual treatment or a waiting list. One of these
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studies had two intervention groups (receiving psychological
therapy) and one control group (receiving usual care) (Moreno
2013). None of the included studies described a placebo
comparator intervention, but five included studies compared an
intervention with enhanced or structured care (i.e. more than just
usual care or a waiting list condition) (Fjorback 2013; Sattel 2012;
Schröder 2012; Speckens 1995; Sumathipala 2000). We had not
foreseen this comparator at the protocol stage, so we added this
later as an additional comparison. Examples of the enhanced care
control condition were a basic training for GPs in the detection
and management of psychiatric disorders (Speckens 1995). See
Characteristics of included studies for details.
One study used compared two psychological therapies (Schröder
2013). This study also included a waiting list group, but we excluded
data from this group from our analysis as participants were not
randomly assigned to this group (see Other potential sources
of bias section for details). We found no studies that compared
psychological interventions with physical therapies.
In one study, GPs in both study arms were trained in
diagnosis and management of medically unexplained symptoms
(Schaefert 2013). In addition, the GPs in the intervention group
conducted group sessions for people with MUPS, together with a
psychosomatic specialist.
In six studies, in both study arms a consultation letter was sent to
the primary care physician after baseline assessment, in addition
to the planned psychological therapy (Allen 2006; Escobar 2007;
Fjorback 2013; Katsamanis 2011; Moreno 2013; Schröder 2012).
This was not a reason for exclusion, and we categorised these
studies according to the main comparison. In sensitivity analyses,
we assessed the effect of the interventions excluding these studies.
Scale used to measure outcomes
As described in the section Types of outcome measures, we
aimed to retrieve data about our primary outcomes: severity
of somatic symptoms and acceptability and on our secondary
outcomes: depression and anxiety, dysfunctional cognitions,
emotions or behaviours, adverse events, treatment response,
functional disability and quality of life, and healthcare use.
Severity or intensity of somatic symptoms (or both) was most
often measured using the PHQ-15 (Kroenke 2002, five studies),
the subscale 'Somatisation' of the SCL-90R (Derogatis 1986, five
studies), the SOMS (Rief 1997, three studies), the BSI (Derogatis
1983, three studies), and the Clinical Global Impession Scale for
Somatoform Disorders (CGI-SD; APA 2000, three studies). Two
studies used more than one instrument for severity or intensity
of somatic symptoms (or both) (Escobar 2007; Martin 2007). Two
other studies did not report severity or intensity of somatic
symptoms (or both) (Kashner 1995; Lidbeck 1997). Acceptability
was calculated from provided data about the total number
of randomised participants in the study groups and the total
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number of participants who completed assessments at end of
treatment (also in the control group). For anxiety and depressive
symptoms, studies mostly used Hospital Anxiety and Depression
Scale (HADS) subscales (Zigmond 1983, five studies), SCL-90R
subscales (Derogatis 1986; three studies), and PHQ-9 (Kroenke
2001, three studies). Dysfunctional cognitions, emotions, and
behaviours were mostly operationalised as health anxiety, and
measured by the WI (Pilowsky 1967, seven studies). Withdrawals
due to adverse events were incidentally registered by the authors.
Treatment response was mainly registered using the clinician-rated
CGI (Guy 1976, three studies). Functional disability was mainly
measured using the SF-36 (Ware 1992, 10 studies) and the Short
Form 12 Questionnaire (SF-12; a shortened version of the SF-36,
three studies). No standardised questionnaire was used to measure
healthcare use, and mostly consultation counts (as counted by
physicians or participants) were reported.
Excluded studies
Reasons for exclusion of studies were recorded for all studies that
were read in full-text. Common reasons included the absence of
a randomisation procedure or a participant selection method that
did not include a standardised interview or questionnaire. We also
excluded three studies in which GPs were trained to provide some
psychological therapy (Blankenstein 2001; Toft 2010; Van der FeltzCornelis 2006); these studies were included in another Cochrane
review (Rosendal 2013). The Characteristics of excluded studies
table provides an overview of all excluded studies.
Ongoing studies
Searches of trial databases and personal communication identified
eight ongoing studies that appear to meet the inclusion criteria
for this review (Agger 2012; Hassett 2007; Olde Hartman 2013;
Rief 2013; Schröder 2014; Sitnikova 2014; Steel 2011; Zimmermann
2014). No findings have yet been reported or obtained from these
studies. The Characteristics of ongoing studies table provides an
overview of these ongoing studies.
Studies awaiting classification
There are six studies awaiting classification, mostly due to
unavailability of the full-text articles. We attempted to contact all
study authors and searched for the articles in various sources. All
studies awaiting classification are potentially eligible studies that
could not yet be incorporated into the review (see Characteristics
of studies awaiting classification table).

Risk of bias in included studies
We classified the methodological quality of the 21 studies according
to The Cochrane Collaboration's tool for assessing the risk of bias
(see above). The final ratings are reported in the Characteristics of
included studies table. A risk of bias summary graph (Figure 2) and
summary figure (Figure 3) are also presented.

Non-pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

20

Cochrane

Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 3. (Continued)

Allocation
Sequence generation
While all studies specified that participants were randomly
allocated to conditions (or GP practices randomised to treatment
or control conditions), there were two studied that did not describe
how sequence generation was performed (Kashner 1995; Schröder
2013). Therefore, we rated them as 'uncertain'. We rated the other
studies as 'low risk' as they all used random sequence generation
methods, whether by computer or non-digital, for example, using
random number tables (Kolk 2004; Martin 2007), or a sequence of
labelled cards in envelopes or bags (Fjorback 2013; Schilte 2001;
Schweickhardt 2007; Sumathipala 2000).
Allocation concealment
For five studies, it was unclear who performed allocation, or
whether the person allocating participants to the trial groups was
independent. Therefore, we rated these studies 'unclear' (Allen
2006; Escobar 2007; Kashner 1995; Katsamanis 2011; Schröder
2013). We rated the remaining 16 studies 'low risk of bias' as there
was an adequate description of the person performing allocation or
the relation to the researchers and therapists(e.g. "randomisation
was carried out independently by a nurse who was not participating
in the study") (Lidbeck 1997).
Blinding
Blinding of participants and personnel
In 18 studies, blinding of participants and personnel was not
possible, due to the nature of the interventions (e.g. psychological
group therapy versus waiting list). As this may have influenced
the judgement, we rated almost all studies 'high risk'. We rated
two studies 'unclear' because one of the two groups (participants
or personnel) was blinded and the other was not (Sumathipala
2000; Van Ravesteijn 2013). One study did not describe blinding of
personnel (Schröder 2013), and, therefore, we rated it 'unclear'.
Blinding of outcome assessment
In 19 studies, blinding of outcome assessment was not possible as
most outcomes were participant reported. In one study, outcomes
were assessed by blinded interviewers, but they did this together
with the participants (who were not blinded) (Escobar 2007). We
rated this study 'unclear'. One study mainly used clinician-rated
instruments (Moreno 2013). The outcome assessor was blinded,
but, as there also were a few participant report instruments (and
participants were not blinded), we rated this study 'unclear'.
Incomplete outcome data
All studies reported follow-up rates; nine (43%) studies reported a
loss to follow-up of 20% or less. We rated these studies 'low risk'. We
rated one study 'unclear', because it had a high loss to follow-up,
but corrected for this statistically by multiple imputation (Fjorback

2013). The remaining 11 studies reported high loss to follow-up
(greater than 20%) and, therefore, we rated them 'high risk'.
Selective reporting
Seventeen studies reported all intended outcomes and, therefore,
we rated them 'low risk'. For one study, a protocol was lacking,
therefore it was impossible to evaluate the possibility of selective
outcome reporting (Fjorback 2013). We rated this study 'unclear'.
We rated the remaining three studies 'high risk'. In Kashner 1995,
the outcome 'days in bed' was described as assessed, but was not
reported in the article. In Moreno 2013, healthcare use and CGI were
mentioned as outcomes in the protocol, but they were not reported.
Schilte 2001 performed follow-up measurements at six, 12, and 24
months, but only reported outcomes of the last follow-up moment.
Treatment fidelity
Sixteen studies used a treatment manual or protocol for studied
treatments. We rated them 'low risk'. Three studies did not apply
a structured intervention according to a protocol (Burton 2012;
Kolk 2004; Schilte 2001), therefore, we rated them 'high risk'. The
two remaining studies did provide information about a form of
structure in treatment, but did not mention a protocol or manual
for this. We rated them 'unclear'.
Researcher allegiance
In 18 studies, researchers did not report to have a preference for
one of the treatment modalities. In the studies of Burton 2012,
Lidbeck 1997, and Schaefert 2013, an author was also (one of) the
therapist(s), which may have caused some bias. Therefore, we rated
these studies 'unclear'.
Other potential sources of bias
We included two multiple intervention studies (Moreno 2013;
Schröder 2013). In the first study, data were presented for each
groups to which participants were randomised, so no other
potential sources of bias were found (rating: 'low risk'). In the
second study, participants were randomised for CBT or progressive
muscle relaxation (PMR) using random sequences. When both
groups were full, newly included participants were allocated to the
waiting list group. In a later stage, these participants were included
in both intervention groups. As participants were their own controls
due to this method, we decided to exclude data from the waiting list
group from analysis. For this reason, we rated this study 'unclear'.
One of the studies was a CRCT (Schaefert 2013). GPs were
randomised, after which individuals were recruited. We considered
the randomisation method and statistical analysis appropriate for
the study design.
In the studies of Schilte 2001 and Katsamanis 2011, we found
considerable baseline imbalances. In the study of Schweickhardt
2007, a high percentage (29%) of participants from the control
group became involved in psychotherapy. This may have

Non-pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

23

Cochrane

Library

Trusted evidence.
Informed decisions.
Better health.

influenced the results, although this study provided data for only
one outcome (acceptability) and the effects were in the same order
of magnitude as in other studies. We rated these three studies
'unclear'.

Effects of interventions
See: Summary of findings for the main comparison Psychological
therapy compared with usual care or waiting list for somatoform
disorders and medically unexplained physical symptoms;
Summary of findings 2 Psychological therapy compared with
enhanced or structured care for somatoform disorders and
medically unexplained physical symptoms
For the description of the results, we stratified the comparisons in
the following way (as per the categories of therapies presented in
Types of interventions, where data allowed):
1. Psychological therapies versus usual care or waiting list:
a. CBT versus usual care or waiting list;
b. behavioural therapy versus usual care or waiting list;
c. third-wave CBT versus usual care or waiting list;
d. psychodynamic therapy versus usual care or waiting list;
e. integrative therapies versus usual care or waiting list;
2. Psychological therapies versus enhanced or structured care:
a. CBT versus enhanced or structured care;
b. third-wave CBT versus enhanced or structured care;
c. psychodynamic therapy versus enhanced or structured care;
3. Psychological therapy versus another psychological therapy:
a. CBT versus behavioural therapy.
Most studies provided data for some of the outcomes. One study did
not provide any data that were suitable for meta-analysis, because
the authors only reported change scores (Schilte 2001). Across
all comparisons, outcomes, and time points, we created 44 forest
plots. Most of these included data from only a limited number of
studies: 25 of the forest plots included three or fewer studies, only
two included 10 or more studies. Below, we present the results of
the meta-analyses. We also give attention to the subgroups that
included a considerable proportion of the studies contributing to
the overall comparisons: CBT versus usual care or waiting list and
CBT versus enhanced or structured care, because these subgroups
were more homogeneous in terms of type of intervention than
the overall comparisons. In terms of risk of bias, the studies that
provided outcomes for the meta-analyses were representative for
the whole group (i.e. covered the broad spectrum of risk of bias
assessments across items).
1. Pschological therapy versus usual care or waiting list
Fifteen studies, with 1805 randomised participants, compared
some form of psychological therapy with usual care or waiting list
controls. They addressed the following psychological therapies:
1. CBT versus usual care or waiting list: 10 studies, 1037
randomised participants (Allen 2006; Burton 2012; Escobar
2007; Kashner 1995; Lidbeck 1997; Martin 2007; Moreno 2013;
Schweickhardt 2007; Sumathipala 2000; Zonneveld 2012);
2. behavioural therapy versus usual care or waiting list: two
studies, 209 randomised participants (Katsamanis 2011; Schilte
2001);
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3. third-wave CBT versus usual care or waiting list: one study, 125
randomised participants (Van Ravesteijn 2013);
4. psychodynamic therapy versus usual care or waiting list: one
study, 328 randomised participants (Schaefert 2013);
5. integrative therapies versus usual care or waiting list: one study,
106 randomised participants (Kolk 2004).
In four of these studies, this was combined with a consultation letter
sent to the primary care physician after baseline assessment, in
both treatment arms (Allen 2006; Escobar 2007; Katsamanis 2011;
Moreno 2013). A consultation letter provided recommendations
for the primary care physician tailored to the individual person's
diagnosis, symptoms, and problems. In one study, the GPs in both
treatment groups were trained in diagnosis and management of
MUPS (Schaefert 2013).
Below we describe the main results, sorted by outcomes. Graded
evidence (i.e. using the GRADE approach) is only described for the
outcomes that were selected for the 'Summary of findings' tables.
Apart from CBT, for each of the other types of psychological
therapy only one study provided outcomes. Hence, for each of these
separate treatment types there was insufficient evidence. Below,
we described results for the whole group and for the subgroup of
studies that compared CBT with usual treatment.
Primary outcomes
1.1 Severity of somatic symptoms

Combining all studies that compared some psychological therapy
with usual care or waiting list, psychological therapies were
significantly more effective at end of treatment, though the effect
was small (SMD -0.34; 95% CI -0.53 to -0.16; 10 studies, 1081
analysed participants, Analysis 1.1). Heterogeneity was moderate
(I2 = 49%), and the overall quality of the evidence was low
(Summary of findings for the main comparison). Compared with
usual care, the subgroup of studies that used CBT were also
significantly more effective in reducing severity of symptoms at
end of treatment (SMD -0.37; 95% CI -0.69 to -0.05; 6 studies, 593
participants, random-effects model; Analysis 1.1, subgroup 1.1.1).
Heterogeneity was substantial (I2 = 70%), and the overall quality
of the evidence was low. The point estimates of all but one of the
studies favoured the CBT group. The two studies with the smallest
effects offered low-intensity CBT (Burton 2012; Martin 2007). A
post-hoc analysis without these two studies provided an SMD of
-0.58 (a moderate effect size) (95% CI -0.77 to -0.38) and reduced
heterogeneity (I2 = 0%.
At follow-up, measurements within one year of follow-up, the effect
of psychological therapies remained significant (SMD -0.24; 95% CI
-0.37 to -0.11; 7 studies, 950 participants; I2 = 0%). The same was
the case for the subgroup of CBT studies (SMD -0.29; 95% CI -0.49
to -0.09; 4 studies, 496 participants; Analysis 1.2, subgroup 1.2.1).
Heterogeneity was low (I2 = 17%).
Only two studies (all of CBT) with 228 participants provided data for
this severity of symptoms beyond one year of follow-up (SMD -0.52;
95% CI -0.80 to -0.24; Analysis 1.3). Heterogeneity was low (I2 = 0%).
1.2 Acceptability

Compared with usual care, psychological therapies resulted in a
higher proportion of drop-outs (RR acceptability 0.93; 95% CI 0.88
to 0.99 favouring usual care; 14 studies, 1644 participants; Analysis
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1.4). Heterogeneity was moderate (I2 = 70%). For the studies
comparing CBT with usual care, results were of the same magnitude
but no longer statistically significant (RR acceptability 0.93; 95%
CI 0.85 to 1.01 favouring usual care; 10 studies, 1037 participants;
Analysis 1.4, subanalysis 1.4.1). Heterogeneity was considerable
(I2 = 78%). See under Subgroup analysis and investigation of
heterogeneity for results of a subgroup analysis. The overall quality
of the evidence for this outcome was moderate.
Secondary outcomes
1.3 Severity of anxiety or depressive symptoms (or both)

For participant-rated anxiety symptoms, there was no significant
difference at end of treatment (SMD 0.06; 95% CI -0.20 to 0.32, 4
studies, 270 participants; Analysis 1.5). For the studies comparing
CBT with usual care, results were similar (SMD 0.07; 95% CI -0.22
to 0.37; 3 studies, 185 participants; Analysis 1.5). Within one year of
follow-up only two studies were available (SMD 0.18; 95% CI -0.22
to 0.58; 134 participants; Analysis 1.7).
For clinician-rated anxiety symptoms at end of treatment, there
was a statistically significant difference at end of treatment in
favour psychological therapies (SMD -0.40; 95% CI -0.63 to -0.17; 3
studies, 320 participants; Analysis 1.6). Within and beyond one year
of follow-up, differences remained statistically significant (within
one year: SMD -0.66; 95% CI -1.15 to -0.18, 2 studies both CBT, 251
participants; Analysis 1.8; beyond one year: SMD -0.91; 95% CI -1.26
to -0.55; 1 study, 156 participants; Analysis 1.9).
For participant-rated depressive symptoms, there was no
significant difference at end of treatment (SMD -0.03; 95% CI -0.22 to
0.16; 6 studies, 661 participants; Analysis 1.10). Similar results were
found for the studies that compared CBT with usual care (SMD 0.09;
95% CI -0.13 to 0.31; 4 studies, 325 participants; Analysis 1.10), and
for outcomes after not more than one year of follow-up (SMD 0.04;
95% CI -0.34 to 0.42; four studies, 535 participants; Analysis 1.12).
For clinician-rated depressive symptoms, there was a statistically
significant difference at end of treatment in favour of p
sychological therapies (SMD -0.25; 95% CI -0.48 to -0.02; 3 studies,
316 participants; Analysis 1.11). Within one year of follow-up, the
difference was no longer statistically significant (SMD -0.55; 95% CI
-1.17 to 0.07; 2 studies, 251 participants; Analysis 1.13). Only one
study reported on this outcome beyond one year after treatment
(SMD -0.81; 95% CI -1.16 to -0.46; 156 participants; Analysis 1.14).
1.4 Dysfunctional cognitions, emotions, and behaviours

Three studies, two of which compared CBT with usual care, with 440
participants, reported on dysfunctional cognitions, emotions, and
behaviours. At end of treatment, there was no significant difference
between the two groups (SMD -0.11; 95% CI -0.37 to 0.16; Analysis
1.15). The quality of the evidence was moderate. At follow-up within
one year, differences remained non-significant (SMD -0.16; 95% CI
-0.38 to 0.07; Analysis 1.16).
1.5 Adverse events

Only three studies, all comparing CBT with usual care, reported on
adverse events during the treatment period. One study could not
be included in the meta-analysis, because no adverse events were
found in both groups. The pooled result of the other two studies

Cochrane Database of Systematic Reviews

also showed no significant differences between both conditions (RR
1.31; 95% CI 0.47 to 3.66; 445 participants; I2 = 0%; Analysis 1.17).
1.6 Treatment response (clinician rated)

All four studies addressing clinician-rated treatment response
comparing CBT with usual care. At end of treatment, results
strongly favoured the treatment group (RR 3.30; 95% CI 2.08 to 5.21;
4 studies, 391 participants; I2 = 19%; Analysis 1.18). We considered
the quality of the evidence to be low for this outcome. Three studies
provided data for clinician-rated treatment response within one
year after end of treatment, still in favour of the treatment group (RR
2.53; 95% CI 1.25 to 5.10; 332 participants; I2 = 59%; Analysis 1.19).
At longer follow up (greater than one year after treatment) only two
studies reported outcomes, highly favouring the treatment group
(RR 10.31; 95% CI 2.95 to 36.02; 240 participants; Analysis 1.20).
1.7 Functional disability and quality of life

Seven studies, of which four addressing CBT reported on functional
disability and quality of life, using a variety of instruments. At
the end of treatment, a statistically significant effect was found
favouring the psychological therapies (SMD 0.17; 95% CI 0.03 to
0.32; 7 studies, 730 participants; I2 = 0%; Analysis 1.21). We judged
the evidence to be moderate. At follow-up within one year after
treatment, differences were similar but no longer significant (less
than one year: SMD 0.16; 95% CI -0.01 to 0.33; 4 studies, 526
participants; I2 = 0%; Analysis 1.22). After one year, only one study
provided data for functional disability and quality of life (Analysis
1.23).
Four studies compared CBT with usual care. At end of treatment, a
non-significant difference was found favouring CBT (SMD 0.15; 95%
CI -0.06 to 0.37; 4 studies, 341 participants; I2 = 0%; Analysis 1.21,
subanalysis 1.21.1).
1.8 Healthcare use

Six studies assessed healthcare use, operationalised in different
ways, with moderate quality of evidence. During the treatment
phase, two studies found a significant difference in the number of
participant-initiated doctor visits and medication usage in favour
of CBT (SMD -0.68; 95% CI -1.06 to -0.30; 117 participants; Analysis
1.24). In the period less than one year after treatment, perhaps a
more relevant timeframe, four studies found no clear evidence of
a difference (SMD -0.09; 95% CI -0.31 to 0.12; 532 participants; I2
= 20%; Analysis 1.25). We judged the quality of the evidence to be
moderate. For one of the studies, the effect was in the opposite
direction, that is, favouring the control group (Kolk 2004). No study
provided data for healthcare use beyond one year after treatment.
See footnotes of analyses for details about the way healthcare use
was assessed.
2. Psychological therapy versus enhanced or structures care
Five studies with 680 randomised participants compared a certain
psychological therapy with enhanced or structured care (see
Characteristics of included studies for details). They addressed the
following treatments:
1. CBT versus enhanced or structured care: three studies,
349 randomised participants (Schröder 2012; Speckens
1995;Sumathipala 2008);
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2. third-wave CBT versus enhanced or structured care: one study,
120 randomised participants (Fjorback 2013);
3. psychodynamic therapy versus enhanced or structured care:
one study, 211 randomised participants (Sattel 2012).
In two of these studies, treatment was combined with a
consultation letter sent to the primary care physician after baseline
assessment, in both treatment arms (Fjorback 2013; Schröder
2012).
Below we describe the main results, sorted by outcomes. Apart
from CBT, only one or two trials provided data for each of the three
other types of psychological therapy; hence, for each of these other
treatment types there was insufficient evidence. Below, we do not
describe the results for these subgroups separately. The reader is
referred to the combined forest plots for each outcome.
Primary outcomes
2.1 Severity of somatic symptoms

Five studies (with 624 analysed participants) assessed severity of
somatic symptoms comparing some psychological therapy versus
enhanced care (pooled SMD -0.19; 95% CI -0.43 to 0.04; I2 = 53%;
Analysis 2.1). We considered the quality of the evidence to be
low (Summary of findings 2). Within one year of follow-up, this
effect was similar but now statistically significant (SMD -0.21; 95%
CI -0.40 to -0.02; 5 studies, 593 participants; I2 = 25%; Analysis
2.2). Only two studies each comparing a different psychological
therapy to enhanced care, assessed severity of somatic symptoms
beyond one year after treatment (SMD -0.32; 95% CI -0.73 to 0.10;
172 participants; Analysis 2.3). The subgroup of studies comparing
CBT with enhanced care showed similar results. Heterogeneity was
substantial at the end of treatment (I2 = 62%) and moderate within
one year after treatment (I2 = 39%).
2.2 Acceptability

Five studies, with 679 analysed participants, showed that
psychological therapies were less acceptable in terms of dropouts than enhanced care (RR 0.93; 95% CI 0.87 to 1.00; Analysis
2.4). Heterogeneity was moderate (I2 = 36%), and we judged the
quality of the evidence to be moderate. The largest subgroup was
CBT. Compared with enhanced care, moderate-quality evidence
showed that there was no clear difference between CBT and
enhanced or structured care (RR 0.91; 95% CI 0.82 to 1.02; 3 studies,
331 participants; Analysis 2.4, subgroup 2.4.1). Heterogeneity was
moderate to considerable (I2 = 50%).
Secondary outcomes
2.3 Severity of anxiety or depressive symptoms (or both)

Five studies assessed severity of anxiety or depressive symptoms
(or both) at end of treatment (SMD -0.14; 95% CI -0.30 to
0.02; 624 analysed participants; I2 = 0%; Analysis 2.5), showing
no clear difference. Similar results were found within one year
after treatment (SMD -0.13; 95% CI -0.29 to 0.03; 5 studies, 593
participants; Analysis 2.6) and beyond one year after treatment
(SMD -0.26; 95% CI -0.55 to 0.03; 2 studies, 184 participants; Analysis
2.7).
The studies investigating CBT showed no significant difference
in level of anxiety and depressive symptoms between CBT and
enhanced care at end of treatment (SMD -0.17; 95% CI -0.40 to
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0.05; 3 studies. 307 participants; Analysis 2.5, subanalysis 2.5.1)
and within one year after treatment (SMD -0.17; 95% CI -0.40 to
0.06; 3 studies, 289 participants; Analysis 2.6, subanalysis 2.6.1).
Heterogeneity was low (I2 = 0% at end of treatment and within one
year after treatment). Only one CBT study reported on severity of
anxiety or depressive symptoms (or both) beyond one year after
treatment (Analysis 2.7).
2.4 Dysfunctional cognitions, emotions, and behaviours

Four studies, with 499 analysed participants, provided data for
dysfunctional cognitions, emotions, and behaviours at end of
treatment, showing no clear evidence of a difference between
psychological therapy and enhanced care (SMD -0.09; 95% CI -0.29
to 0.10; I2 = 14%; Analysis 2.8). We judged quality of the evidence
to be moderate. At follow-up within one year after treatment, the
difference was statistically significant (P value = 0.05), favouring
the psychological therapy over enhanced care (SMD -0.24; 95%
CI -0.49 to 0.00; 4 studies, 477 participants; I2 = 42%, Analysis
2.9). Beyond one year of follow-up, only two studies reported on
dysfunctional cognitions, emotions, and behaviours and showed
no significant difference (SMD -0.58; 95% CI -1.27 to 0.11; 2 studies,
184 participants; I2 = 82%; Analysis 2.10).
The two studies comparing CBT with enhanced care showed
no clear evidence of a difference in dysfunctional cognitions,
emotions, and behaviours at end of treatment (SMD -0.28;
95% CI -0.57 to 0.01; 2 studies, 182 participants; Analysis 2.8).
Heterogeneity was low (I2 = 0%). However, within one year
after treatment, levels of dysfunctional cognitions, emotions, and
behaviours were significantly lower for CBT (SMD -0.45; 95% CI -0.83
to -0.07; 2 studies, 173 participants; Analysis 2.9), though more
heterogeneous (I2 = 37%). This effect was even more significant
at more than one year after treatment, although this comparison
only included one study (SMD -0.94; 95% CI -1.36 to -0.51; 94
participants; Analysis 2.10) (Schröder 2012).
2.5 Adverse events

None of the studies comparing psychological therapy versus
enhanced or structures care reported information about adverse
events.
2.6 Treatment response

None of the included studies comparing psychological therapy
versus enhanced or structures care reported about treatment
response using a standardised method as described in Secondary
outcomes. One study reported about treatment response, but for
this outcome measure the SF-36 (Ware 1992) was used (Schröder
2012). In this review, we used the outcomes of this questionnaire
in the analyses of functional disability. Another study reported
about participants' perceived change in symptoms (Speckens
1995). At all measurement moments after baseline, participants
were asked if their symptoms were "recovered", "improved", "the
same", or "worse" since the previous measurement, using a nonstandardised questionnaire. At the end of treatment, 32 (82%)
participants in the intervention group declared that symptoms
were improved or recovered versus 24 (64%) participants in the
control group. Six months after treatment, 27 (73%) participants
of intervention group reported recovery or improvement versus 23
(59%) participants of the control group.
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2.7 Functional disability and quality of life

Secondary outcomes

At end of treatment, four studies with 497 analysed participants
reporting on functional disability and quality of life, found no
significant difference (SMD 0.13; 95% CI -0.05 to 0.30; I2 = 0%;
Analysis 2.11). We considered the quality of the evidence to be
moderate. Within one year of follow-up, there was a small effect in
favour of psychological therapies (SMD 0.20; 95% CI 0.02 to 0.38; 5
studies, 727 participants; I2 = 0%; Analysis 2.12). Only two studies
reported on functional disability and quality of life beyond one
year of follow-up and there was no clear evidence of a difference
between the interventions (SMD 0.22; 95% CI -0.16 to 0.60; 2 studies,
184 participants; Analysis 2.13).

3.3 Severity of anxiety or depressive symptoms (or both) at end of
treatment

For the studies comparing CBT with enhanced care, at end
of treatment, moderate-quality evidence showed no significant
difference in terms of level of function/quality of life, with a large
CI but homogeneous population (SMD 0.21; 95% CI -0.08 to 0.51;
2 studies, 182 participants; I2 = 0%; Analysis 2.11). There was a
small but significant difference in favour of CBT within one year
after treatment (SMD 0.30; 95% CI 0.00 to 0.60; 2 studies, 173
participants; Analysis 2.12). At this time point, heterogeneity was
low (I2 = 0%). After one year of follow-up, only one study provided
data. In this study, CBT resulted in a significantly higher level of
function compared with enhanced care (SMD 0.42; 95% CI 0.01 to
0.83; 94 participants; Analysis 2.13).

The study comparing CBT with PMR did not report about adverse
events.

There was no significant difference in level of depression and
anxiety between CBT and PMR at end of treatment (SMD 0.01; 95%
CI -0.42 to 0.44; 84 participants; Analysis 3.3).
3.4 Dysfunctional cognitions, emotions, and behaviours

The study did not report about dysfunctional cognitions, emotions,
and behaviours.
3.5 Adverse events

3.6 Treatment response

The study comparing CBT with PMR did not report about treatment
response.
3.7 Functional disability and quality of life

There was no significant difference in level of function between CBT
and PMR at end of treatment (SMD 0.28; 95% CI -0.15 to 0.71; 84
participants; Analysis 3.4).
3.8 Healthcare use

2.8 Healthcare use

Only two studies provided usable data for this analysis and
quality of the evidence was low (Sumathipala 2008; Sattel 2012).
There were no significant differences healthcare use between
psychological therapies and enhanced care, neither at end of
treatment (Analysis 2.14), nor within one year after end of
treatment (Analysis 2.15). See footnotes of analyses for details
about the way healthcare use was assessed.
3. Psychological therapy versus other psychological therapy
Only one included study addressed psychological therapy versus
other psychological therapy (Schröder 2013, 173 randomised
participants). The study compared CBT with PMR therapy. The
study also included a waiting list group, but we excluded this group
from analyses as participants in the waiting list group were not
randomly assigned (for details, see the Other potential sources of
bias section).
Primary outcomes
3.1 Severity of somatic symptoms

No significant difference was found for severity of somatic
symptoms between CBT and PMR at end of treatment (SMD 0.10;
95% CI -0.33 to 0.53; 84 participants; Analysis 3.1).
3.2 Acceptability

There was no significant difference in drop-out rates between CBT
and PMR during treatment (SMD 0.98; 95% CI 0.83 to 1.15; 90
participants; Analysis 3.2).

The study comparing CBT with PMR did not report about healthcare
use.
Subgroup analyses and investigation of heterogeneity
For most comparisons and outcomes, we considered the number of
studies to be too small to explore possible sources of heterogeneity.
Sensitivity analyses
Although we stated in our protocol that we would only perform
sensitivity analyses when at least 10 studies were available, we
performed some analyses with fewer studies, in response to peer
reviewers' requests.
Consultation letters
For our first comparison, we repeated the analysis for the primary
outcomes excluding the studies that included consultation letters
in both study arms. For symptom severity at end of treatment,
the original analysis included 10 studies with 1081 participants
(pooled SMD -0.34; 95% CI -0.53 to -0.16; I2 = 49%; Analysis 1.1).
Excluding the three studies with consultation letters resulted in
seven remaining studies with 722 participants, and a pooled of SMD
-0.22 (95% CI -0.40 to -0.03; I2 = 24%) (Allen 2006; Escobar 2007;
Moreno 2013).
At follow-up measurements within one year of follow-up, the
original analysis showed that the effect of psychological therapies
compared with usual care CBT remained significant (SMD -0.24;
95% CI -0.37 to -0.11; 7 studies, 950 participants; Analysis 1.2).
Heterogeneity was low (I2 = 0%). Excluding the same three studies
with a consultation letter as above resulted in four remaining
studies with 594 participants, and a pooled SMD of -0.14 (95% CI
-0.31 to 0.02) and also low heterogeneity (I2 = 0%).
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Outliers
For our first comparison, with 14 studies, the outcome acceptability
showed considerable heterogeneity (I2 = 70%; Analysis 1.4), the
effect was small but statistically significant (RR 0.93; 95% CI 0.88
to 0.99). One of the studies was a clear outlier (Kashner 1995),
with only 20/44 (45%) participants in the CBT group completing
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the treatment phase versus all of the 26 participants in the control
group (100% acceptability) (see also the funnel plot; Figure 4).
Removing this study from the analysis (a post hoc choice) reduced
the heterogeneity from 70% to 33%. The pooled results for the
remaining studies resulted in a somewhat smaller effect (RR 0.95;
95% CI 0.92 to 0.99; 13 studies, 1574 analysed participants). As the
outlying study had an extreme low acceptability in the intervention
group, publication bias was not an issue.

Figure 4. Funnel plot of comparison: 1 Psychological therapies versus usual care or waiting list, outcome: 1.4
Acceptability.

Reporting bias
In few studies, we considered reporting bias to be a serious
problem. However, our assessment was suboptimal, as for most
of the studies no protocol was available, so we could not compare
the published outcomes with the planned outcomes. One study
evidently assessed more outcomes than initially reported (Moreno
2013), but this was at least partially overcome by a later publication,
and by additional outcome data provided by the authors on
request. The only funnel plot we were able to produce (because
enough studies were available) did reveal one outlier, but this did
not suggest any publication bias (see Figure 4).

DISCUSSION
Summary of main results
We added two 'Summary of findings' tables to create a structured
overview of the main review results, using the GRADE methodology
(Summary of findings for the main comparison; Summary of

findings 2). These tables only addressed the most important
outcome measures (marked with an asterisk in the section 'Types
of outcome measures') of the two main comparisons. A summary
of the main findings for all comparisons follows below.
Psychological therapy versus usual care
Fifteen studies compared some form of psychological therapy
with usual care or a waiting list. Combining 10 of these studies,
the psychological therapy was significantly more effective on
symptom severity at end of treatment, though the effect was
small. Heterogeneity was considerable and the overall quality of
the evidence was low. Six of the 10 studies compared CBT with
usual care; for this subgroup it was also apparent that CBT was
more effective in reducing severity of symptoms at the end of
treatment. The treatment effect of psychological therapies as a
whole was also noted within one year of follow-up (seven studies).
After one year, the evidence was limited to two studies (both CBT),
but still in favour of the psychological therapy. Results for treatment
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response, one of our secondary outcomes, supported the findings
for symptom severity, with moderate-quality evidence.
Regarding the other primary outcome, acceptability, we found a 7%
difference in drop-outs, favouring the usual care group. The quality
of the evidence was moderate. After we removed an apparent
outlier, the result was smaller (5%), but still statistically significant.
There was no significant difference in drop-out rates between CBT
and usual care.
For participant-rated symptoms of depression and anxiety, there
was no significant difference at the end of treatment or at followup. However, in three studies using clinician-rated instruments,
the level of anxiety and depression was slightly lower in the
psychological therapy groups at the end of treatment. For anxiety,
this difference became larger at follow-up. For clinician-rated
depressive symptoms, this effect fluctuated during follow-up (no
effect within one year (two studies) and a large effect after one
year of follow-up (one study)). Only three studies reported adverse
effects and dysfunctional cognitions, emotions, and behaviours.
There was no clear evidence of a difference on these outcomes.
There was a small difference in functional disability at the end of
treatment favouring psychological therapies. This effect was not
apparent during follow-up. Two studies (both on CBT) found a small
difference in favour of psychological therapies on healthcare use
during treatment, four studies found no effect within one year of
follow-up. Due to the small number of studies, these results should
be considered with caution.
Only two studies compared behavioural therapy with usual care,
of which only one provided relevant data (Katsamanis 2011). In
this study, there were no significant differences for any of the
outcomes. Only one study compared third-wave CBT (mindfulness
therapy) with usual care (Van Ravesteijn 2013). In this study,
mindfulness was more acceptable than usual care, but no evidence
of differences was found with respect to other outcomes. One
study compared a variety of psychological therapies with usual
care (therapy depended on the orientation of the 15 participating
therapists) (Kolk 2004). In this study, there was no evidence of
differences with respect to any of the outcomes. This comparison
had a high external validity as it emulated the way the referral
process normally works.
Psychological therapy versus enhanced or structured care
Five studies compared a certain psychological therapy with
enhanced or structured care. The quality of the evidence was
moderate for most outcomes. At the end of treatment, there was no
clear evidence of a difference for symptom severity, but there was a
small statistically significant difference within one year after end of
treatment. The psychological therapy groups had a 7% higher dropout rate than the control groups.
There was no clear evidence of a difference between the groups in
terms of severity of anxiety or depressive symptoms (or both) at
the end of treatment and within one year after treatment. There
was no clear evidence of a difference between the groups in terms
of dysfunctional cognitions, emotions, and behaviours at end of
treatment, but at follow-up within one year of treatment there was
a small effect in favour of psychological therapy over enhanced
care. None of the studies in this comparison reported information
about adverse events or treatment response in a standardised way.
For functional disability and quality of life, there was no clear
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evidence of a difference at the end of treatment, but there was a
small significant difference within one year of follow-up. There were
no significant differences in healthcare use between psychological
therapies and enhanced care.
Three of the studies compared CBT with enhanced or structured
care. For symptom severity, CBT showed similar results as the
whole group. There were no differences in drop-out rates. In
addition, there were no significant differences in levels of anxiety
and depressive symptoms at the end of treatment and within
one year after treatment. Only one study reported data after one
year. At the end of treatment, CBT did not result in lower levels
of dysfunctional cognitions, emotions, and behaviours, compared
with enhanced care. However, within one year of treatment, these
levels were lower for CBT (two studies). Only one study reported
beyond one year of treatment. The level of functional disability at
the end of treatment was comparable for CBT and enhanced care.
Within and after one year of treatment there was a small difference
in favour of CBT, although only a few studies were included in these
analyses. Only one CBT study reported data about healthcare use
and found no evidence of difference.
Psychological therapy versus another psychological therapy
Only one study compared two forms of psychological therapy (CBT
versus PMR). There were no differences between the groups for any
of the outcomes.

Overall completeness and applicability of evidence
The aim of this review was to assess the effects of
non-pharmacological interventions for somatoform disorders
(specifically somatisation disorder, undifferentiated somatoform
disorder, somatoform disorders unspecified, somatoform
autonomic dysfunction, pain disorder, and alternative somatoform
diagnoses proposed in literature) and MUPS in adults in
comparison with treatment as usual, waiting list controls,
attention placebo, psychological placebo, enhanced care, and
other psychological or physical therapies.
Studies
A thorough literature search in electronic databases and many
other resources such as conference proceedings, international trial
registers, grey unpublished literature, and reference lists resulted
in 21 studies that could be included in this review. In comparison
to other existing reviews about non-pharmacological interventions
for MUPS or somatoform disorders (e.g. Kleinstäuber 2011; Kroenke
2007; Rosendal 2013), this number of eligible studies is quite
high. Hence, a considerable number of studies was available in
order to address our questions. However, only a few studies
contributed to most of the outcomes. In addition, due to the small
number of studies, we were unable to consider the effect of study
characteristics (setting, severity, chronicity) on the outcomes.
We believe that the included studies cover a broad spectrum of
settings, and both RCTs and CRCTs were included. Participants were
recruited in various ways and from various healthcare settings,
including primary care, secondary care, tertiary care, and the
open population. In the included studies, therapists had different
backgrounds (e.g. GPs, psychologists, and other physicians) and
different levels of experience. A limitation of the included studies
was the relatively low number of included participants per study as
most studies only included 25 to 75 participants per study arm.
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A critical issue concerns the fact that somatoform disorders
are conceptually overlapping with certain functional somatic
syndromes, which we excluded from the current review when
studies only focused on one of these (e.g. chronic fatigue
syndrome and irritable bowel syndrome). However, the results
of the current review should be interpreted as part of a
portfolio of various Cochrane reviews covering somatoform
disorders (Hoedeman 2010; Ipser 2009; Ruddy 2005; Thompson
2007); the Cochrane review on pharmacological interventions for
somatoform disorders, which is currently being developed (see
Kleinstäuber 2013 for protocol) and Cochrane reviews focusing on
different functional syndromes (e.g. Moore 2014).
It is debatable whether our inclusion criterion that selection of
participants should include a diagnostic interview or questionnaire
to establish MUPS or somatoform disorder was not too strict. We
excluded several potentially relevant randomised trials because
they did not fulfil this criterion. It is unclear whether these excluded
studies included participants of similar severity as the included
studies.
Participants
With only two exceptions (Sumathipala 2000; Sumathipala 2008),
studies were performed in developed countries (Western Europe
and USA).
Most studies randomised more women than men. This is in line
with existing reviews, as MUPS and somatoform disorders are
more common among women. Included studies cover a broad
age range. However, as the mean age of participants was in
the 30s or 40s in most of the studies, it may be possible that
younger and older people were relatively underpresented. Severity
of MUPS at baseline was mostly analysed based on the number
of symptoms or duration (or both) of symptoms. The number
of symptoms at baseline varied widely, ranging from a lifetime
number of symptoms of seven (Martin 2007) to a current number of
symptoms of 32 (Schröder 2012). Baseline duration, only reported
in nine studies, ranged on average from four to 25 years. This
suggests that most of the included participants may have had
chronic symptoms at baseline. Included studies also reported high
psychiatric co-morbidity rates, percentages of participants with a
current co-morbid axis 1 disorder varied between 41% (Zonneveld
2012) and 92% (Escobar 2007). Taking these findings together, we
can say that a limitation may be that participants of included
studies were people with relatively severe forms of somatoform
disorders and MUPS. The milder forms, with lower levels of comorbidity may have been underpresented. In contrast, people with
milder symptoms may need less intensive therapy.
Interventions
Fourteen of the included studies compared CBT with another
intervention. As a result, relatively robust conclusions could be
drawn about the effectiveness of CBT. The number of studies
describing other psychological therapies (such as behavioural
therapies, third-wave CBT, or psychodynamic therapies) was too
low to draw conclusions about these forms of therapy. Duration and
number of treatment sessions varied widely between the included
studies.
It is especially remarkable that we found no studies on physical
therapies (such as running therapy). We believe that there is a clear
need for this type of research.
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Many included studies used forms of enhanced care or other forms
of therapy as the control treatment. A limitation of this method may
be an underestimation of the treatment effect, due to small intergroup differences. This is illustrated since these studies found fewer
and smaller effects than studies comparing a treatment with usual
care.
Outcomes
In this review, the outcome of functional impairment introduced a
problem, as a certain number of studies used SF-36 subscales as
the outcome measure. As a result, we reported physical functioning
and mental functioning or even subdomains separately. We
decided to pool the two main domains into one outcome, but this
led to the limitation that differences in effects for physical and
mental functioning, as found in some studies (e.g. Zonneveld 2012),
disappeared.
Another problem of the current review was that, with one
exception, there were not enough studies to assess reporting bias
with funnel plots. According to recommendations of the Cochrane
Handbook for Systematic Reviews of Interventions, there should be
at least 10 studies to perform this (Sterne 2011). In future updates of
this review, the addition of new studies may enable us to produce
funnel plots for more comparisons and outcomes.
Adverse effects were very infrequently reported and various ways of
reporting were used. Therefore, it was impossible to extract these in
a standardised way in order to include them in our meta-analytical
calculations, except for the first comparison (psychological therapy
versus usual care or waiting list). We also have to emphasise again
that RCTs and CRCTs are not sufficient to gain information about
the more rare or longer-term (or both) adverse events.
The difference in effect between participant-reported symptoms
of anxiety and depression and physician-reported symptoms is
interesting. In most studies, both participants and physicians were
aware of the treatment that was provided, but physicians may have
been more biased towards active treatment than participants. In
contrast, we should realise that the studies that asked participants
to rate their symptoms were not always the same as the studies that
asked physicians, so it is possible that other study characteristics
have caused these differences.

Quality of the evidence
According to the first quality criterion risk of bias defined by the
guidelines by GRADE, Figure 2 and Figure 3 showed that in regard
to different types of biases most of our included studies showed
a low risk. However, a few specific domains were often rated as
being at high risk of bias across the studies. Especially for blinding
of the outcome measurement, we identified a high risk of bias
in most of the included studies. Most studies could not blind the
outcome reporters, mostly the participants, due to the nature of
the intervention. A high risk of bias in blinding of participants
and personnel was found for the same reason. Nine studies (43%
of studies) reported incomplete outcomes, defined as a loss to
follow-up of more than 20%. Reasons for loss to follow-up were not
systematically described. Another study aspect that affected the
quality of the evidence was the generally low number of included
participants per study. It has to be taken into account that several
of the included studies were performed before the publication
and implementation of current quality criteria for conducting and
reporting RCTs.

Non-pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

30

Cochrane

Library

Trusted evidence.
Informed decisions.
Better health.

The small number of studies did not allow us to assess the effects
in subgroups of participants or interventions. Apart from CBT, all
other comparisons between specific therapies and usual care or
enhanced care, the number of studies was too small (often only one
study). We did not consider indirectness (a GRADE item comparing
the interventions and outcomes in which we are interested to what
was actually studied in the included studies) and publication bias to
be important sources of risk of bias, publication bias because of our
thorough search process; the overall completeness of reporting,
and the fact that several studies that did not find an effect.

Potential biases in the review process
This review has several methodological strengths. The quality of
meta-analyses depends on the robustness of the search methods
used. In this review, the electronic search was thorough and
large in scale with broad parameters. We evaluated published and
unpublished studies. The selection criteria were broad, which led
to the selection of a relatively high number of studies. We also
included non-English studies. As a result, it seems likely that all
or almost all evidence in the searched databases that should have
been included was included. However, as we did not search Asian
databases, this may have led to a potential bias.
The study was performed according to a pre-published protocol.
Different review authors performed evaluation of studies for
selection, extract data, and assess risk of bias, with the possibility
of consulting another review author to resolve disputes. However,
due to the fact that not all choices that had to be made were
foreseen, there were also post hoc decisions. Excluding studies
that trained GPs to deliver some psychological therapy was one
of these decisions. In addition, we performed the allocation of
the included studies to the different groups of treatment for
analyses post hoc. Another post hoc decision was the addition of
enhanced or structured care as a comparator. We made decisions
very carefully and included achieving consensus between several
review authors with specific knowledge in the field. However, some
studies were difficult to categorise, as, for example, treatments
included elements of different treatment categories. Therefore,
allocation of these studies remained slightly arbitrary. Another post
hoc decision was to combine the physical component scale and the
mental component scale of the SF-36 into one outcome. Other post
hoc decisions were to carry out sensitivity analyses by excluding
studies that included consultation letters in both study groups, and
by excluding studies with the least intensive interventions.
Although we attempted to obtain missing data from the authors of
included studies, it was not possible in every case to obtain these
data, and, therefore, the included studies were not represented
fully in the meta-analyses. This may also have led to a certain form
of bias, although it is difficult to say in what direction this bias
would be.
As described in the section Types of outcome measures,
we aimed to retrieve data about severity/intensity of MUPS;
acceptability; depression and anxiety; dysfunctional cognitions,
emotions, or behaviours; adverse events; treatment response;
functional disability; and quality of life. However, the number
of studies reporting on many of our outcomes was relatively
low. Results about depression; anxiety; dysfunctional cognitions,
emotions, and behaviours; adverse events; and treatment response
were frequently lacking. Therefore, we could not draw robust
conclusions about these outcome measures.
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Although acceptability was a primary outcome of our study, we
restricted this to the period from randomisation to the end of
treatment. We did not take into account the acceptability of the
interventions in the recruitment phase. Participants for whom the
intervention or control condition was unattractive probably did not
participate. This affects the external validity of study findings.
In this review, we used point estimates at all follow-up periods
to evaluate treatment effect, instead of scores based on change
from baseline. We chose this method as these results were
retrievable from most of the studies, and combining follow-up
outcome data with change from baseline data was considered
inappropriate given our choice of SMDs due to the variety of
outcome measures that had to be combined (Higgins 2011, Chapter
9.4.5.2). However, pooling the results of follow-up measurements
has the disadvantage that baseline values (and possible baseline
differences) are not taken into account. As data were pooled in most
analyses, we believe that distortions such as these are generally
corrected by the other studies in the analyses. Some studies only
reported data about change from baseline (without the actual
baseline data) (e.g. Burton 2012; Fjorback 2013). These data could
not be used in this review. We contacted authors in order to be
obtain the required data, and were successful in many cases though
not all.

Agreements and disagreements with other studies or
reviews
Several systematic reviews have addressed non-pharmacological
treatments for participants with some form of somatoform disorder
or MUPS (Allen 2002; Blankenstein 2001 (thesis, chapter 2); Guthrie
1996; Hofmann 2012; Huibers 2007; Kleinstäuber 2011; Koelen
2014; Kroenke 2000; Kroenke 2007; Looper 2002; Nezu 2001;
Rosendal 2013; Sumathipala 2007). As many of the included studies
in our review were published after 2005, we focused this discussion
on the systematic reviews that were published after 2005.
In general, we can say that the results of this review are in line
with results of existing reviews. In most reviews, the majority of
included studies concerned CBT in some form, and small effect
sizes were found. In other reviews, also limited evidence was found
for other forms of psychological therapies. Studies investigating
physical therapies for somatoform disorders or MUPS were also
hardly reported in other reviews.
Hofmann et al. evaluated the effectiveness of CBT for a broad
range of conditions, including somatoform disorders and chronic
pain and fatigue (Hofmann 2012). Within the somatoform disorders
category of DSM-IV, meta-analyses primarily examined the efficacy
of psychological interventions for hypochondriasis and body
dysmorphic disorder, which were both excluded from this review.
For chronic fatigue and pain, the effect of a range on treatments
was reviewed, including relaxation techniques, mindfulness-based
techniques, acceptance-based techniques, biofeedback, psychoeducation, and behavioural and cognitive behavioural treatments.
Results of these meta-analyses revealed varying effect sizes for
these treatments depending on the type of chronic pain targeted;
however, CBT treatments for chronic pain were consistently in the
small-to-medium effect size range. For fatigue, effect sizes were
medium.
Huibers et al. published one Cochrane review focusing on
psychosocial interventions provided by GPs (Huibers 2007). They
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included 10 studies, addressing five distinct disorders or health
complaints, one of which was somatisation, for which three RCTs
were found. One of these was also included in the current review
(Lidbeck 1997). The authors of the Cochrane review concluded
that there was little evidence available for the use of psychosocial
interventions by GPs, while the conclusions of the three separate
studies were slightly more positive, indicating that the model of
training GPs in psychosocial interventions could be beneficial and
with modifications might be useful in practice.
Kleinstäuber et al. evaluated the effect of short-term psychotherapy
on multiple medically unexplained symptoms (Kleinstäuber 2011).
They included a relatively high number of studies (27 studies),
showing a considerable overlap with this review (nine studies also
in our review). Most of the 18 studies that we did not include
in our review were either not randomised or used a participant
selection procedure that did not fulfil our criteria. Like our review,
they found small but stable effect sizes of CBT on severity of
symptoms versus usual care. For quality of life and medical
healthcare utilisation, non-significant effects were found directly
after psychotherapy, which increased to significant small effects at
follow-up assessment. For depression and anxiety, a small effect
was found, which disappeared over time. The authors concluded
that current psychotherapeutic concepts do not sufficiently focus
on co-morbid depression or anxiety.
Rosendal et al. published one Cochrane review focusing on
enhanced care for people with functional somatic symptoms and
disorders, performed by generalists in primary care (Rosendal
2013). Seven studies fulfilled their inclusion criteria, three of
which were also potential candidates for inclusion in this review
(Blankenstein 2001; Larisch 2004; Toft 2010, see Excluded studies).
For most outcomes, they found small and non-significant overall
effect sizes. They concluded that current evidence does not
answer the question whether enhanced care delivered by frontline
primary care professionals has an effect or not on the outcome of
people with functional somatic symptoms. They pointed out that
enhanced care may have an effect when delivered per protocol to
well-defined groups of people with functional disorders, but that
this needs further investigation.
Sumathipala searched for systematic reviews and trials published
since 2000, addressing treatments for people with medically
unexplained symptoms (Sumathipala 2007). He found six
systematic reviews and 14 new trials. He concluded that CBT
was efficacious for either symptom syndromes or for the broader
category of medically unexplained symptoms, reducing physical
symptoms, psychological distress, and disability. He found limited
level II evidence for other interventions such as collaborative
care models, consultation letters, reattribution therapy, and
bioenergetics exercise. Sumathipala 2007 included a relatively low
number of studies in primary care.
In 2014, one systematic review was published on psychotherapy
compared with treatment as usual for severe somatoform disorders
(Koelen 2014). Ten randomised and six non-randomised trials were
included. Of the randomised trials, two were also included in our
review. One of the other randomised trials may also be relevant for
our review and was listed under Studies awaiting classification, to
be examined for a future update (Nickel 2006). The authors of this
systematic review concluded that psychotherapy was effective, but
further studies are needed to examine specific interventions and
mechanisms of change.
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AUTHORS' CONCLUSIONS
Implications for practice
The overall quality of the evidence provided by 21 randomised
controlled trials was low to moderate. All psychological therapies
combined were superior to usual care or waiting list condition for
symptom severity, our first primary outcome, but effect sizes were
small. As a single treatment, only cognitive behavioural therapy
(CBT) was adequately studied to allow conclusions for practice.
Compared with usual care or waiting list conditions, CBT reduced
somatic symptoms, with a small effect and substantial differences
in effects between CBT studies. The effects were durable within and
after one year of follow-up.
Compared with enhanced or structured care, psychological
therapies generally were not more effective for most of the
outcomes. CBT was also not superior to enhanced care.
The question remains how specific CBT is over structured
improvements of care. No major adverse events were reported in
the intervention groups, although most studies did not describe
adverse events as an explicit outcome measure. Apart from CBT,
neither psychological nor other non-pharmacological therapies
have been adequately studied.
In daily practice, a substantial percentage of people with
medically unexplained physical symptoms (MUPS) may not be
willing to accept psychologically oriented treatments. Whether
such acceptance is associated with the effect of psychological
treatments for the total MUPS population was not clear. Due to
the small number of studies, we could not draw conclusions about
the effect of characteristics such as a profession and experience of
the therapist, about treatment intensity and treatment location, on
treatment efficacy.
Further optimisation of CBT to target optimal participant profiles
and match treatment providers, treatment characteristics, and
participants could improve outcomes. Motivating and preparing
people for CBT is important for this participant group (Timmer
2006). As drop-out rates were not much lower than in control
groups, this indicates that when a person has accepted
involvement in the treatment, the prospects that the treatment will
be completed are good.

Implications for research
Based on the findings in this review, we can make several
recommendations for future research. The number of studies
investigating various treatment modalities other than CBT needs
to increase to build a broader and more varied evidence-base for
the treatment of somatoform disorders and MUPS. As physical
therapies may offer a more acceptable starting point for treatment
for these people than psychological approaches, investigating the
effectiveness of physical therapies is to be considered. We found no
such studies.
Most studies in our review focused on chronic manifestations of
physical symptoms, often of considerable severity. It is conceivable
that interventions were more effective in people with milder
symptoms, or of shorter duration, but this needs further testing. A
related conceptual issue is that chronic conditions deserve a World
Health Organization chronic care or chain care approach as acute
treatments will not suffice. Preventing symptoms from become
chronic may be a relevant outcome to be added in future studies.
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In future research, more attention should be paid to the
impact of interventions on risk factors for recurrence and
persistence of symptoms in somatoform disorders and MUPS.
These factors include anxiety; depression; and dysfunctional
cognitions, emotions, and behaviours. Most included studies in this
review did not report on all of these factors. Specific attention to
the effect of treatment duration and number of treatment sessions
is also needed. In the studies included in this review, duration
and number of sessions varied widely, and it is yet unclear which
treatment intensities are effective for which participants.
Psychological treatments were not superior to enhanced care. It
could be argued that an active comparator such as enhanced care
underestimates treatment effects. However, as this comparative
treatment is probably cheaper than more intensive psychological
interventions, it would deserve further study (cf. Rosendal 2013).
In our view, teaching people how to tolerate uncertainty and
deal with their bodily symptoms can be problematic and will
probably always involve high levels of clinical skills. One potential
intermediate factor is the amount of trust that people have in their
therapist or physician, a factor to be taken into account in the
design of new studies (van der Feltz-Cornelis 2004).
There is a clear need for developing and testing strategies for
motivating and preparing people for CBT. CBT is the only evidencebased psychological treatment available at the moment.
A more structural question is, how psychological therapies for
participants with somatoform disorders can be better integrated
into the healthcare system. Can the healthcare system be
restructured in such a way that it facilitates the access of people
with somatoform disorders to psychological therapies?
As the cost of treatment can be substantial, but also the cost of
the disorder in terms of absenteeism and healthcare use, costeffectiveness needs to be addressed in future studies.
Future studies should include more participants, preferably use
a uniform set of validated outcome measurements, and extend
follow-up assessments beyond one year after treatment.
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Finally, as newer-generation antidepressants and particularly
natural products also reduce somatic symptoms, a preference-led
or profile-led approach may be possible (Unutzer 2002). The aim
would be to evaluate to what extent an intervention (consisting
of a choice between non-pharmacological and pharmacological
therapy combined with chain care), would improve symptoms over
usual care.
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CHARACTERISTICS OF STUDIES
Characteristics of included studies [ordered by study ID]
Allen 2006
Methods

Study design: randomised controlled trial

Participants

Diagnosis: DSM-IV diagnosis of somatisation disorder
Method of diagnosis: participants (18-70 years) with English fluency and literacy, a DSM-IV diagnosis
for somatoform disorder and a CGI-SD score ≥ 4 were included
Exclusion criteria: unstable major medical condition, medication regimen that has not been stable
for at least 2 months prior to baseline, active suicidal ideation, history of psychosis, current psychoactive substance dependence, pregnant women or attempting to conceive, participants in psychotherapy
concurrent with the period between baseline and 3 months appointments
Total number randomised: 84
Age: for intervention group, M = 45.5 (SD = 8.5); for control group, M = 47.9 (SD = 11)
Sex: 89% women; 11% men for intervention group 84% women (n = 36), for control group 95% (n = 39)
Severity of symptoms at baseline: not reported
Duration of symptoms at baseline: for intervention group M = 24.95 (SD = 11.54) years, for control
group M = 25 (SD = 15.12) years
Setting: participants were recruited through medical clinics and through advertisements in the community (70% referred by physician), after informed consent they received a telephone screening interview. Treatment: department of Psychiatry of medical school
Location: New Jersey, USA
Number of treatment centres: 1
Co-morbidities: 65% current co-morbid DSM-IV axis I disorder; 70% (n = 30) for intervention group,
59% (n = 24) for control group
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(Continued)

Adjunctive therapy: not mentioned
Adjunctive medication: not mentioned
Interventions

Participants were randomly assigned to either
1. CBT + PCI (n = 43)
Duration: 10 sessions during a period of 3 months
Treatment protocol: CBT: manualised intervention for people with somatoform disorder, with detailed guidelines for each session, focused on stress management, activity regulation, emotional
awareness, cognitive restructuring, and interpersonal communication (Allen 2006, refs 5 and 6 for details)
PCI: standard consultation letter sent to the treating physician including recommendations for the ongoing treatment (Allen 2006, Table 1 for details)
Therapist: 4 therapists, master- or doctoral-level psychologists with at least 3 years of supervised training in CBT. All received a special training in CBT for SD before the trial
2. PCI alone (n = 41)
Duration: NA
Treatment protocol: standard consultation letter sent to the treating physician including recommendations for the ongoing treatment (Allen 2006, Table 1 for details).
Therapist/face-to-face contact: none

Outcomes

Time points for assessment: baseline and 3 months, 9 months, 15 months after baseline
Primary outcome:
1. severity of somatisation (CGI-SD)
2. improvement (CGI-SD)
Secondary outcome:
1. participants' rating of physical functioning (MOS-36)
2. severity of somatic symptoms (SSS)
3. healthcare utilisation (medical records)
Potential mediator
1. participant expectations of improvement

Notes

Date of study: September 1999 - April 2003
Funding source: National Institute of Mental Health
Declarations of interest among the primary researchers: none

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Computer-generated random number sequence was used
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Allocation concealment
(selection bias)

Unclear risk

Not mentioned

Blinding of participants
and personnel (performance bias)
All outcomes

High risk

Participants and therapists were not blinded

Blinding of outcome assessment (detection bias)
All outcomes

High risk

Study personnel were masked to participants treatment condition (independent evaluators), but participants were not blinded, and most outcomes were
participant reported

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

< 20% missing per follow-up moment

Selective reporting (reporting bias)

Low risk

All intended outcomes reported

Treatment fidelity

Low risk

The treatment was described in a manual containing detailed guidelines for
the conduct of each session (Allen 2006, page 1513)

Researcher allegiance

Low risk

No indication that researchers had a preference for 1 of the treatment modalities

Other bias

Low risk

No other sources of bias

Burton 2012
Methods

Study design: randomised controlled trial

Participants

Diagnosis: medically unexplained symptoms (according to a PHQ-14 score > 10 and a GP check)
Method of diagnosis: adults aged 18-65 years and registered with participating practices were eligible
if they met all 3 criteria: 1. they had been referred at least twice to specialists in the preceding 3 years;
2. they currently reported multiple physical symptoms (PHQ > 10); and 3. their GP believed that their
symptoms were unlikely to be adequately explained by physical disease
Exclusion criteria: participants who were unable to leave the house independently, other health or
social problems precluded an invitation to take part in a study, thoughts of self harm more than a few
times in a week (PHQ-9), current self reported alcohol or drug problems, and current or planned engagement in psychological therapy
Total number randomised: 32
Age: for intervention group, M = 45.9 (SD = 12.7); for control group, M = 49.2 (SD = 10.1)
Sex: for intervention group 56.3% women (n = 9), 43.7% men (n = 7); for control group 75% women (n =
12), 25% men (n = 4)
Severity of symptoms at baseline: PHQ-14 score for intervention group M = 13.9 (SD = 3.3), for control
group M = 14.7 (SD = 2.6)
Duration of symptoms at baseline: not reported
Setting: selection in 7 participating practices in primary care (selection based on database search,
postal questionnaire, and check for exclusion criteria by GP), treatment in a secondary care outpatient
symptoms clinic
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Location: North-east Edinburgh, Scotland
Number of treatment centres: 1
Co-morbidities:
Participants with PHQ-9 score > 10 (indicating major depressive disorder: for intervention group 31% (n
= 5); for control group 56% (n = 9)
Participants with GAD-7 score > 10 (indicating generalised anxiety disorder): for intervention group 19%
(n = 3); for control group 31% (n = 5)
Adjunctive therapy: participants in both arms continued to receive usual care from their registered
general practice. This included referral for investigation or treatment of symptoms as the GP deemed
appropriate
Adjunctive medication: none reported
Interventions

Participants were randomly assigned to either
1. Treatment in the symptoms clinic (n = 16)
Duration: 4 sessions, the first session of 1 hour and further sessions of 20 minutes, during a period of 3
months
Treatment protocol: the consultations were structured to first hear the participant's experience of
illness then to propose and negotiate constructive explanations of physical symptoms. These explanations were used as the basis for simple cognitive and behavioural actions to modify symptoms and
their impact. No specific attempt was made to screen for common mental disorders; however, participants were encouraged to describe their emotional responses to symptoms and other events, and diagnostic labels such as depression were discussed collaboratively with the participant rather than imposed by the doctor (see Burton 2012, ref 14 for theoretical basis).
Therapist: an experienced GP with special interest in MUS
2. Usual care (n = 16)
Duration: NA
Treatment protocol: NA
Therapist: NA

Outcomes

Time points for assessment: baseline and 3 months after baseline
Primary outcome:
(systematic identification of participants, trial recruitment and retention, acceptability to participants
(Client Satisfaction Questionnaire))
1. number and severity of physical symptoms (PHQ-14)
2. subjective physical and mental health (SF-12)
3. depressive symptoms (PHQ-9)
4. generalised anxiety (GAD-7)

Notes

Date of study: August 2009 - May 2010
Funding source: Chief Scientist Office
Declarations of interest among the primary researchers: none reported
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Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Randomisation was carried out by automated telephone system using blocked
allocation with variable block size

Allocation concealment
(selection bias)

Low risk

Participants were randomised to either usual care or intervention by the researcher (WN). Treatments were performed by a doctor (CB)

Blinding of participants
and personnel (performance bias)
All outcomes

High risk

Participants and personnel could not be blinded

Blinding of outcome assessment (detection bias)
All outcomes

High risk

Participants were not blinded, and most outcomes were participant reported

Incomplete outcome data
(attrition bias)
All outcomes

High risk

In the intervention group, outcome data were analysed for 11 out of 16 participants. Missing: 31.25% (> 20%)

Selective reporting (reporting bias)

Low risk

All intended outcomes reported

Treatment fidelity

High risk

The consultations were structured, but no protocol or manual has been used
(Burton 2012, page 3)

Researcher allegiance

Unclear risk

The author was also the therapist performing the intervention in the intervention group

Other bias

Low risk

No other sources of bias

Escobar 2007
Methods

Study design: randomised controlled trial

Participants

Diagnosis: MUS (abridged somatisation disorder)
Method of diagnosis: clinicians referred participants when they thought symptoms were a source of
distress OR suspected they had a psychiatric origin. Participants were then interviewed using PHQ and
PRIME-MD, participants were eligible if they had ≥ 4 unexplained symptoms for men and ≥ 6 for women
Exclusion criteria: severe psychiatric diagnosis, requiring more intensive intervention of major physical disorder that explains any of the symptoms
Total number randomised: 172
Age: for intervention group, M = 41.0 (SD = 12.7); for control group, M = 39.6 (SD = 13.4)
Sex: 88% women; 12% men; 86.2% women in intervention group (n = 75); 89.4% women in control
group (n = 76).
Severity of symptoms at baseline:baseline PHQ-15 score for intervention group M = 14.17 (95% CI =
13.03 to 15.32), for control group M = 13.98 (95% CI = 12.82 to 15.13)
Duration of symptoms at baseline: not reported
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Setting: recruited from 2 university based primary care clinics, intervention at Psychiatry department
Location: New Brunswick, New Jersey, USA
Number of treatment centres: 1
Co-morbidities: 92% had a current co-morbid DSM-IV axis I disorder; 92.0% of intervention group (n =
80), 91.8% of control group (n = 78)
Adjunctive therapy: not mentioned
Adjunctive medication: not mentioned
Interventions

Participants were randomly assigned to either
1. CBT + psychiatric consultation letter (n = 87)
Duration: 10 sessions of 50 minutes (first session 90 minutes) during 10-20 weeks (mean of 3 months)
Treatment protocol: standardised CBT intervention according to manual, focusing on reduction of reduction of physical distress and somatic pre-occupation, through training in relaxation techniques, activity regulation, facilitation of emotional awareness, cognitive restructuring and interpersonal communication. Details in book Woolfolk et al. (Woolfolk 2007, ref 18).
Consultation letter: a standard consultation letter was sent to the treating primary care physician, originally developed by Smith et al. (Escobar 2007, ref 13), including recommendations about taking care of
people with MUPS
Therapist: therapists received training on the intervention protocol from 2 of the authors. Therapists'
treatment adherence to the study protocol was rated routinely during the study from evaluations of
taped sessions
2. Usual clinical care + psychiatric consultation intervention (n = 85)
Duration: NA
Treatment protocol: a standard consultation letter was sent to the treating primary care physician
(see above)
Therapist/face-to-face contact: none (other than usual care)

Outcomes

Time points for assessment: baseline and 3 months, 9 months, after baseline
Primary outcome:
1. severity of somatisation (CGI + PHQ-15)
2. improvement of physical symptoms (CGI - improvement)
Secondary outcome:
1. participants' rating of physical functioning (physical subscale of MOS-10)
2. severity of somatic symptoms (VAS)
3. anxiety and depression (HAM-A and HAM-D)

Notes

Date of study: recruitment took place from January 2001 through to February 2005, follow-up until the
end of 2006
Funding source: National Institute of Mental Health
Declarations of interest among the primary researchers: none reported
See Allen 2006 (similar study, same research group)
Additional data provided by Escobar (June 2014)
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Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Computer-generated random number sequence

Allocation concealment
(selection bias)

Unclear risk

No information provided

Blinding of participants
and personnel (performance bias)
All outcomes

High risk

Participants and personnel were not blinded

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

Outcome assessors were blinded (but had to ask participants…)

Incomplete outcome data
(attrition bias)
All outcomes

High risk

21-24% loss to follow-up directly after treatment; 41-48% loss to follow-up 6
months later

Selective reporting (reporting bias)

Low risk

CGI scores not reported (but provided later by first author)

Treatment fidelity

Low risk

Treatment sessions followed a manual with step-by-step guidelines for each
session (Escobar 2007, ref 18)

Researcher allegiance

Low risk

No indication that researchers had a preference for 1 of the treatment modalities

Other bias

Low risk

No other sources of bias

Fjorback 2013
Methods

Study design: randomised controlled trial

Participants

Diagnosis: chronic multi-organ BDS
Method of diagnosis: participants received a 5-7 hour bio-psycho-social assessment, including a laboratory screening battery, schedules for clinical assessment in neuropsychiatry (SCAN)-diagnostic interview, as well as a physical and neurological examination. Participants (aged 20-50 years) with chronic
(≥ 2 years) multi-organ type BDS and moderate-to-severe impairment in daily living were eligible for inclusion
Exclusion criteria: severe psychiatric morbidity, current alcohol or drug abuse, pregnancy, non-Scandinavian origin, no informed consent
Total number randomised: 120
Age: for intervention group, M = 38 (SD = 9); for control group, M = 40 (SD = 8)
Sex: 80% women; 20% men in both study groups, 47 women in intervention group, 48 in control group
Severity of symptoms at baseline: all participants in both study groups had a somatisation disorder
according to ICD-10 codes. In the intervention group, 95% had a somatisation disorder according to the
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DSM-IV codes (n = 56), in the control group 95% (n = 57). 5% of intervention group (n = 3) and 5% of control group (n = 3) had an undifferentiated somatoform disorder (DSM-IV codes)
Duration of symptoms at baseline: for intervention group M = 12 (SD = 10.6), for control group M = 15
(SD = 12.6) years
Setting: primary care physicians and hospital wards referred participants both from rural and urban
areas. Intervention took place at the Research Clinic for Funcional Disorders and Psychosomatics in
Aarhus University Hospital
Location: Arhus region, Denmark
Number of treatment centres: 1
Co-morbidities: 71% of intervention group (n = 42) and 62 % (n = 37) of control group had lifetime psychiatric co-morbidity. 22% of intervention group (n = 13) and 20% of control group (n =12) had a current
major depressive disorder (DSM-IV codes). 24% of intervention group (n = 14) and 23% of control group
(n = 14) had a current anxiety disorder (DSM-IV codes)
Adjunctive therapy/medication: consultation letter; letter to social authorities, when needed; advise
to taper off morphine derivatives and benzodiazepines (all also in comparison group)
Interventions

Participants were randomly assigned to either
1. Mindfulness therapy (n = 59)
Duration: 8 weekly session and 1 in week 12 (3.5 hours each) during a period of 12 weeks
Treatment protocol: participants received information about the nature, course, and treatment of
BDS, a treatment manual, 9 group treatment modules based on a mindfulness-based stress reduction
and a cognitive-behavioural approach (closely following the manual by Jon Kabat Zinn (Fjorback 2013,
ref 22, 36, 36). A consultation letter was sent to participants' primary care physicians, and letters to social authorities were sent when needed (see Fjorback 2013 Table 1 for details)
Therapist: 2 psychiatrists with experience in BDS and CBT and in psychotherapy of meditation
2. Enhanced TAU (n = 60) (see Fjorback 2013 Figure 1 for details)
Duration: 1 x 2-hour session
Treatment protocol: participants received information about the nature, course, and treatment of
BDS, a consultation letter to participants' primary care physicians, letters to social authorities when
needed, an individual CBT treatment plan according to a manual and an individual psychiatric consultation within the first month after clinical assessment (see Fjorback 2013 Figure 1 for details)
Therapist: psychiatrist

Outcomes

Time points for assessment: baseline and 3 months, 9 months, 15 months after baseline
Primary outcome:
1. mean change in SF-36 PCS between baseline and 15 months
Secondary outcome:
1. change in other health-related quality of life measures of the SF-36
2. illness worry (WI-8)
3. physical symptoms (SCL-90-R Somatisation Subscale)
4. severity of depression and anxiety (SCL-8)
5. participants reporting improvement (greater than half a SD)
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Notes

Date of study: recruitment took place between April 2007 and September 2008, follow-up until the end
of 2009
Funding source: Danish Agency for Science Technology and Innovation, Aase and Ejnar Danielsens
Fund, Trygfonden
Declarations of interest among the primary researchers: none reported

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Randomisation was prepared by a statistician

Allocation concealment
(selection bias)

Low risk

They used pre-defined concealed random numbers tied to consecutive assessments of participants resulting in opaque envelopes numbered in succession
containing assigned treatment

Blinding of participants
and personnel (performance bias)
All outcomes

High risk

Participants and personnel were not blinded, given difference in treatment
content, intensity, and duration

Blinding of outcome assessment (detection bias)
All outcomes

High risk

All outcomes were participant reported, and these were not blinded

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

> 20% no data at follow up, but multiple imputation may have solved this
problem

Selective reporting (reporting bias)

Unclear risk

No protocol available. Secondary outcome probability of change > 0.5 SD predefined?

Treatment fidelity

Low risk

Treatment followed a model based on a manual (Fjorback 2013, table 1 and ref
39)

Researcher allegiance

Low risk

No indication that researchers had a preference for 1 of the treatment modalities

Other bias

Low risk

No other sources of bias

Kashner 1995
Methods

Study design: randomised controlled trial

Participants

Diagnosis: somatisation disorder
Method of diagnosis: inclusion criteria were diagnosis of somatisation disorder, history of ≥ 13 unexplained symptoms, the first beginning < 30 years of age, severe enough to seek treatment, take medication, or reduce functioning. This was determined by a research psychiatrist, using a checklist of 37
items that made up diagnostic criteria of somatisation disorder, according to DSM-III-R criteria
Exclusion criteria: the absence of a primary care provider who agreed to allow the research team to
see the participant, lack of transportation to the medical centre, indication of moving out of town during study
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Total number randomised: 70
Age: mean age 44.2 years (no SD provided)
Sex: 84% women (n = 59); 16% men (n = 11)
Severity of symptoms at baseline: inclusion criterion: ≥ 13 unexplained symptoms
Duration of symptoms at baseline: inclusion criterion: 1 symptom starting before age 30 years
Setting: recruitment: internists, GPs, and general population (through advertisements in local media).
Treatment: at medical centre
Location: Central Arkansas, USA
Number of treatment centres: 1
Co-morbidities: unknown
Adjunctive therapy: not mentioned
Adjunctive medication: not mentioned
Co-intervention: none reported
Interventions

Participants were randomly assigned to either
1. Group therapy intervention + consultation letter (n = 44)
Duration: 8 small group sessions of 2 hours every other week, during a 4-month period
Treatment protocol: the overall goals were to develop a source of peer support, share methods of coping with physical problems, enable participants to increase their ability to perceive and express emotion, and enjoy the experience of participating in the group. Treatment in groups of 4-6, according to
a structured protocol, with a class atmosphere, including didactic presentations, small group discussions, therapy exercises, and group discussions. See Kashner 1995 p.464-5 for details
Co-intervention (both groups): a standard psychiatric consultation letter was sent to the primary care
physician, diagnosing the participant with somatisation disorder and including recommendations for
its management
Therapist: master's level clinicians
2. Consultation letter only (n = 26)
Co-intervention (both groups): standard psychiatric consultation letter sent to primary care physician,
diagnosing the participant with somatisation disorder and including recommendations for its management
Duration: NA
Treatment protocol: NA
Therapist: NA

Outcomes

Time points for assessment: baseline and 4 months, 8 months and 12 months after baseline
Outcomes:
(unclear what is primary and what is secondary)
1. RAND Health Status (4 domains)
2. days in bed (count)
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3. healthcare utilisation (costs)
Notes

Date of study: started in 1987, end unclear (healthcare costs were adjusted for inflation using 1990 dollar rates)
Funding sources: Robert Wood Johnson Foundation, National Institute of Mental Health, VA Health
Services Research and Development Program for Mental Health
Declarations of interest among the primary researchers: not reported

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

Not reported

Allocation concealment
(selection bias)

Unclear risk

Not reported

Blinding of participants
and personnel (performance bias)
All outcomes

High risk

Participants and personnel not blinded to intervention

Blinding of outcome assessment (detection bias)
All outcomes

High risk

Outcome assessors did not know whether participant was in experimental or
control group, but most outcomes were participant reported and these were
not blinded

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

All participants completed study

Selective reporting (reporting bias)

High risk

Days in bed described as assessed but no results reported

Treatment fidelity

Low risk

Treatment was based on a structured protocol developed before the study
(available from the authors)

Researcher allegiance

Low risk

No indication that researchers had a preference for 1 of the treatment modalities

Other bias

Low risk

No other sources of bias

Katsamanis 2011
Methods

Study design: randomised controlled trial

Participants

Diagnosis: subthreshold somatisation disorder (abridged somatisation)
Method of diagnosis: participants (18-70 years old) were eligible if no major medical illness explained
symptoms after detailed physical and laboratory assessment; individuals must have met criteria for ≥ 4
MUPS out of the 42 somatic symptoms listed in the CIDI rated as currently present if males and at least
6 if female, according to a diagnostic interview
Exclusion criteria: history of alcohol/drug abuse (within last 12 months), bipolar or psychotic, unstable medical condition, pregnancy, active suicidal ideation
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Total number randomised: 48 (10 dropped out, baseline data reported for only 38)
Age: intervention group 83% < 40 years (n = 15); control group 40% < 40 years (n = 8)
Sex: 79% women; 21% men; for intervention group 83.3% women (n = 15), for control group 75.0% (n =
15)
Severity of symptoms at baseline: unclear, participants in both groups met a CGI rating of 4, which
equals moderate somatisation
Duration of symptoms at baseline: not described
Setting: participants were recruited from primary medical clinics and community (advertisements).
Treatment: department of psychiatry of a medical school
Location: New Jersey, USA
Number of treatment centres: 1
Co-morbidities: 55% met criteria for severe depression (n = 21, HAM-D 17 criteria), 40% for mild-tomoderate depression (n = 15, HAM-D 17 criteria) and 85% for significant anxiety (n = 23, HAM-A criteria)
Adjunctive therapy: not mentioned
Adjunctive medication: psychotropic medication were allowed (Katsamanis 2011, table 3)
Interventions

Participants were randomly assigned to either
1. Psychophysiological treatment + psychiatric consultation intervention (PCI) (n = 24)
Duration: 10 weekly sessions during a period of 10 weeks
Treatment protocol: psychophysiological treatment: treatment consisted of a manualised intervention, described to participants as an intervention which comprises of a set 'self regulation' techniques
that are specifically targeted at particular symptoms of body systems, aiming to assist in coping with
physical discomfort and stress (Katsamanis 2011, page 221 for details)
PCI: a standard consultation letter was sent to the principal treating physician making recommendations for the ongoing treatment (Katsamanis 2011, Table 1 for details)
Therapist: 4 therapists, either master or doctoral level psychologists, 3 of them certified as biofeedback clinicians with at least 3 years of supervised training in psychophysiological treatment
2. PCI alone (n = 24)
Duration: NA
Treatment protocol: standard consultation letter sent to the treating physician including recommendations for the ongoing treatment (Katsamanis 2011, table 1 for details).
Therapist: NA

Outcomes

Time points for assessment: baseline, halfway the intervention (5 weeks) and at the end of treatment
(10 weeks)
Primary outcome:
1. severity of somatisation (CGI-SD, clinician rated)
Secondary outcome:
1. level of depression and anxiety (HAM-D and HAM-A)
2. participants' rating of physical functioning (MOS, SF-36)
3. participants' rating of mental functioning (MOS, SF-36)
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Notes

Date of study: the study took place between June 2006 and August 2008
Funding source: National Institue of Mental Health
Declarations of interest among the primary researchers: design based on Allen. Cross-over group
(receiving treatment after wait condition) not used

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Computer-generated random number sequence

Allocation concealment
(selection bias)

Unclear risk

Not reported

Blinding of participants
and personnel (performance bias)
All outcomes

High risk

Personnel and participants not blinded

Blinding of outcome assessment (detection bias)
All outcomes

High risk

Outcome assessors were masked but almost all outcomes were participant reported

Incomplete outcome data
(attrition bias)
All outcomes

High risk

10/48 dropped out and for several outcomes even more (> 20%)

Selective reporting (reporting bias)

Low risk

All intended outcomes reported

Treatment fidelity

Low risk

Treatment was based on a manual, containing guidelines, developed before
the study (available from the authors)

Researcher allegiance

Low risk

No indication that researchers had a preference for 1 of the treatment modalities

Other bias

Unclear risk

Large difference in age between groups suggests randomisation failed

Kolk 2004
Methods

Study design: randomised controlled trial

Participants

Diagnosis: multiple medically unexplained symptoms
Method of diagnosis: participants with relatively recent onset (3-12 months) of symptoms were tested for eligibility was assessed with a standardised interview and had to fit to 3 additional criteria: 1. the
GP confirmed the medically unexplained nature of their symptoms presented at enrolment, 2. between
18-60 years of age, 3. sufficient understanding of the Dutch language
Exclusion criteria: current psychotherapy or a primary diagnosis of mood, anxiety or psychotic disorder requiring treatment
Total number randomised: 106 (4:1)
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Age: for intervention group, M = 35.5 (SD = 9.4); for control group, M = 35.0 (SD = 8.9)
Sex: 69% women; 31% men; for intervention group 67% women (n = 54), for control group 78% women,
(n = 14)
Severity of symptoms at baseline: not described
Duration of symptoms at baseline: not described
Setting: recruited in general practices and via advertisements in open population (about 50/50 from
each source). Treatment: department of Clinical Psychology of a university
Location: Amsterdam, the Netherlands
Number of treatment centres: 1
Co-morbidities: in intervention group, participants had M = 2.34 (SD = 1.9) chronic diseases, in control
group, M = 1.89 (SD = 1.7)
Adjunctive therapy: not mentioned
Adjunctive medication: not mentioned
Interventions

Participants were randomly assigned to either
1. Psychological intervention (n = 83)
Duration: maximum 12 x 1-hour sessions once a week or every 2 weeks during a maximum period of 6
months
Treatment protocol: depending on therapist (1 of 15 qualified therapists): cognitive behavioural,
client-centred or eclectic therapy, reflecting usual treatment practice
Therapist/face-to-face contact: 1 out of 15 trained therapists
2. Usual care (n = 23)
Duration: NA
Treatment protocol: after the intake, participants were referred back to the GP for care as usual, intake reports were also sent to GP
Therapist: 1 of 15 trained therapists

Outcomes

Time points for assessment: baseline and 6 and 12 months after baseline
Primary outcome:
1. severity of somatisation (somatisation scale of the SCL-90)
Secondary outcome:
1. self reported psychological symptoms (anxiety and depression: SCL-90)
2. registered unexplained and explained symptoms in general practice (database)
3. GP consultations (database)

Notes

Date of study: unclear
Funding source: Nationaal Fonds Geestelijke Volksgezondheid / ZAO Zorgverzekeringen
Declarations of interest among the primary researchers: not reported

Risk of bias
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Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Random number table

Allocation concealment
(selection bias)

Low risk

Sealed envelopes, opened after pretest

Blinding of participants
and personnel (performance bias)
All outcomes

High risk

Participants and personnel could not be blinded

Blinding of outcome assessment (detection bias)
All outcomes

High risk

Self report questionnaires mostly

Incomplete outcome data
(attrition bias)
All outcomes

High risk

> 20% drop-outs

Selective reporting (reporting bias)

Low risk

All intended outcomes reported

Treatment fidelity

High risk

Treatment depended on therapist, no manual or protocol was used

Researcher allegiance

Low risk

No indication that researchers had a preference for 1 of the treatment modalities

Other bias

Low risk

No other sources of bias

Lidbeck 1997
Methods

Study design: randomised controlled trial

Participants

Diagnosis: somatisation disorder
Method of diagnosis: participants received an interview and a physical examination. Participants
(30-60 years old) were eligible in case of presence of somatisation disorder in accordance with the definition of functional somatic symptoms and ≥ 1 symptoms fulfilling the criteria of specific functional disorders as outlined in the International Classification of Health Problems for Primary Care-2.
Exclusion criteria: major mental disorder, current psychological of psychiatric treatment, acute or
transient functional symptoms, drug abuse, chronic pain disorder, inability to speak Swedish fluently
Total number randomised: 50
Age: for intervention group, M = 43.8 (SD = 9.3); for control group, M = 44.6 (SD = 7.4)
Sex: 84% women; 16% men; for intervention group 84.8% (n = 28) female, for control group 82.4% female (n = 14)
Severity of symptoms at baseline: in intervention group 14/33 participants had ≥ 4 symptoms
(42.4%), in the control group 9/17 participants had ≥ 4 symptoms (52.9%).
Duration of symptoms at baseline: in the intervention group the mean duration of illness was 9.2
years, in the control group 6.6 years.
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Setting: recruitment: GPs and hospital doctors; treatment: outpatient clinic of Preventive Medicine
Unit at Helsingborg County Hospital
Location: Helsingborg, Sweden
Number of treatment centres: 1
Co-morbidities: 19/50 (38%) of all participants were previously treated by psychologist/psychiatrist
Adjunctive therapy: not mentioned
Adjunctive medication: allowed and recorded
Interventions

Participants were randomly (2 : 1) assigned to either
1. Group therapy using a short cognitive-behavioural treatment model (n = 43)
Duration: 8 weekly sessions of 3 hours, and 1 final session after 3 months
Treatment protocol: group sessions of CBT focused on reducing dread of somatic diseases and included the following items: 1. thorough physical examination, 2. education to explain stress symptoms in
order to enable cognitive restructuring, 3. relaxation training (Lidbeck 1997, table 2 for details)
Therapist: a physician (the author), who was specialised in internal, family, and social medicine and
who had received training in stress relaxation
2. Waiting list control group (n = 17)
Duration: NA
Treatment protocol: NA
Therapist: NA

Outcomes

Time points for assessment: baseline and 3 months, 9 months after baseline
Outcomes:
1. social problems (SPQ)
2. illness behaviour (IBQ)
3. anxiety and depression (HADS)
4. sleep disturbance (SDI)
5. medication usage (questionnaire)

Notes

Date of study: unclear (probably early 1990s)
Funding source: not mentioned
Declarations of interest among the primary researchers: not mentioned
Lidbeck 2003 provides 1.5-year follow-up data, but only for intervention group

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

"using pair-wise grouping, i.e. subjects with similar symptoms, duration of
symptoms, age etc, were randomly allotted to either the treatment or the control group" (personal communication with Lidbeck)
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Allocation concealment
(selection bias)

Low risk

"randomization was carried out independently by a nurse who was not participating in the study"(Lidbeck 1997, p.17)

Blinding of participants
and personnel (performance bias)
All outcomes

High risk

Participants and personnel were not blinded

Blinding of outcome assessment (detection bias)
All outcomes

High risk

Participants filled in questionnaires and were not blinded

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Only 1 drop-out, no missing data

Selective reporting (reporting bias)

Low risk

All intended outcomes reported

Treatment fidelity

Unclear risk

Treatment was structured, but no information provided about a manual

Researcher allegiance

Unclear risk

The author was also the therapist performing the intervention in the intervention group

Other bias

Low risk

No other sources of bias

Martin 2007
Methods

Study design: randomised controlled trial

Participants

Diagnosis: multiple somatoform symptoms
Method of diagnosis: participants were selected after presentation of ≥ 2 MUPS in the last 6 months,
leading to significant clinical distress, according to their GP or to a screening questionnaire. A diagnostic interview (IDCL and Mini-DIPS) was used to assess study criteria and DSM-5 psychiatric diagnoses
Exclusion criteria: severe current medical condition, chronic medical disease explaining the symptoms, psychotic symptoms, substance dependence
Total number randomised: 140
Age: for intervention group, M = 45.7 (SD = 13.6); for control group, M = 51.7 (SD = 15,9) (significant difference at P value < 0.05)
Sex: for intervention group 68.6% female (n = 48); for control group, 81.4% female (n = 57)
Severity of symptoms at baseline: number of somatoform symptoms, lifetime: for intervention group
M = 7.6 (SD = 3.9), for control group M = 6.6 (SD = 3.6); DSM-IV Somatoform Disorder: for intervention
group 91.4% (n = 64), for control group 87.1% (n = 61)
Duration of symptoms at baseline:years from onset of somatoform symptoms: for intervention group
M = 9.2 (SD = 11.2), for control group M = 11.8 (SD = 12.8)
Setting: participants were recruited in primary care practices, general population (news reports), or
via 'other ways', treatment took place at an outpatient treatment centre in the university hospital (secondary care)
Location: Marburg, Germany
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Number of treatment centres: 1
Co-morbidities: affective disorder: for intervention group 66.7% (n = 46); for control group 52.2% (n =
36)
DSM-IV anxiety disorder: for intervention group 41.4% (n = 29); for control group 32.9% (n = 22)
Adjunctive therapy: none reported
Adjunctive medication: none reported
Interventions

Participants were randomly assigned to either
1. CBT (n = 70)
Duration: 1 session of 3-4 hours, 2 weeks after baseline
Treatment protocol: treatment consisted of 1 session in groups of 2-4 participants. Treatment followed a structured manual with 5 central modules: psychophysiological explanation of symptoms, relaxation, importance of cognition, activity instead of avoidance behaviour, and treatment options and
healthcare utilisation (Martin 2007, page 296 for details).
Therapist: clinical psychologist or medical specialist for psychotherapeutic medicine, both licences
CBT specialists
2. Standard medical care (n = 70)
Duration: NA
Treatment protocol: NA
Therapist: NA

Outcomes

Time points for assessment: baseline, 4 weeks, and 6 months after baseline
Primary outcome:
1. healthcare utilisation (structured interview, not at 4 weeks)
2. number and severity of somatoform symptoms (BSI and SOMS-7)
Secondary outcome:
1. health anxiety (WI)
2. general psychopathological symptoms (GSI)
3. Depressive symptoms (BDI)
4. health-related internal control (KKG)

Notes

Date of study: trial conducted between August 2001 - December 2002
Funding source: German Ministry of Research, Education and Science
Declarations of interest among the primary researchers: none reported

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Randomisation was based on a predefined list of binary variables, using blocking procedures to ensure comparable sample sizes (page 295)
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Allocation concealment
(selection bias)

Low risk

Study assistants enrolled and assigned participants to the groups according to
the randomisation list

Blinding of participants
and personnel (performance bias)
All outcomes

High risk

Participants and personnel could not be blinded

Blinding of outcome assessment (detection bias)
All outcomes

High risk

Participants were not blinded, and most outcomes were participant reported

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Loss to follow-up at 6 months 15.7% in both groups (< 20%)

Selective reporting (reporting bias)

Low risk

All intended outcomes are reported

Treatment fidelity

Low risk

The treatment followed a structured manual with 5 central modules (in German), available on request (Martin 2007, page 296)

Researcher allegiance

Low risk

No indication that researchers had a preference for 1 of the treatment modalities

Other bias

Low risk

No other sources of bias

Moreno 2013
Methods

Study design: randomised controlled trial

Participants

Diagnosis: DSM-IV diagnosis of abridged somatisation disorder
Method of diagnosis: participants (aged 18-65 years) were eligible if they were able to understand
and read Spanish and fulfilled the criteria for ASD (somatic symptom indexes 4 (men) and 6 (women)).
In addition, they had to be stable on pharmacotherapy in the previous month and needed to sign informed consent. The Othmer-DeSouza test was used as a screening tool
Exclusion criteria: any primary psychiatric diagnosis other than somatoform disorders, severe personality disorder, non-white (not mentioned in design paper), inability to attend intervention sessions
Total number randomised: 168
Age: for individual CBT group, M = 43.1 (SD = 11.4); for group CBT group, M = 49.2 (SD 8.6); TAU control
group, M = 44.1 (SD = 11.7)
Sex: 86% women; 14% men; for TAU group 87.5% women (n = 42), for individual CBT group 82.14%
women (n = 46), for group CBT group 89.06% women, n = 57.
Severity of symptoms at baseline: not described
Duration of symptoms at baseline: most participants had symptoms for > 2 years: for TAU group
79.16% (n = 38), for individual CBT group 87.5% (n = 49), for group CBT group 87.5% (n = 56)
Setting: recruitment in primary healthcare centres. Treatment setting not mentioned, but carried out
by 2 psychologists
Location: provinces of Zaragoza, Mallorca, Huesca in Spain
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Number of treatment centres: unknown
Co-morbidities: approximately 10% had a co-morbid depressive disorder, 40% had a co-morbid anxiety disorder, and 30% had a depressive and anxiety co-morbid disorder
Adjunctive therapy: not mentioned
Adjunctive medication: not mentioned
Interventions

Participants were randomly assigned to either
1. Individual CBT + standardised letter to family doctor (n = 56)
Duration: 10 weekly sessions of 1 hour, during a period of 10 weeks
Treatment protocol: CBT: muscle relaxation training, behaviour modification, emotional mindfulness,
cognitive restructuring, social skills, based on Escobar 1998; standardised letter with treatment advice
for GP based on Smith 1991
Therapist: psychologists
2. Group CBT + standardised letter to family doctor (n = 64)
Duration: 10 weekly sessions of 2 hours, during a period of 10 weeks
Treatment protocol: CBT: muscle relaxation training, behaviour modification, emotional mindfulness,
cognitive restructuring, social skills, based on Escobar 1998; standardised letter with treatment advice
for GP based on Smith 1991
Therapist: psychologists
3. TAU: standardised letter to family doctor only (n = 48)
Duration: NA
Treatment protocol: standardised letter with treatment advice for GP based on Smith 1991
Therapist: NA

Outcomes

Time points for assessment: baseline, after 10 weeks (immediately after treatment) and 6 and 12
months after treatment (i.e. about 9 and 15 months after baseline)
Primary outcome:
1. severity of somatisation (Screening for Somatic Disorders and SSS scale)
2. anxiety and depression (HADS)
Secondary outcome:
1. quality of life (SF-36: reported in Gili 2014)
2. self declared health services (according to design paper (Magallon 2008), but not reported)
3. global improvement (CGI) (according to design paper (Magallon 2008), but not reported)

Notes

Date of study: data collection began in March 2008 and ended in June 2010
Funding source: Red de Investigacion en Actividades de Prvencion y Promocion de la Salud
Declarations of interest among the primary researchers: authors declared that they had no competing interests

Risk of bias
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Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Computer-generated random number sequence (Maggalon 2008, p. 4)

Allocation concealment
(selection bias)

Low risk

Allocation was carried out by an independent person who was not involved in
the study (p.602)
Using central telephone. Sequence will be concealed until interventions are
assigned (Moreno 2013, Magallon 2008, p. 4)

Blinding of participants
and personnel (performance bias)
All outcomes

High risk

Personnel and participants could not be blinded

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

Study personnel that carried our the measurements were unaware of which
treatment the participant was given. GPs were also kept blind to intervention,
as participants were asked not to reveal their treatment condition. However,
some outcomes were participant rated and participants could not be blinded
(Moreno 2013, p. 602)

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

< 20% drop-out, and intention-to-treat analysis with last observation carried
forward

Selective reporting (reporting bias)

High risk

Healthcare use and CGI were mentioned in protocol but not reported
Quality of life reported in Gili 2014

Treatment fidelity

Low risk

There were 2 different treatment conditions following the same protocol: individual and group formats (Moreno 2013, ref 23)

Researcher allegiance

Low risk

No indication that researchers had a preference for 1 of the treatment modalities

Other bias

Low risk

No other sources of bias

Sattel 2012
Methods

Study design: randomised controlled trial

Participants

Diagnosis: DSM-IV diagnosis of multisomatoform disorder
Method of diagnosis: participants were screened with the PHQ-15 and SF-36, then SCID, modified to
check for presence of multisomatoform disorder (at least 3 current somatoform symptoms that are
functionally disabling and that an organic disease or another mental disorder cannot sufficiently explain, and a history of somatoform symptoms over at least 2 years, resulting in healthcare use
Exclusion criteria: insufficient cognitive abilities, severe, chronic and disabling somatic disease or
severe co-morbid mental disorder that caused major impairment in social functioning (e.g. schizophrenia, severe forms of bipolar disorder or substance misuse), risk of suicide, people undergoing psychotherapy at the time of the screening or inability to speak German. In addition, a small number of
people with a DSM-IV diagnosis of hypochondriasis were excluded
Total number randomised: 211
Age: for intervention group, M = 47.9 (SD = 10.8); for control group, M = 48.0 (SD = 12.4)
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Sex: 66% women; 34% men; for intervention group 63% women (n = 67), for control group 69% women
(n = 72)
Severity of symptoms at baseline:number of SCID somatoform symptoms: for intervention group M =
10.0 (SD = 3.9), for control group M = 10.6 (SD = 4.0)
Duration of symptoms at baseline: for intervention group M = 10.4 years (SD = 5.5), for control group
M = 10.8 (SD = 5.5)
Setting: recruited from outpatients departments of neurology and internal medicine as well as from
pain treatment centres and an orthopaedics private clinic. Treatment setting: outpatient departments
of psychosomatic medicine
Location: southern Germany (Munich, Düsseldorf, Hannover, Heidelberg, Münster and Regensburg)
Number of treatment centres: 6
Co-morbidities: unknown
Adjunctive therapy: not mentioned
Adjunctive medication: not mentioned
Interventions

Participants were randomly assigned to either
1. Psychodynamic interpersonal psychotherapy (n = 107)
Duration: 12 weekly sessions, 1st session 90 minutes, other sessions 45 minutes, during a period of 12
weeks
Treatment protocol: manualised treatment consisted of 3 phases: 1. emphasis lay on building a therapeutic relationship with underscoring the legitimacy of bodily complaints and relaxation was introduced, 2. clarifying the participant's emotions, 3. concentrates on termination issues (Sattel 2012, ref
20)
Therapist: 4 psychologists and 4 physicians with at least 3 years of training in psychotherapy, who
were trained in the use of the manual
2. Enhanced medical care (n = 104)
Duration: 3 approximately 30-minute sessions at 6-week intervals
Treatment protocol: participants received education and counselling regarding therapeutic alternatives based on evidence-based guidelines for the treatment of somatoform disorders/functional somatic syndromes in primary and somatic specialist care
Therapist: physicians specifically trained in EMC

Outcomes

Time points for assessment: baseline, 3 months (end of treatment), and 9 months after end of treatment
Primary outcome:
1. SF-36 - PCS at 9 months' follow-up
Secondary outcome:
1. SF-36 - MCS
2. PHQ-15 somatisation module
3. PHQ-9 depression module
4. Health anxiety: WI
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5. doctor visits, use of antidepressants, and use of psychotherapy
Notes

Date of study: between June 2006 and December 2007 participants were selected, follow-up continued until the beginning of 2009
Funding source: German Research Foundation
Declarations of interest among the primary researchers: the authors report no conflicting interests

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Randomisation was computer generated

Allocation concealment
(selection bias)

Low risk

After receiving informed consent, the authors submitted a randomisation request, which was received within 24 hours

Blinding of participants
and personnel (performance bias)
All outcomes

High risk

Participants and personnel were not blinded

Blinding of outcome assessment (detection bias)
All outcomes

High risk

Participant administered questionnaires: blinding impossible

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

< 20% drop-outs, multiple imputation, and intention to treat

Selective reporting (reporting bias)

Low risk

All intended outcomes reported

Treatment fidelity

Low risk

The used treatment manual was developed jointly and pilot-tested over the
course of 3 years (Sattel 2012, page 61)

Researcher allegiance

Low risk

No indication that researchers had a preference for 1 of the treatment modalities

Other bias

Low risk

No other sources of bias

Healthcare use: blinding unclear

Schaefert 2013
Methods

Study design: cluster-randomised controlled trial

Participants

Diagnosis: MUS
Method of diagnosis: participants were eligible in case of: 1. persistent (> 6 months) bodily complaints
without sufficient explanatory peripheral organ pathology (according to GP), 2. MUS as the main treatment issue, 3. PHQ-15 score of ≥ 5, 4. relevant health anxiety on the WI-7 (score ≥ 4), or a combination of
these
Exclusion criteria: age < 18 or > 70 years, living further than 20 miles away from the respective practice; ongoing psychotherapy; substance abuse; severe psychiatric disorder (e.g. major depression, psy-
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chosis, dementia); severe organic disease; inability to complete the questionnaire, or ongoing litigation
due to disability, pension or compensation for personal suffering
Total number randomised: 328
Age: for intervention group, M = 50.8 (SD = 12.0); for control group, M = 46.6 (SD = 12.9)
Sex: for intervention group 75.3% women (n = 128), 24.7% men (n = 42); for control group 74.6%
women (n = 100), 25.6% men (n = 34)
Severity of symptoms at baseline:
somatic symptom severity according to PHQ-15-score:
LOW (0-9): for intervention group 28.2% (n = 48) for control group 30.6% (n = 41)
MEDIUM (10-14): for intervention group 38.2% (n = 65) for control group 35.8% (n = 48)
HIGH (15-30): for intervention group 33.5% (n = 57) for control group 33.6% (n = 45)
Duration of symptoms at baseline: for intervention group M = 6.74 years (SD = 5.4), for control group
M = 5.00 years (SD = 4.6)
Setting: participants were recruited and treated by GPs in primary care
Location: Heidelberg area, Germany
Number of treatment centres: 35 GPs (from 34 practices)
Co-morbidities:
Depressive symptoms: for intervention group 33.5% (n = 57); for control group 43.3% (n = 58)
Generalised anxiety: for intervention group 16.6% (n = 28); for control group 21.8% (n = 29)
Panic disorder: for intervention group 21.8% (n = 29); for control group 17.3% (n = 23)
Musculoskeletal system disorders: for intervention group 45%; for control group 51%
Hypertension: for intervention group 39%; for control group 39%
Endocrine/alimentary/metabolic disorders: for intervention group 34%; for control group 34%
Gastrointestinal system disorders: for intervention group 25%; for control group 29%
Adjunctive therapy: none reported
Adjunctive medication: none reported
Interventions

Participants were randomly assigned to either
1. GP training in diagnosis and management of MUPS and group leading (GP level) + an interpersonal
approach of psychodynamically based therapy (participant level) (n = 183)
Duration: GP level: 4 training sessions, in total 15.5 hours (diagnosis + management of MUPS) + 3 sessions, in total 12 hours (group leading)
participant level: 10 weekly sessions of 90 minutes + 2 booster sessions 3 and 9 months later
Treatment protocol: GP level: guideline based curriculum for training of GPs in diagnosis and management of MUPS, consisting of lectures, discussions and role plays (Schaefert 2013, ref 42 for details) + GP
training in group leading (methodology not described)
Participant level: manualised group intervention consisting of an interpersonal approach of psychodynamically based therapy, with embedded cognitive behavioural elements (Schaefert 2013, table 1 and
ref 43 for details)
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Therapist: GP level: the investigators; participant level: GP + 1-3 psychosomatic specialists (with ≥ 3
years of training in psychosomatic therapy)
2.GP training in diagnosis and management of MUPS (n = 145)
Duration: GP level: 4 training sessions, in total 15.5 hours (diagnosis + management of MUPS)
Treatment protocol: guideline based curriculum for training of GPs in diagnosis and management of
MUPS, consisting of lectures, discussions and role plays (Schaefert 2013, ref 42 for details)
Therapist: GP level: the investigators
Outcomes

Time points for assessment: baseline and 6 months, 12 months after baseline
Primary outcome:
Quality of life (SF-36, PCS and MCS)
Secondary outcome:
Somatic symptom severity (PHQ-15)
Depression (PHQ-9)
Anxiety and panic (PHQ anxiety and panic, only at baseline)
Stress (PHQ stress)
Health anxiety (WI)
Healthcare utilisation (GP documentation and self report)

Notes

Date of study: participant recruitment started in November 2007 in both groups and ended in September 2008 in the intervention group and in December 2009 in the control group, follow-up continued until the end of 2010
Funding source: German Federal Ministry of Education and Research
Declarations of interest among the primary researchers: none reported

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

GPs were unit of randomisation, randomisation was performed in a data and
co-ordinating centre

Allocation concealment
(selection bias)

Low risk

Blinded randomisation was performed by a statistician under independent
management. The GPs were informed by a research assistant

Blinding of participants
and personnel (performance bias)
All outcomes

High risk

No blinding of participants and personnel possible

Blinding of outcome assessment (detection bias)
All outcomes

High risk

Participants were not blinded, and most outcomes were participant reported

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Incomplete data in intervention group at 6 months 20.8%, at 12 months 21.9%
Incomplete data in control group at 6 months 31.8%, at 12 months 25.6%
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Selective reporting (reporting bias)

Low risk

All intended outcomes reported

Treatment fidelity

Low risk

The participating GPs were trained with a guideline-based curriculum in the diagnosis and management of MUS (Schaefert 2013, ref 41, 42)

Researcher allegiance

Unclear risk

Some of the authors were also providing the intervention

Other bias

Low risk

No other sources of bias

Schilte 2001
Methods

Study design: randomised controlled trial

Participants

Diagnosis: somatisation
Method of diagnosis: participants of 20-45 years who had ≥ 15 contacts in the past 3 years and who
had ≥ 5 somatisation symptoms according to a somatisation scale (based on all symptoms listed in
DSM-IIIR)
Exclusion criteria: cancer, AIDS, rheumatoid arthritis, multiple sclerosis, dementia, schizophrenia,
mental disorder, and psychosis. Included people with other chronic diseases, such as asthma, osteoarthritis, or cardiovascular diseases
Total number randomised: 161
Age: for intervention group M = 38 (IQR = 33-41), for control group M = 39 (IQR = 36-41)
Sex: for intervention group 80% female (n = 61), for control group 78% female (n = 59)
Severity of symptoms at baseline: mean somatisation score (scale 0-48): for intervention group M = 20
(IQR = 16-25), for control group M = 22 (IQR = 17-22)
Duration of symptoms at baseline: unknown
Setting: participants were recruited in the registration network of primary physicians (primary care).
the intervention took place at participants' homes
Location: Maastricht area, the Netherlands
Number of treatment centres: 77 participants' homes
Co-morbidities: of the 77 participants who actually received the intervention, 34 had an active depressive or anxiety disorder (16 depressive, 30 anxiety) according to the DSM-IV screening. 2 participants
fulfilled criteria of DSM-IV hypochondriasis and 18 of a DSM-IV chronic benign pain syndrome
Adjunctive therapy: none reported
Adjunctive medication: none reported

Interventions

Participants were randomly assigned to either
1.Disclosure intervention (n = 81):
Duration: unknown
Treatment protocol: treatment consisted of 2 meetings with a disclosure doctor + an optional meeting with the doctor and the GP. They were invited to disclose emotionally important events in their life.
If not mentioned spontaneously, the doctor asked questions about family life, health, work situation,
and childhood
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Therapist: a trained disclosure doctor and in the third session also the GP
2.Usual care (n = 80):
Duration: NA
Treatment protocol: NA
Therapist: NA (care as usual by own GP)
Outcomes

Time points for assessment: baseline, 6, 12 and 24 months after baseline
Primary outcome:
1. Healthcare use (number of visits to all health care)
Secondary outcome:
1. Subjective health (scale)
2. Severity of symptoms (SCL-90 subscore)
3. Depressive symptoms (SCL-90 subscore)
4. Anxiety (SCL-90 subscore)
5. Sick leave (number of weeks of sick leave over the preceding 6 months)

Notes

Date of study: unknown, published in 2001
Funding source: Netherlands Organisation for Scientific research
Declarations of interest among the primary researchers: none reported

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

The randomisation was stratified (1 stratum per practice), using a sequence of
labelled cards in opaque, sealed, numbered envelopes

Allocation concealment
(selection bias)

Low risk

An independent person produced the randomisation envelopes, and the research assistant, who did not apply the intervention, executed the randomisation procedure

Blinding of participants
and personnel (performance bias)
All outcomes

High risk

Although the general practitioners knew which participant received the intervention, they were not told which participants participated as controls. Participants could not be blinded for the intervention

Blinding of outcome assessment (detection bias)
All outcomes

High risk

Participants were not blinded, and most outcomes were participant reported

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

In the intervention group 70/81 (86.4%) participants completed the trial (and
questionnaire at 2 years follow-up)

Selective reporting (reporting bias)

High risk

In the control group 67/80 (83.7%) participants completed the trial (and questionnaire at 2 years' follow-up) (Schilte 2001, page 87) (loss to follow-up < 20%)
Only results at 24 months of follow-up are reported
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Treatment fidelity

High risk

No protocol or manual for treatment (Schilte 2001, page 323)

Researcher allegiance

Low risk

No indication that researchers had a preference for 1 of the treatment modalities

Other bias

Unclear risk

Results were not corrected for baseline imbalances

Schröder 2012
Methods

Study design: randomised controlled trial

Participants

Diagnosis: BDS
Method of diagnosis: participants received a thorough biopsychosocial assessment including a review of all clinical records, a SCAN interview, a physical and neurological examination, and a laboratory
screening battery were performed. Participants aged 20-45 years with chronic (i.e. ≥ 2 years' duration)
BDS of the severe multi-organ type, which requires functional somatic symptoms from at least 3 of 4
bodily systems, and moderate to severe impairment in daily living (Schröder 2012, ref 18 and 19 for details)
Exclusion criteria: severe psychiatric morbidity (psychotic and bipolar disorders, alcohol or drug misuse), people involved in litigation, those who were pregnant and those who were not fluent in the Danish language (operationalised as non-Scandinavian origin)
Total number randomised: 120
Age: for intervention group, M = 35.4 (SD = 6.3); for control group, M = 36.2 (SD = 6.5)
Sex: for intervention group 74% women (n = 40), 26% men (n = 14); for control group 83% women (n =
55), 17% men (n = 11)
Severity of symptoms at baseline: number of functional somatic symptoms: for intervention group M
= 32.3 (SD = 7.5), for control group M = 32.6 (SD = 10.0).
Duration of symptoms at baseline: for intervention group M = 6.7 (IQR = 3-14), for control group M =
9.5 (IQR = 4-15)
Setting: the intervention took place in cooperation with the university general hospital in Aarhus, Denmark. Participants were referred from all primary care physicians and hospital wards in the western
part of Denmark.(primary and secondary care)
Location: Western part of Denmark (Jutland), which covers a population of approximately 2 million
persons living in both urban and rural areas.
Number of treatment centres: unclear
Co-morbidities:
Major depressive disorder: for intervention group 17% (n = 9); for control group 21% (n = 14)
Dysthymia: for intervention group 4% (n = 2); for control group 5% (n = 3)
Anxiety disorder: for intervention group 19% (n = 10); for control group 18% (n = 12)
At least 1 of the above diagnoses: for intervention group 30% (n = 16); for control group 36 (n = 24)
Lifetime psychiatric co-morbidity: for intervention group 57% (n = 31); for control group 61% (n = 40)
Adjunctive therapy: none reported

Non-pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

71

Cochrane

Library
Schröder 2012

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

(Continued)

Adjunctive medication: none reported
Interventions

Participants were randomly assigned to either
1.STreSS intervention (n = 54)
Duration: 9 x 3.5 hour sessions during a period of 4 months
Treatment protocol: 1. Comprehensive lifetime review of case notes and clinical records; 2. Comprehensive biopsychosocial assessment and individualised information about the nature,course and treatment options for the symptoms; 3. Letter to participant's primary care physician and referring doctor
(if not the primary care physician) regarding diagnosis and illness history as well as treatment recommendations in case of co-morbid depression or anxiety; 4. 'Usual care' delivered by primary care physician and specialists; 5. 9 modules of manualised psychotherapy, based on a cognitive-behavioural approach. Each participant was allowed to receive 2 supplemental individual consultations in case of new
important physical symptoms or major psychiatric problems; 6. Letter with management recommendations for functional somatic symptoms sent to primary care physician; 7. Treatment manual, including schedule, symptom diary, educational material, worksheets and homework assignment for the 9
treatment modules; 8. Consultancy service by telephone for primary care physicians and specialists;
9. Close cooperation with social authorities or the participant's employer, when needed (see Schröder
2012a, figure 1 for details)
Therapist: consultants or senior residents in psychiatry with at least 2 years of training in cognitive-behavioural treatment, experience with group treatment and expertise in the field of functional somatic
syndromes. The senior residents were supervised.
2.Enhanced usual care (n = 66)
Duration: 4 months
Treatment protocol: 1. Comprehensive lifetime review of case notes and clinical records; 2. Comprehensive biopsychosocial assessment and individualised information about the nature,course and treatment options for the symptoms; 3. Letter to participant's primary care physician and referring doctor (if
not the primary care physician) regarding diagnosis and illness history as well as treatment recommendations in case of co-morbid depression or anxiety; 4. 'Usual care' delivered by primary care physician
and specialists (see Schröder 2012a, figure 1 for details)
Therapist/face-to-face contact: GP, occasionally assisted by a mental care specialist

Outcomes

Time points for assessment: baseline, 4 months, 10 months, 16 months after baseline
Primary outcome:
1. treatment response (improvement in the SF-36 aggregate score 'physical functioning', 'bodily pain'
and 'vitality')
2. PCS (subscore SF-36)
Secondary outcome:
1. health anxiety (WI)
2. subjective physical symptoms (physical subscale SCL-90)
3. mental well-being (SCL-8, severity of depression and anxiety)

Notes

Date of study: between March 2005 and December 2006 the case notes of all participants referred were
screened for eligibility, follow-up continued until 16 months after
Funding source: Central Denmark Region, the Aarhus University Hospital Research Initiative, the A.P.
Møller Foundation for the Advancement of Medical Science and the Medical Association for the County
of Aarhus
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Declarations of interest among the primary researchers: none reported
Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

In a block randomisation protocol participants were randomised by means of
a computer algorithm that used predefined concealed random numbers and
stratified for gender and psychiatric lifetime co-morbidity status. We used the
ratio 9 : 11 (STreSS vs. enhanced usual care) because we expected a higher attrition rate in those allocated to enhanced usual care

Allocation concealment
(selection bias)

Unclear risk

It was not described who performed the allocation

Blinding of participants
and personnel (performance bias)
All outcomes

High risk

Referring doctors and therapists were aware of the assignment, as were the
participants

Blinding of outcome assessment (detection bias)
All outcomes

High risk

Questionnaires were sent by post and administered by independent research
assistants who were unaware of the allocation of participants. However, participants were not blinded, and most outcomes were participant reported

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Incomplete data in intervention group at total of all time points 20.3% (11 out
of 54 participants)

Selective reporting (reporting bias)

Low risk

All intended outcomes reported

Treatment fidelity

Low risk

Treatment was based on manualised modules (Schröder 2012, appendix)

Researcher allegiance

Low risk

No indication that researchers had a preference for 1 of the treatment modalities

Other bias

Low risk

No other sources of bias

Incomplete data in control group at total of all time points 36.4% (24 out of 66
participants) (see Schröder 2012, figure 2 for details)

Schröder 2013
Methods

Study design: randomised controlled trial

Participants

Diagnosis: multiple somatoform symptoms
Method of diagnosis: participants ≥ 18 years of age with at least 2 somatoform symptoms according to
IDCL (for DSM-IV). For each recorded symptom, the researchers checked whether there was substantial
suffering or impairment. A medical evaluation was performed by a physician to exclude medically explained symptoms
Exclusion criteria: medically explained symptoms, serious concentration or language problems, suicidal tendencies, psychotic symptoms
Total number randomised: 173 (134 actually started treatment, lower numbers in Zaby 2008)
Age: for intention-to-treat sample (n = 134) M = 48.02 years (SD = 12.34) (no baseline imbalances between study groups)
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Sex: for intention-to-treat sample (n = 134) 76.9% women (n = 103), 23.1% men (n = 31) (no baseline imbalances between study groups)
Severity of symptoms at baseline: number of symptoms M = 9.9 (SD = 5.5)
Duration of symptoms at baseline: ≥ 6 months
Setting: participants were consecutively recruited in co-operation with primary care physicians, psychotherapists, and by advertisements in local newspapers in the southwest of Germany
Treatments were conducted in the outpatient treatment centre for psychological intervention at the
University of Landau and the University of Mannheim, Germany
Location: Landau and Mannheim region, Germany
Number of treatment centres: 2
Co-morbidities:
Panic disorder: for intention-to-treat sample 20.1% (n = 27)
Social phobia: for intention-to-treat sample 9.0% (n = 12)
Specific phobia: for intention-to-treat sample 6.0% (n = 8)
Generalised anxiety: for intention-to-treat sample 10.4% (n = 14)
Major depressive disorder: for intention-to-treat sample 18.7% (n = 25)
Adjunctive therapy: participants were free to seek further care
Adjunctive medication: participants were free to seek further care
Interventions

Participants were randomly assigned to either
1. CBT (n = 49)
Duration: manualised group training with 8 weekly sessions of 90 minutes in 8 groups of 4-11 members
Treatment protocol: the CBT used in this study was developed on the basis of theoretical considerations (Deary et al. 2007) and standardised guidelines for psychological therapy of somatoform disorders, as published elsewhere (Rief 1999; Rief 2002; Sharpe 1992). The manual contained detailed guidelines for conducting each session. Aim of treatment was to create a model to understand bodily discomfort, with integrated biological, psychological and social factors (see Zaby 2008, table 1 for extended information about the group sessions).
Therapist: psychological psychotherapists who were supervised regularly
2. Progressive muscle relaxation (n = 41)
Duration: manualised group training with 8 weekly sessions of 90 minutes in 11 groups of 4-11 members
Treatment protocol: the progressive muscle relaxation treatment was based on modifications of Jacobson's original program by Bernstein and Borkovec, following a manual (Zaby 2008). It involved
learning to tense and relax groups of muscles beginning with a large number of small groups (in this
case 16) and then proceeding in steps to a smaller number of large groups (first 7, then 4 groups) (for
details, see Schröder 2013, page 299)
Therapist/face-to-face contact: psychological psychotherapists who were supervised regularly
3. Waiting list control (excluded from analysis, as participants in waiting list group were not randomly
assigned)
Duration: NA
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Treatment protocol: participants with a waiting time for the intervention longer than 4 weeks, less
than 3 months were included in the waiting list group
Therapist/face-to-face contact: NA
Outcomes

Time points for assessment: baseline, directly post-treatment (8 weeks) and 6 months after baseline
Primary outcome:
1. Intensity and number of symptoms (SOMS-7)
Secondary outcome:
1. Depression (HADS-D)
2. Anxiety (HADS-A)
3. Physical and mental health (SF-12, PWB, and MWB subscale)
4. Medical care utilisation in previous 6 months (interview at baseline and 6 months)

Notes

Date of study: participants were recruited from April 2005 until May 2006. Treatments were conducted
between April 2005 and October 2008
Funding source: the study was supported by a grant awarded to Annette Schröder by the German Research Foundation (DFG)
Declarations of interest among the primary researchers: none reported

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

Participants were randomised for CBT or PMR using random sequences, exact method not described. When both groups were full, newly included participants were included in the waiting list group. As this group was not randomly
assigned we excluded data from this group from analysis

Allocation concealment
(selection bias)

Low risk

The randomisation was performed by a person who was not involved in assessment or treatment delivery

Blinding of participants
and personnel (performance bias)
All outcomes

Unclear risk

Participants could not be blinded. Blinding of personnel not described

Blinding of outcome assessment (detection bias)
All outcomes

High risk

Participants were not blinded, and most outcomes were participant reported

Incomplete outcome data
(attrition bias)
All outcomes

High risk

In both intervention groups 23% of participants dropped out before the first
treatment (> 20%)

Selective reporting (reporting bias)

Low risk

All intended outcomes reported

Treatment fidelity

Low risk

CBT and PMR were conducted as a manualised group training (Schröder 2013,
treatment conditions)
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Researcher allegiance

Low risk

No indication that researchers had a preference for 1 of the treatment modalities

Other bias

Unclear risk

Participants were randomised for CBT or PMR. When both groups were full,
newly included participants were included in the waiting list group. In a later
stage, these participants were included in both intervention groups. (source:
email contact with author) As participants are their own control participant
due to this method, we decided to exclude data from the waiting list group
from analysis

Schweickhardt 2007
Methods

Study design: randomised controlled trial

Participants

Diagnosis: somatisation
Method of diagnosis: participants (18-65 years old) were included if they screened positive for the
SOMS-2 and the GHQ-12 and if the attending hospital physician was not able to provide a clear physical
explanation for the complaints. The screening criteria for SOMS were 4 somatoform symptoms for men
and 6 for women, and the cut-off for the GHQ was ≥ 2. Other inclusion criteria were: persistent symptoms for at least 3 months, ≥ 5 annual doctor's visits or 2 hospitalisations during the past year as a result of the respective symptoms and availability for ≥ 6 months
Exclusion criteria: severe mental disorders, e.g. major depression with suicidal ideation, eating disorders, alcohol or substance abuse, an organic disease deemed responsible for most of the symptoms,
psychotherapy - ongoing or completed during the past 3 years, pregnancy and low intellectual capacity
Total number randomised: 91
Age: for intervention group, M = 44.43 (SD = 13.329); for control group, M = 49.22 (SD = 11.084)
Sex: for intervention group 69.4% women (n = 34), for control group 71.4% women (n = 30)
Severity of symptoms at baseline: 55 of the participants (92%) had a somatoform disorder
Duration of symptoms at baseline: unknown
Setting: general hospital (inpatients). Data were collected in the Departments of Neurology, Internal
Medicine, General Medicine and Orthopedics of the University Hospital. A research assistant visited the
participating units 3 times per week and systematically examined all new participants
Location: Freiburg, Germany
Number of treatment centres: 1 (although 4 different departments)
Co-morbidities: diagnostic interviews were conducted with 60 participants (66%). 24 (40%) were had
depression and 18 (32%) had an anxiety disorder
Adjunctive therapy: none reported
Adjunctive medication: none reported

Interventions

Participants were randomly assigned to either
1. Short-term psychotherapeutic intervention (n = 49)
Duration: 5 sessions of approximately 50 minutes, during a period of 2 weeks
Treatment protocol: treatment consisted of a program predominantly based on the reattribution
model, the World Health Organization training package for primary care physicians, cognitive behav-
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ioural techniques and a psychodynamic approach (see Schweickhardt 2007, table 1 for the session topics and ref 29 for the treatment manual)
Therapist: licensed psychotherapists (3 physicians and 2 psychologists), who have been working with
somatising participants for several years
2. Psychoeducational reading material (n = 42)
Duration: NA
Treatment protocol: psychoeducational reading material consisting of 9 pages describing the aetiology, course, and treatment recommendation of somatoform symptoms
Therapist/face-to-face contact: NA
Outcomes

Time points for assessment: baseline, 2 weeks, 3 months and 6 months after baseline
Primary outcome:
1. Changes regarding motivation for psychotherapy (FPTM)
2. Contact with a psychotherapist
Secondary outcome:
1. number and intensity of somatoform symptoms (SOMS-7)
2. changes regarding emotional distress (HADS, GHQ)
3. quality of life (SF-12)

Notes

Date of study: participants were recruited between June 2002 and May 2004. The last follow-up assessments were performed in November 2004
Funding source: this clinical trial was supported by grants from the German Research Association
(Deutsche Forschungsgemeinschaft)
Declarations of interest among the primary researchers: none reported

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Envelopes containing the allocation information were created in a random order. Participants who had fulfilled all inclusion criteria were assigned to the 2
different groups

Allocation concealment
(selection bias)

Low risk

Randomisation was performed by an independent statistician. He was not
aware of the therapy allocation or the details of the study design

Blinding of participants
and personnel (performance bias)
All outcomes

High risk

Participants were not blinded due to the study conditions. Data were collected
by independent research assistants, it is unknown if they were blinded

Blinding of outcome assessment (detection bias)
All outcomes

High risk

Participants were not blinded, and most outcomes were participant reported

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Missing data at 6-month follow-up for psychotherapy motivation and the secondary outcomes were up to 28.5% in the intervention group and 23.8% in the
control group (> 20%)
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Selective reporting (reporting bias)

Low risk

All intended outcomes reported

Treatment fidelity

Low risk

Treatment was based on a manual regarding therapy goals, basic concepts
and operationalisation of the individual therapy steps (Schweickhardt 2007,
ref 29)

Researcher allegiance

Low risk

No indication that researchers had a preference for 1 of the treatment modalities

Other bias

Unclear risk

A high percentage (29%) of the participants from the control group became involved in psychotherapy. This might have influenced the results

Speckens 1995
Methods

Study design: randomised controlled trial

Participants

Diagnosis: MUS
Method of diagnosis: participants (aged 18-64, Dutch natives) with no explanation for their symptoms
according to their internist were interviewed by the researchers. Those with a mean intensity of symptoms score of ≥ 5 (88%) or a HADS anxiety/depression score of ≥ 10 and ≥ 5 points on functional impairment score (12%) were eligible
Exclusion criteria: organic psychiatric disorders (e.g. dementia) or with chronic alcoholism, psychosis,
or suicidal ideas and those currently having psychological or psychiatric treatment
Total number randomised: 79
Age: for intervention group, M = 36.4 (SD = 12.4); for control group, M = 37.8 (SD = 12.8)
Sex: for intervention group 46% women (n = 18), 54% men (n = 21); for control group 53% women (n =
21), 47% men (n = 19)
Severity of symptoms at baseline: number of symptoms for intervention group M = 12.9 (SD = 6.7), for
control group M = 13.0 (SD = 7.5)
Duration of symptoms at baseline: unknown
Setting: general medical outpatient clinic of Leiden university hospital (recruitment and treatment)
Location: Leiden, the Netherlands
Number of treatment centres: 1
Co-morbidities: psychiatric disorders (based on caseness in the present state examination at baseline): 46% (n = 18) in intervention group; 28% (n = 11) in control group
Adjunctive therapy: none reported
Adjunctive medication: none reported

Interventions

Participants were randomly assigned to either
1. CBT (n = 39)
Duration: 6-16 x 1-hour sessions during a maximum period of 6 months
Treatment protocol: a broad CBT approach was used in view of the heterogeneous nature of the participants' problems. The main therapeutic techniques included identification and modification of dys-
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functional automatic thoughts and behavioural experiments aimed at breaking the vicious cycle of the
symptoms and their consequences. The methods used were similar to those described by Salkovskis
and Sharpe et al. (for details: Speckens 1995, ref 2 and 12)
Therapist: a physician trained in CBT and a behavioural therapist
2. Control group (n = 40)
Duration: 1 x 90-minute session every 3 months (for doctors)
Treatment protocol: treatment consisted of optimised medical care. The quality of care was enhanced
by basic training by 3 researchers in the detection and management of psychiatric disorders
Therapist: the researchers
Outcomes

Time points for assessment: baseline 6 months and 12 months after baseline
Outcomes:
1. change in physical symptoms (perceived change, frequency and intensity according to non-standardised questionnaire)
2. psychological distress (GHQ and HADS anxiety and depression subscale)
3. functional impairment (SIP subscales and numerical analogue scales on functional impairment)
4. hypochondriacal beliefs (IAS subscales health anxiety and illness behaviour and WI)
5. healthcare use (frequency of visits to GP, based on visit counts by participant and doctor, only at 12
months)

Notes

Date of study: from March 1992 to March 1993 participants were recruited, follow-up continued until 1
year after
Funding source: Dutch Ministry of Education and Sciences and the Ministry of Welfare, Public Health
Care and Culture
Declarations of interest among the primary researchers: none reported

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Randomisation was performed using computerised randomisation in blocks of
4 (confirmed by email)

Allocation concealment
(selection bias)

Low risk

Randomisation was performed by an independent person (confirmed by
email)

Blinding of participants
and personnel (performance bias)
All outcomes

High risk

Participants and personnel were not blinded

Blinding of outcome assessment (detection bias)
All outcomes

High risk

Participants were not blinded, and most outcomes were participant reported

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Drop-out rates were low at all follow-ups (< 20%)
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Selective reporting (reporting bias)

Low risk

All intended outcomes reported

Treatment fidelity

Unclear risk

A certain structure in methodology, but no manual or protocol was used
(Speckens 1995, p. 1329)

Researcher allegiance

Low risk

No indication that researchers had a preference for 1 of the treatment modalities

Other bias

Low risk

No other sources of bias

Sumathipala 2000
Methods

Study design: randomised controlled trial

Participants

Diagnosis: medically unexplained complaints
Method of diagnosis: participants (16-65 years old) with ≥ 5 medically unexplained symptoms and
repeated consultations during the last 6 months underwent a physical examination by a GP and a research psychiatrist plus a re-assessment through 2 questions by the research psychiatrist: 1. What are
your symptoms/problems, why are you here today? and, 2. Are there any other symptoms/problems?
Finally 1 question was asked about how many visits participants had in last 6 months according to current symptoms, to make sure that they fitted inclusion criteria. After inclusion the standardised BSI
questionnaire was filled out by all participants.
Exclusion criteria: dementia, psychosis, active suicidal thoughts, alcohol dependence or current treatment for a psychiatric disorder
Total number randomised: 68
Age: for intervention group, M = 38.1 (SD = 13); for control group, M = 38.7 (SD = 14)
Sex: for intervention group 64.7% women (n = 22), 35.3% men (n = 12); for control group 76.5% women
(n = 26), 23.5% men (n = 8)
Severity of symptoms at baseline: number of symptoms: for intervention group M = 7.8 (SD = 1.7), for
control group M = 8.2 (SD = 1.9)
Duration of symptoms at baseline: 57% was > 2 years ill, in the intervention group 20.6% (n = 7) had <
6 months symptoms, in the control group 14.7% (n = 5)
Setting: participants were selected by GPs and treated in general outpatient clinic of a general hospital
where participants initiate their own visits without prior appointments (primary care)
Location: Colombo, Sri Lanka
Number of treatment centres: 1
Co-morbidities: not described
Adjunctive therapy: none described
Adjunctive medication: none described

Interventions

Participants were randomly assigned to either
1. CBT (n = 34)
Duration: 6 x 30-minute structured sessions over a period of 3 months
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Treatment protocol: treatment consisted of structured regular visits to 1 professional carer thereby
hoping to reduce unstructured visits to different practitioners and co-ordinating care. Treatment was
based on the principles of CBT, using modifications of that described by Salkovskis and Sharpe et al.
and Goldberg et al.'s reattribution technique for details Sumathipala 2000, ref Salkovskis, Sharpe and
Goldberg). Through structured sessions, participants were made aware of the psychological component of their condition, and helped to reduce unnecessary medical consultations and investigations.
When possible, 1 non-professional carer, usually the spouse, was involved. The intervention group was
managed by a research psychiatrist using the above specified intervention strategy. A treatment manual was prepared to keep the therapeutic sessions uniform
Therapist: research psychiatrist
2. Control group (n = 34)
Duration: NA
Treatment protocol: the controls received assessments but no intervention in terms of a structured
therapy. They continued to receive care from their usual carers and could visit the doctors of their
choice. The controlled group received appointments for a follow-up assessment after 3 months
Therapist/face-to-face contact: NA
Outcomes

Time points for assessment: baseline and 3 months after baseline
Outcomes:
1. level of distress/psychiatric morbidity (GHQ-30)
2. number and severity of symptoms (BSI + 2 open-ended questions)
3. number of participant initiated doctor visits (diary)
4. participants perceived satisfaction with previous treatment (VAS scale)

Notes

Date of study: participant recruitment took place from consecutive participants attending the clinic
from 15 December 1997 to the end of March 1998, the treatment and re-assessments continued until
the end of June 1998
Funding source: The Wellcome Trust (international programme) provided a project grant
Declarations of interest among the primary researchers: none reported

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

A list of treatment assignments was prepared in advance using simple randomisation by random numbers generated from a calculator. These were
available in 68 sealed opaque envelops bearing sequential registration numbers on the outside of the envelope

Allocation concealment
(selection bias)

Low risk

An epidemiologist who did not take part in the data collection was responsible
for randomisation

Blinding of participants
and personnel (performance bias)
All outcomes

Unclear risk

The first research psychiatrist opened the envelope to reveal the random
treatment allocation. The non-clinical research assistant and the second psychiatrist remained blind to the group status throughout the study. Participants
could not be blinded

Blinding of outcome assessment (detection bias)
All outcomes

High risk

Participants were not blinded, and most outcomes were participant reported
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Incomplete outcome data
(attrition bias)
All outcomes

High risk

At 3 months, loss to follow-up was 30% in the intervention group and 38% in
control group (> 20%)

Selective reporting (reporting bias)

Low risk

All intended outcomes reported

Treatment fidelity

Low risk

Treatments were structured. A treatment manual was prepared to keep the
therapeutic sessions uniform. (Sumathipala 2000, p. 750)

Researcher allegiance

Low risk

No indication that researchers had a preference for 1 of the treatment modalities

Other bias

Low risk

No other sources of bias

Sumathipala 2008
Methods

Study design: randomised controlled trial

Participants

Diagnosis: MUS
Method of diagnosis: participants (16-65 years old) with ≥ 5 MOS and repeated consultations during
the last 6 months were selected by the primary care doctors. They underwent an extensive physical examination by trial co-ordinator and trial physician plus an independent reassessment through 2 questions: 1. What are your symptoms/problems, why are you here today? and, 2. Are there any other symptoms/problems? to elicit the number of symptoms and visits in the previous 6 months. After inclusion
the standardised BSI questionnaire was filled out by all participants
Exclusion criteria: dementia, psychosis or alcohol dependence current treatment for a psychiatric disorder
Total number randomised: 150
Age: aged 16-58 years, M 35 years
Sex: for intervention group 79% women (n = 59), 21% men (n = 16); for control group 77% women (n =
58), 23% men (n = 17)
Severity of symptoms at baseline: number of symptoms M = 8.6 (SD = 2.2)
Duration of symptoms at baseline: M = 42.0 months (SD = 40)
Setting: a general outpatient clinic of a general hospital where participants initiate their own visits
without prior appointments (primary care)
Location: Colombo, Sri Lanka
Number of treatment centres: 1
Co-morbidities: not described
Adjunctive therapy: none described
Adjunctive medication: none described

Interventions

Participants were randomly assigned to either
1. CBT (n = 75)
Duration: 6 x 30-minute structured sessions over a period of 3 months (of which 3 mandatory)
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Treatment protocol: treatment consisted of structured regular visits to 1 professional carer thereby
aiming to reduce unstructured visits to different practitioners and co-ordinating care. Treatment was
based on the principles of CBT, using modifications of that described by Salkovskis and Sharpe et al.
and Goldberg et al.'s reattribution technique for details Sumathipala 2000, ref Salkovskis, Sharpe and
Goldberg)
Treatment started with a SEMI interview by 1 of the authors: results, summary, and formulation based
on findings were passed on to primary care physician, they were also trained to use this information to
inform the strategy for their CBT intervention. Participants in the intervention group completed a diary, which was used during training. The CBT training was a short course consisting of 5 sessions covering the basis of MUS; the relevance of the explanatory model, elicited by the SEMI, to the CBT model of such symptoms; and the CBT treatment approach. Training was accomplished through lectures,
supplemented by case vignettes and role-play of therapeutic sessions by simulated participants based
on case scenarios from the pilot trial, all with reference to the intervention manual (for details: Sumathipala 2008, ref 30)
Therapist: trained primary care physicians
2. Structured care (n = 75)
Duration: 6 x 30-minute structured sessions over a period of 3 months (of which 3 mandatory)
Treatment protocol: treatment started with a SEMI interview by 1 of the authors: only results were
passed on to primary care physician, they were not trained to use this information to inform the strategy for their CBT intervention
No CBT was given, but during the 6 sessions the physicians were free to manage the participants as
they wished within the sessions. No training or supervision was provided for these doctors, and the intervention was not manualised
Therapist: untrained primary care physicians
Outcomes

Time points for assessment: baseline, 3 months, 6 months, 9 months and 12 months after baseline
Outcomes:
1. number of symptoms (as counted by researcher)
2. level of distress/psychiatric morbidity (GHQ-30)
3. number and severity of symptoms (BSI + 2 open-ended questions)
4. number of participant initiated doctor visits (diary)

Notes

Date of study: not described
Funding source: The Wellcome Trust (international programme) provided a project grant
Declarations of interest among the primary researchers: none reported

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Trial participants were first randomised to the 2 intervention groups using a
random permuted block design, with a block size of 4. Next, participants were
randomly allocated to 1 of the 3 doctors selected to deliver the intervention to
which they had been allocated

Allocation concealment
(selection bias)

Low risk

Randomisation codes were generated by a statistician in the UK and passed on
to the independent epidemiologist (M.R.N.A.) in Sri Lanka, who executed the
random allocation of treatment condition
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Blinding of participants
and personnel (performance bias)
All outcomes

High risk

Neither the primary care doctors who delivered the interventions nor the participants who received them could be masked to their allocation because of
the nature of the interventions

Blinding of outcome assessment (detection bias)
All outcomes

High risk

Participants were not blinded, and most outcomes were participant reported

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Loss to follow-up was highest after 6 and 12 months: 20% at both time points
in the intervention group and 28% (6 months) and 30% (12 months) in the
structured care group (> 20%)

Selective reporting (reporting bias)

Low risk

All intended outcomes are reported

Treatment fidelity

Low risk

Treatments were structured. A treatment manual was prepared to keep the
therapeutic sessions uniform (Sumathipala 2000, p. 750)

Researcher allegiance

Low risk

No indication that researchers had a preference for 1 of the treatment modalities

Other bias

Low risk

No other sources of bias

Van Ravesteijn 2013
Methods

Study design: randomised controlled trial

Participants

Diagnosis: MUS
Method of diagnosis: men and women (aged 18-70 years) belonging to the 10% most frequently attending in the past year, who had physical symptoms for at least 6 months that were not (fully) explained by a physical disease or by substance abuse (according to the GP) were selected. They had to
experience functional impairment due to these physical symptoms and they had to be eligible according to a MINI SCID interview
Exclusion criteria: frequent attendance for other reasons than physical symptoms, physical symptoms
fully explained by somatic diseases, no significant distress or functional impairment due to the symptoms, psychosis or bipolar disorder in medical history, current alcohol or drug abuse, cognitive impairment, problems with the Dutch language, and previous mindfullness-based cognitive therapy
Total number randomised: 125
Age: for intervention group, M = 47.6 (SD = 11); for control group, M = 46.5 (SD = 12)
Sex: for intervention group 80% women (n = 49), 20% men (n = 12); for control group 68% women (n =
38), 32% men (n = 18)
Severity of symptoms at baseline:somatisation disorder 13% in intervention group (n = 8), 13% in
control group (n =7); pain disorder 18% (n =11) in intervention group, 21% (n = 12) in control group
Duration of symptoms at baseline: not described
Setting:primary care, potential participants were selected from the digital databases, screened for exclusion criteria by the GP, invited by letter and interviewed by telephone
Location: area of Nijmegen, a medium-sized city in the Netherlands, general practices were located in
neighbourhoods with both low and higher socioeconomic standards
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Number of treatment centres: unknown
Co-morbidities: hypochondriasis 3% (n = 2) in intervention group, 2% (n = 1) in control group; depressive disorder 15% in intervention group (n = 9), 23% in control group (n = 13); anxiety disorder 25% in
intervention group (n = 15), 25% in control group (n = 14); hypertension 30% in intervention group (n =
18), 20% in control group (n = 11), arthrosis 18% in intervention group (n = 11), 14% in control group (n
= 8), asthma/bronchitis 18% in intervention group (n = 11), 11% in control group (n = 6); diabetes mellitus type II 10% in intervention group (n = 6), 9% in control group (n = 5)
Adjunctive therapy: none reported
Adjunctive medication: none reported
Interventions

Participants were randomly assigned to either
1. Mindfullness-based cognitive therapy (n = 64)
Duration: 8 weekly group sessions of 2.5 hours + 1 silent day (6 hours) during a period of 8 weeks
Treatment protocol: the programme protocol was based on the mindfullness-based cognitive therapy format for people with recurrent depression (see Van Ravesteijn 2013, ref 11) consisted of formal
meditation exercises such as body scan, sitting meditation, walking meditation, and mindful movement. Participants were also encouraged to cultivate awareness of everyday activities, such as eating
or taking a shower. In addition, the programme included cognitive techniques such as psychoeducation, monitoring and scheduling of activities, identification of negative automatic thoughts, and devising a relapse prevention plan. In the section on psychoeducation, information about respecting physical and mental boundaries and dealing with impairments was included. The silent day was included to
give participants the opportunity to deepen their mindfulness practice. To support home practice, participants received a folder with information about the individual sessions, homework assignments, and
forms to keep a record of their practice, together with CDs with guided meditations and movement exercises
Therapist: 2 experienced mindfulness trainers who had both participated in a 2-year mindfulness
training programme and who had many years of practice experience and experience with courses (both
over 30 courses)
2. Enhanced usual care (n = 61)
Duration: NA
Treatment protocol: participants in the enhanced usual care condition received usual care provided
by their GP and other healthcare professionals. The term 'enhanced usual care' was considered appropriate as all participants received a psychiatric interview. The GP was explicitly informed about the psychiatric diagnoses resulting from the interview
Therapist: NA

Outcomes

Time points for assessment: baseline, end of treatment and 9 months after baseline
Primary outcome:
1. general health status (VAS of EuroQoL 5D)
Secondary outcome:
1. mental and physical function (SF-36, MCS and PCS subscales)
2. physical and mental symptoms (PHQ-15 and PHQ-9)
3. health anxiety (WI)
4. healthcare utilisation (contact count by participant)
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Notes

Date of study: participants were recruited from December 2009 to August 2010, follow-up continued
until 9 months after
Funding source: the study was funded by research grants from The Netherlands Organization for
Health Research and Development (ZonMW)
Declarations of interest among the primary researchers: none reported

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

A computer-generated permuted-block randomisation table was used, with
block size 20. The participant identification number was matched with the corresponding name to inform each participant about the allocation

Allocation concealment
(selection bias)

Low risk

The assistant performing allocation was blinded (participants had unique
identification numbers)

Blinding of participants
and personnel (performance bias)
All outcomes

Unclear risk

The research assistant was blinded for interview data. However, other personnel and participants could not be blinded due to the nature of the intervention

Blinding of outcome assessment (detection bias)
All outcomes

High risk

Participants were not blinded and most outcomes were participant reported

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Loss to follow-up was < 20% in both research groups, at all follow-up times

Selective reporting (reporting bias)

Low risk

All intended outcomes reported

Treatment fidelity

Low risk

Treatment followed a structured training protocol (Van Ravesteijn 2013, p.
198)

Researcher allegiance

Low risk

No indication that researchers had a preference for 1 of the treatment modalities

Other bias

Low risk

No other sources of bias

Zonneveld 2012
Methods

Study design: randomised controlled trial

Participants

Diagnosis: UPS (according to SCID interview)
Method of diagnosis: participants (aged 18-65 years old, who were able to speak, read, and write
Dutch) were eligible if their UPS persisted ≥ 6 months and if their UPS was classified as undifferentiated
somatoform disorder or chronic pain disorder according to the criteria of the Structured Clinical Interview for DSM-IV Axis I Disorders/ Patient edition (SCID-I/P)
Exclusion criteria: UPS not being the principal somatic disease; undifferentiated somatoform disorder
or chronic pain disorder not being the principal DSM-IV-TR classification; handicaps like cognitive mental impairment with or without blindness impending the participant to participate in the training
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Total number randomised: 162
Age: for intervention group, M = 46 (IQR = 38-53); for control group, M = 44 (SD = 35-52)
Sex: for intervention group 79.8% women (n = 67), 20.2% men (n = 17); for control group 82.1% women
(n = 64), 17.9% men (n = 14)
Severity of symptoms at baseline: undifferentiated somatoform disorder 38.1% for intervention
group (n = 32) 39.7% for control group (n = 31); chronic pain disorder 61.9% for intervention group (n =
52), 60.3% for control group (n = 47)
Duration of symptoms at baseline: for intervention group M = 8 years, for control group M = 9.5 years
Setting: primary care, outpatient clinic and secondary community mental-health service physicians'
received periodical postcards informing them when and how to refer patients. Participants were also
recruited via announcements in local newspapers and on websites of patients' associations. Treatment
setting unclear
Location: Rotterdam area, the Netherlands
Number of treatment centres: unknown
Co-morbidities: for intervention group 45.2% had ≥ 1 DSM-IV axis I disorders (n = 38), for control group
this was 37.2% (n = 29) (for details about specific axis I and axis II disorders, see Zonneveld 2012, table
2)
Adjunctive therapy: not mentioned
Adjunctive medication: not mentioned
Interventions

Participants were randomly assigned to either
1. Group training (n = 84)
Duration: 13 weekly 2-hour sessions in groups of 5-9 participants (mean 6), in a period of 13 weeks
Treatment protocol: treatment consisted of cognitive-behavioural therapy based on the consequences model. In this model, psychological and social factors, are labelled as consequences of UPS. In
the long term, these consequences might produce self perpetuating vicious circles that maintain or aggravate UPS. By changing and reducing the consequences, beliefs are addressed indirectly, after which
the beliefs can still be addressed directly. Focus is on improvement of quality of life. Based on this tailored cognitive-behavioural model, a manual was developed for a group training called 'Coping with
the consequences of unexplained physical symptoms' (for details Zonneveld 2012, ref 38). Sessions
concern psychoeducation on arousal, habits, activity, emotions, beliefs, physical fitness, information
processing, breathing and relaxation, and relapse prevention
Therapist: 6 psychologists with a Master's degree, 4 of whom had had at least 3 years' post-Master's experience with group therapy or CBT, or both and who familiarised themselves with this method
2. Waiting list (n = 78)
Duration: 13 weeks
Treatment protocol: NA
Therapist/face-to-face contact: NA

Outcomes

Time points for assessment: baseline and directly post-treatment (further follow-ups are without a
control group)
Primary outcome:
1. improvement in quality of life (SF-36, PCS and MCS)
Secondary outcome:

Non-pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

87

Cochrane

Library
Zonneveld 2012

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

(Continued)

1. improvement in quality of life (SF-36, 8 individual subscales)
2. intensity of psychological problems (SCL-90-R, 8 subscales including depression and anxiety)
Notes

Date of study: participants were recruited between February 2005 and September 2008. The follow-up
ended in December 2009; 1 year after the intervention group of the last randomisation had completed
the training
Funding source: the study was funded by RIAGG Rijnmond
Declarations of interest among the primary researchers: none reported

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Participants were assigned to the training or to the waiting list according to a
computer generated randomisation list

Allocation concealment
(selection bias)

Low risk

The randomisation was performed by an investigator who had no clinical involvement in the trial and was working in a different building that the building
were assessment and enrolment were done

Blinding of participants
and personnel (performance bias)
All outcomes

High risk

Participants and trainers could not be blinded for group assignment, as the
control condition was a simple waiting list. The data were imported and
analysed after participants had completed the trial

Blinding of outcome assessment (detection bias)
All outcomes

High risk

Participants were not blinded and most outcomes were participant reported

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Of the 84 participants in the intervention group, 23 dropped out (27.4%), of the
78 participants in the control group, 6 dropped out (7.7%) (intervention group
loss to follow-up > 20%)

Selective reporting (reporting bias)

Low risk

All intended outcomes reported, no means/SDs reported, but on our request
these were provided for the meta-analysis

Treatment fidelity

Low risk

The training was manual-based (Zonneveld 2012, ref 24, 28)

Researcher allegiance

Low risk

No indication that researchers had a preference for 1 of the treatment modalities

Other bias

Low risk

No other sources of bias

AIDS: acquired immune deficiency syndrome; BDS: bodily distress syndrome; BSI: Brief Symptom Inventory; CBT: cognitive behavioural
therapy; CGI-SD: Clinical Global Impession Scale for Somatoform Disorders; CIDI: Composite International Diagnostic Interview; DSM:
Diagnostic and Statistical Manual of Mental Disorders; GAD: Generalised Anxiety Disorder Scale; GHQ: General Health Questionnaire;
GP: general practitioner; GSI: General Symptom Index; HADS: Hospital Anxiety and Depression Scale; HAM-A: Hamilton Anxiety Rating
Scale; HAM-D: Hamilton Depression Rating Scale; IAS: Illness Attitude Scales; IBQ: Illness Behaviour Questionnaire; ICD: International
Classification of Diseases; IDCL: International Diagnostic Checklists; IQR: interquartile range; KKG: Krankheit und Gesundheit; M: mean;
MCS: Mental Component Scale; Mini-DIPS: mini-Diagnostische Interview bei psychischen Störungen; MOS: Medical Outcomes Study; MUS:
medically unexplained symptoms; MWB: Mental Well-Being; n: number; NA: not available; PCI: psychiatric consultation intervention;
PCS: Physical Component Score; PHQ: Patient Health Questionnaire; PRIME-MD: Primary Care Evaluation of Mental Disorders; PWB:
Psychological Well-Being; ref: reference; SCAN: Schedules for Clinical Assessment in Neuropsychiatry; SCID: Structured Clinical Interview
for Mental Disorders; SCL: Symptom Checklist; SD: standard deviation; SDI: Sleep Debt Index; SF-12: 12-item Short Form; SIP: Session
Initiation Protocol; SPQ: Social Problem Questionnaire; SSS: Severity of Somatic Symptoms; TAU: treatment as usual; UPS: unexplained
physical symptoms; VAS: visual analogue scale; WI: Whitely Index.
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Characteristics of excluded studies [ordered by study ID]
Study

Reason for exclusion

Aiarzaguena 2007

Compared 2 forms of CBT

Arnold 2009

This study was not randomised

Barsky 2013

No separate analysis for participants with somatisation (only for total group, including people with
hypochondriacal health anxiety as their main problem)

Bernal 1995

A non-pharmacological intervention (relaxation therapy) was combined with a pharmacological
one (antidepressants)

Blankenstein 2001

GP training study

Bleichhardt 2004

Compared CBT with CBT+ BT

Cano-Vindel 2013

Treatment as usual in the control group included pharmacological treatment

Detaille 2013

Not MUPS or somatoform disorder

Gottschalk 2011

This (pilot) study was not randomised

Grepmair 2007

The study did not concern people with MUPS of somatoform disorders explicitly

Gyllensten 2003

No separate analysis for people with somatisation/MUPS

Hellmann 1990

Participant selection procedure did not include a diagnostic interview or questionnaire to establish
MUPS or somatoform disorders

Hiller 2003

This study was not randomised

Hiller 2004

This study was not randomised

Houtveen 2013

The study had a prospective study design (no randomised controlled study)

Klapow 2001

Participants were not required to have medically unexplained symptoms or somatoform disorders

Kocken 2008

Participant selection procedure did not include a diagnostic interview or questionnaire to establish
MUPS or somatoform disorders

Larisch 2004

GP training study

Lopez-Garcia-Franco 2012

Participant selection procedure did not include a diagnostic interview or questionnaire to establish
MUPS or somatoform disorders

Lupke 1996

The study was not randomised

McLeod 1997

Participant selection procedure did not include a diagnostic interview or questionnaire to establish
MUPS or somatoform disorders

Morriss 2007

Participant selection procedure did not include a diagnostic interview or questionnaire to establish
MUPS or somatoform disorders

Nanke 2003a

Compared 2 forms of BT
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Study

Reason for exclusion

Payne 2009

The study was not randomised

Peters 2002

Participant selection procedure did not include a diagnostic interview or questionnaire to establish
MUPS or somatoform disorders

Pols 2008

Treatment was focused on depressive symptoms, not on MUPS

Rasmussen 2006

Participants include high healthcare utilisers, the participant selection procedure did not include a
diagnostic interview or questionnaire to establish MUPS or somatoform disorders

Rembold 2011

The study was not randomised

Rosendal 2007

No separate analysis for people with somatisation/MUPS

Rost 1994

The intervention consisted of a consultation letter

Ryan 2004

Participant selection procedure did not include a diagnostic interview or questionnaire to establish
MUPS or somatoform disorders

Schade 2011

Participant selection procedure did not include a diagnostic interview or questionnaire to establish
MUPS or somatoform disorders

Schwarz 2012

The study was not randomised

Sharpe 2011

Participant selection procedure did not include a diagnostic interview or questionnaire to establish
MUPS or somatoform disorders

Smith 2006

Participant selection procedure did not include a diagnostic interview or questionnaire to establish
MUPS or somatoform disorders and the intervention included pharmacological treatment

Smith 2009

Participant selection procedure did not include a diagnostic interview or questionnaire to establish MUPS or somatoform disorders and for a certain percentage of the participants intervention included pharmacological treatment

Toft 2010

GP training study

Tschuschke 2007

The study was not randomised

Tyrer 2011

The study was not randomised

Van der Feltz-Cornelis 2006

Intervention aimed at psychiatric consultation model, combined with GP training

Whitehead 2002

Only people with chronic fatigue syndrome

Wiefferink 1997

Participant selection procedure did not include a diagnostic interview or questionnaire to establish
MUPS or somatoform disorders

BT: behavioural therapy; CBT: cognitive behavioural therapy; GP: general practitioner; MUPS: medically unexplained physical symptoms.

Characteristics of studies awaiting assessment [ordered by study ID]
Burwell-Walsh 2002
Methods

Randomised controlled trial (cross-over?)
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Participants

Couples in which 1 of the partners met criteria for somatoform disorder or undifferentiated somatoform disorder as determined by the SOMS and who scored ≤ 101 on the Dyadic Adjustment
Scale participated in this study

Interventions

Emotion focused couples therapy versus waiting list controls

Outcomes

Unclear. Abstract only reports on reported symptoms

Notes

Study included in Kleinstäuber 2011

Crompton 2003
Methods

Phase 1 - the development of a client manual that will be used as an adjunct to therapy
Phase 2 - randomised trial in primary care

Participants

People with MUPS

Interventions

Reattribution therapy

Outcomes

Modified Social Adjustment Scale (primary outcome measure) Illness Perception Questionnaire
(IPQ), Hospital Anxiety and Depression Scale (HADS), Ecomomis Questionnaire (EQ), SCL-90-R
(Measures psychological and somatic symptoms) and number of contacts with primary and secondary health care services (derived from participant questionnaire and case notes)

Notes

Registration in research register, article untraceable

Gournay 1998
Methods

Randomised clinical trial in primary health care

Participants

People with medically unexplained problems

Interventions

Intervention group: CBT by F-grade community mental health nurses (advice)
Control group: CBT by F-grade community mental health nurses (treatment)

Outcomes

Unknown

Notes

Registration in research register, article untraceable

Lopez-Garcia-Franco 2009
Methods

Cluster-randomised controlled trial in primary care

Participants

People with symptoms of somatisation

Interventions

Intervention group: cognitive behavioural group therapy
Control group: care as usual
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Primary outcome measures:
- Perceived quality of life (SF-12)
- Questionnaires on Global Clinical Impression (PGI and CGI questionnaire)
- Number of examinations (number of requested and programmed doctor's examinations during
the period of study)
- Prescribed medicine
- Temporary labor disability (TLD)

Notes

Registration in research register, article untraceable

Mussgay 2006
Methods

Randomised controlled trial in inpatients

Participants

Inpatients with anxiety and somatisation disorders

Interventions

Intervention group: standard treatment + additional exercise training regimen
Control group: standard treatment

Outcomes

- Respiration, weight, and body fat
- Anxiety and depression (Hospital and Depression Scale, HADS), general state of health (SF-36),
and complaints (Symptom Check List, SCL-90-R, and the Giessener Beschwerdebogen, GBB),
amount of everyday activity and sport activity (Freiburger Fragebogen fuer Koerperliche Aktivitaet,
FFKA), and a Screening for Somatoform Disorders instrument (SOMS). -an ergometric test was used
to establish individual aerobic fitness (aerob/anaerob threshold based on lactate measurement)
and training heart rate

Notes

Article untraceable

Nickel 2006
Methods

Randomised trial

Participants

Turkish immigrants in a tertiary care German hospital

Interventions

Bioenergetic training, gymnastics, gestalt therapy, behavioural therapy, social therapy

Outcomes

Symptom severity, depression, anxiety, somatisation, aggressiveness and others

Notes

Woolfolk 2007
Methods

Clinical trial

Participants

People with somatisation
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Interventions

Affective cognitive behavioural therapy versus treatment as usual

Outcomes

Unknown

Notes

Article (book chapter) - untraceable

CBT: cognitive behavioural; therapy; CGI: Clinical Global Impression Scale; MUPS: medically unexplained physical symptoms.

Characteristics of ongoing studies [ordered by study ID]
Agger 2012
Trial name or title

Treatment of Multi-organ Bodily Distress Syndrome. A Randomized Controlled Trial of the Effects
of Acceptance and Commitment Therapy Given as Group Therapy or Workshop Compared to Standard Treatment (Stress-4)

Methods

Randomised controlled trial, 3-arm parallel study

Participants

First-time referred participants fulfilling diagnostic criteria for BDS multi-organ type with symptoms for more than 3 of 4 symptom categories; moderate or severe impact on daily life; symptoms
lasting for at least 2 years
Aged 20-50 years; born in Denmark or have Danish parents. The participant understands, speaks,
writes and read Danish

Interventions

1. Experimental: Group Therapy: ACT given as conventional group therapy in groups of 7-8 participants 3,5 hours each session, 9 sessions during 3 month
2. Experimental: Workshop. ACT given as a one-day workshop with 15 participants with a following
individual consultation
3. Standard treatment; one single advisory consultation given 2 weeks after randomisation

Outcomes

Primary Outcome Measures:Global Clinical Improvement Scale [Time Frame: 14 month after randomisation ] [ Designated as safety issue: No ]Questionnaire, participant-rated improvement of
health since the beginning of the study
Secondary Outcome Measures:SF-36 [ Time Frame: Before randomisation, and at 6, 14 and 20
months after randomisation ] [ Designated as safety issue: No ]Questionnaire, participant-rated.
Assessment of physical, social and mental functioning Visual Analogue Scale for pain and worst
symptom [ Time Frame: Before randomisation, and at 6, 14 and 20 month after randomisation ]
[ Designated as safety issue: No ]
Symptom Checklist (SCL) [ Time Frame: Before randomisation, and at 6, 14 and 20 month after
randomisation ] [ Designated as safety issue: No ]Questionnaire, participant-rated. Assessment of
physical, social and mental functioning
WHODAS II [ Time Frame: Before randomisation, and at 6, 14 and 20 month after randomisation ]
[ Designated as safety issue: No ]Questionnaire, participant-rated. Assessment of physical, social
and mental functioning

Starting date

January 2012, planned end date March 2015

Contact information

jlag@clin.au.dk (Johanne Agger)

Notes

ClinicalTrials.gov Identifier: NCT01518647

Hassett 2007
Trial name or title

A Computer-Based Intervention for Medically Unexplained Physical Symptoms
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Methods

Randomised controlled trial

Participants

Participants aged 18-75 seeking medical care for physical symptoms (i.e., persistent fatigue, pain
complaints, and gastrointestinal, cardiovascular or musculoskeletal symptoms). No major medical
illness to explain symptom(s) is found after detailed physical and laboratory assessment. Participants with common disorders such as hypertension, asthma, diabetes, low back strain, etc., will be
included if in the opinion of the physician the presenting physical symptoms are not due to the underlying disorder. In order to enter the study, participants must meet criteria for at least 4 medically unexplained symptoms out of the 42 somatic symptoms listed in the Composite International Diagnostic Interview (CIDI) rated as currently present if males and at least 6 symptoms if females (Escobar's abridged criteria). Participants without ready access to a computer and the Internet will be
excluded from participating. Also excluded will be individuals with life threatening medical illness,
communicative disorder, lack of fluency in English, illiteracy, and major psychiatric conditions including psychoses, bipolar disorder, and alcohol or drug abuse. Participants will be required to add
no medications to their regimen during the study period (approximately 6 weeks)

Interventions

Intervention: Computer-based exercises to be executed at home
Comparator: Sham computer-based exercises to be executed at home

Outcomes

Quick Inventory of Depressive Symptoms
Positive and Negative Affect Scale
Satisfaction with Life Scale

Starting date

2007

Contact information

afton@med.umich.edu

Notes

ClinicalTrials.gov identifier: NCT00468013
According to trial register completed in 2009. Contacted investigator (17 July 2014)

Olde Hartman 2013
Trial name or title

Psychosomatic Therapy, Feasibility and Cost Analysis (PsySom)

Methods

Randomised pilot study consisting of participants with MUS in primary care. Participants will be
followed for 1 year

Participants

People with MUS

Interventions

Participants will be randomised to intervention (usual care and additional psychosomatic therapy)
or control condition (usual care alone)

Outcomes

Primary outcome measures are: the number of participants identified and recruited, perceived
symptom severity, measured on a Visual Analogue Scale (VAS) and participants' self rated symptoms of distress, depression, anxiety and somatisation (4DSQ: The Four Dimensional Symptom
Questionnaire). Other primary outcome measures are the time needed to include the eligible participants, the number of withdrawals in the intervention and control group, compliance in the therapy group and the number of participants who complete the questionnaires
Secondary outcome measures are: symptoms of hyperventilation (NHL: Nijmegen Hyperventilation
List), physical and mental health status and quality of life (SF-36), and level of functioning (MAF:
measure of general functioning). Participant satisfaction with the received therapy is rated on a 5point Likert-type scale. Medical consumption will be measured by the Cost Diary for medical consumption
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Starting date

April 2013

Contact information

Dr T.C. olde Hartman, Radboud University, email: Tim.OldeHartman@radboudumc.nl

Notes

ClinicalTrials.gov Identifier: NCT01935258. Results expected Octiver 2014

Rief 2013
Trial name or title

Enriching Cognitive-Behavioral Therapy With Emotion Regulation Training in Patients With Chronic
Multiple Somatoform Symptoms (ENCERT): A Randomized Controlled Trial

Methods

Randomised controlled trial

Participants

Participants 18-69 years with inclusion Criteria based on DSM-V diagnosis "somatic symptom disorder [SSD] 300.82"

Interventions

ENCERT contains 1. psychoeducation (session 1), 2. relaxation techniques for coping with stress
(sessions 2-4), 3. non-judgmental awareness of body perceptions, (sessions 5-7), 4. modifying illness behaviour and accepting unpleasant body perceptions (sessions 8-13), 5. attention defocusing on positive perceptions plus
emotional self support (sessions 14-15), 6. analysing interpretation processes to understand situational cues (sessions 16-17), and 7. change of behaviour and interpretations (sessions 18-20). The
innovative elements of ENCERT are: improving the awareness for the association of somatic symptoms with emotions, learning non-judgmental awareness and acceptance of unpleasant body perceptions, achieving high-frequent skill exercising with the emotion regulation audio training.
Comparator: CBT. This arm is based on traditional cognitive-behavioural therapy that can be considered the current "treatment of choice", being the only intervention with an evidence grade 1a
(Kroenke 2007). As such, it presents the reference of efficacy and safety for new regimen. The strictly manualised program includes the following components focusing on the special needs of people
with chronic somatoform disorders: psychoeducation providing a framework for psychotherapy,
attention defocusing, reduction of over-interpretation of symptoms, increase of physical activity,
stress reduction

Outcomes

Primary Outcome Measures:Change in somatic symptom severity (Screening for Somatoform Disorders, SOMS-7T) from pre-assessment to four in-between assessments to post-assessment to follow-up [Time Frame: From pre-assessment (admission) to four in-between assessments (9, 13, 17,
21 weeks after admission) to post-assessment (25 weeks after admission) to follow-up (12 months
after admission) ] [ Designated as safety issue: No ]Assessment of somatic symptom severity during
the last 7 days (self rating)
Secondary Outcome Measures:Change in depressive symptoms (Beck Depression Inventory-II,
BDI-II) from pre-assessment to one in-between assessment to post-assessment to follow-up [ Time
Frame: From pre-assessment (admission) to one in-between assessment (13 weeks after admission) to post-assessment (25 weeks after admission) to follow-up (12 months after admission) ]
[ Designated as safety issue: No ]Assessment of depressive symptoms (self rating)
Change in emotion regulation skills (Emotion Regulation Skills Questionnaire, ERSQ) from pre-assessment to one in-between assessment to post-assessment to follow-up [ Time Frame: From preassessment (admission) to one in-between assessment (13 weeks after admission) to post-assessment (25 weeks after admission) to follow-up (12 months after admission) ] [ Designated as safety
issue: No ]Assessment of emotion regulation skills (self rating)
Change in symptom-focused coping strategies (Pain Coping Questionnaire, FESV; Geissner, 2003)
from pre-assessment to one in-between assessment to post-assessment to follow-up [ Time Frame:
From pre-assessment (admission) to one in-between assessment (13 weeks after admission) to
post-assessment (25 weeks after admission) to follow-up (12 months after admission) ] [ Designated as safety issue: No ]Assessment of symptom-focused coping strategies (self rating)
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Change in general psychopathological symptoms (Symptom Checklist-90, SCL-90) from pre-assessment to one in-between assessment to post-assessment to follow-up [ Time Frame: From preassessment (admission) to one in-between assessment (13 weeks after admission) to post-assessment (25 weeks after admission) to follow-up (12 months after admission) ] [ Designated as safety
issue: No ]Assessment of general psychopathological symptoms (self rating)
Change in symptom-caused disability (Pain Disability Index, PDI) from pre-assessment to one inbetween assessment to post-assessment to follow-up [ Time Frame: From pre-assessment (admission) to one in-between assessment (13 weeks after admission) to post-assessment (25 weeks after
admission) to follow-up (12 months after admission) ] [ Designated as safety issue: No ]Assessment
of symptom-caused disability in different areas of life (self rating)
Change in health-related quality of life (EuroQoL-5D, EQ-5D) from pre-assessment to one in-between assessment to post-assessment to follow-up [ Time Frame: From pre-assessment (admission) to one in-between assessment (13 weeks after admission) to post-assessment (25 weeks after
admission) to follow-up (12 months after admission) ] [ Designated as safety issue: No ]Assessment
of health-related quality of life (self rating)
Change in health anxiety (Whiteley Index, WI) from pre-assessment to one in-between assessment
to post-assessment to follow-up [ Time Frame: From pre-assessment (admission) to one in-between assessment (13 weeks after admission) to post-assessment (25 weeks after admission) to follow-up (12 months after admission) ] [ Designated as safety issue: No ]Assessment of health anxiety
(self rating)
Change in social competence, emotion regulation, relaxation abilities, stress management, etc.,
in different areas of life (The Operationalized Assessment of Abilities, OFD) from pre-assessment to
post-assessment to follow-up [ Time Frame: From pre-assessment (admission) to post-assessment
(25 weeks after admission) to follow-up (12 months after admission) ] [ Designated as safety issue:
No ]Observer-based assessment of scores for social competence, emotion regulation, relaxation
abilities, stress management, etc., in different areas of life (job, family, leisure)
Change in healthcare utilisation and indirect costs (Structured Interview for the Assessment of
Health Care Utilization, HCU) from pre-assessment to follow-up [ Time Frame: From pre-assessment (admission) to follow-up (12 months after admission) ] [ Designated as safety issue: No ]Observer-based assessment of HCU and indirect costs. HCU will be transformed to costs using health
economy tables
Inventory of the Assessment of Negative Effects of Psychotherapy (INEP) at post-assessment [ Time
Frame: Post-assessment (25 weeks after admission) ] [ Designated as safety issue: No ]Assessment
of psychotherapy-induced side effects (self rating)
Inventory of the Assessment of Negative Effects of Psychotherapy (INEP) at follow-up [ Time
Frame: Follow-up (12 months after admission) ] [ Designated as safety issue: No ]Assessment of
psychotherapy-induced side effects (self rating)
Starting date

October 2013

Contact information

Winfried Rief, Ph.D. riefw@uni-marburg.de Maria Kleinstäuber maria.kleinstaeuber@Staff.Uni-Marburg.de

Notes

ClinicalTrials.gov identifier: NCT01908855. Results expected 2016

Schröder 2014
Trial name or title

How effective is a walking training for somatoform disorders? A randomized controlled study

Methods

Randomised controlled study

Participants

Participants fulfilling as primary diagnosis the criteria of 1 of the 5 somatoform disorders in the
DSM-IV focusing on multiple somatoform symptoms; participants with co-morbid disorders are eligible; attestation on exclusion of medical causes and physical fitness by a physician; participants
with acute suicidality, psychotic symptoms, and who already exercising sufficiently at the beginning of the study (due to expected ceiling effects) will be excluded
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Interventions

Intervention: walking training based on a walking program by Bös 2006 (see Notes). Participants
will be instructed by a qualified coach. The walking training comprises a weekly session of 90 minutes over 12 weeks. The program manual includes a detailed description of each training session.
Every session builds on 7 sequences: 1. Introduction, 2. warming-up, 3. walking, 4. weight and
strength training/stretching, 5. relaxation, 6. exchange of experiences, 7. movement-/health-related information
Comparator: waiting list

Outcomes

All of the following primary and secondary outcomes are assessed at baseline and week 12.
Primary outcomes: Screening for Somatoform Disorders (SOMS-7T; baseline, week 12); Short Form
36 Questionnaire (SF-36) - subscale Physical Health; physiological parameters (physical constitution, heart rate variability; Freiburg Questionnaire of Physical Activity
Secondary outcomes: Hospital Anxiety and Depression Scale (HADS-D); Cognitions About Body and
Health (CABAH); Whiteley Index (WI); Short Form 36 Questionnaire (SF-36) - subscale Mental Health;
items healthcare use developed by study authors; body mass index
Weekly assessment in the walking group: Symptom Diary of the SOMS-7T; Short Form 12 Questionnaire (SF-12) - subscales Physical and Mental Health; protocol on training frequency

Starting date

June 2011

Contact information

Prof. Dr. Annette Schröder, University Koblenz-Landau, Germany: Schroede@uni-landau.de; Dr.
Jens Heider, University Koblenz-Landau, Germany: heider@uni-landau.de

Notes

Provided by Maria Kleinstäuber (design paper in German)
Literature: Bös K, Tiemann M, Brehm W, Mommert-Jauch P. Walking and more - reaching fitness
step by step [Walking und mehr - Schritt für Schritt zur Fitness] (2nd ed.). Aachen, Germany: Meyer
& Meyer. 2006

Sitnikova 2014
Trial name or title

CIPRUS - Cognitive-behavioural intervention in primary care for undifferentiated somatoform disorder

Methods

Randomised controlled study in general practice

Participants

Inclusion criteria:
1) Being 18 years of age or older
2) Meeting the criteria for undifferentiated somatoform disorder according to DSM IV:
a) The presence of ≥ 1 medically unexplained physical symptoms
b) The symptoms last at least 6 months
c) The symptoms significantly impair functioning/quality of life
Exclusion criteria:
1) Having a medical disorder that explains the symptoms
2) Having a severe psychiatric disorder (i.e. psychosis-related disorders, dementia and bipolar disorder)
3) Having a handicap such as cognitive mental impairment and/or blindness
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4) Being unable to speak or read Dutch
Interventions

Mental health nurse practitioners (MHNP) will offer intervention participants a short structured intervention based on cognitive-behavioural (CB) principles, in addition to usual GP care, to teach
participants how to cope with the consequences of their symptoms. In up to 6 sessions participants
will be provided with psycho-education, problem solving techniques, relaxation techniques, and
activity scheduling. The consequences model of somatoform complaints has successfully been
used in previous Dutch intervention studies and focuses on the consequences or problems that
arise due to somatoform complaints and on their aggravating effects, rather than on causes of
somatoform complaints. This model will be used as the treatment rationale. The focus is not so
much on treating the symptoms, but rather on producing beneficial changes in (physical) functional outcome and quality of life. The MHNPs provide the CB approach of problem solving treatment
(PST) as a means to learn to tackle and cope with the identified consequences. PST teaches problem-solving styles and skills. Several steps to problem solving have been described which will be
practised during the sessions: 1. explanation of treatment rationale and 'contracting', 2. identification and clarification of problems, 3. the setting of clear goals, 4. formulation of alternative solutions, 5. selection of preferred solutions, 6. clarification of the necessary steps to implement solutions, and 7. evaluation of progress. In addition, activity scheduling and progressive relaxation
techniques will be provided as these are important general features of CBT for somatoform complaints. Participants in the control group will not be offered a specific additional intervention other
than the care they would usually receive from the GP

Outcomes

The primary clinical outcome is the development in physical functioning along the total follow-up
period as measured by the physical component summary (PCS) of the RAND-36
The primary outcome measure for the economic evaluation is quality of life as measured by the
EuroQol/EQ-5D. Direct and indirect costs will be assessed with the TIC-P 20 and data on healthcare use extracted from the electronic medical records of the GPs. Direct costs will be based on
the Dutch standard cost prices and the indirect costs will be estimated based on the average of the
population
Secondary outcome measures are the severity of somatisation (PHQ-15) and depressive/anxiety
symptoms (HADS)

Starting date

2014

Contact information

Kate Sitnikova, VUmc Amsterdam, Netherlands, email e.sitnikova@vumc.nl, phone +31204448032

Notes

Dutch Trial Register, identifier NTR4686

Steel 2011
Trial name or title

The management of medically unexplained symptoms in primary care settings in Viet Nam: A clinical trial of cognitive behavior therapy

Methods

Randomised controlled trial, 3 parallel arms

Participants

Primary care participants 18-65 yrs presenting with ≥ 5 or medically unexplained symptoms; participants with co-morbid medically unexplained symptoms and depression and/or anxiety

Interventions

Arm 1: mood enhanced Cognitive Behaviour Therapy for medically unexplained symptoms. Arm
2: Structured Care. Both interventions are administered using once-weekly 30-minute sessions of
one-on-one therapy with a primary care physician over 4 consultations with an option for 2 additional consultations. Arm 1, Cognitive Behaviour Therapy includes an initial ethnographic illness
interview and then metaphor based cognitive restructuring to reduce abnormal illness behaviour,
breathing retraining for anxiety symptoms, and activity scheduling for depression symptoms, with
sleep hygiene instruction. Arm 2, Structured Care involves an initial ethnographic illness interview
followed by time matched clinical sessions with a primary care physician without the CBT content
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Arm 3: Treatment as Usual will involve short primary care consultations consistent with current
practice within Vietnam
The duration of the study for any participant will conclude after the 12-month follow-up assessment, resulting in participation duration of 14 months
Outcomes

Primary Outcome 1: number of reported MUS as recorded by non-treating Primary Care Physician
Primary Outcome 2: Phan Vietnamese Psychiatric Rating Scale: Somatisation Score
Secondary Outcome 1: Vietnamese Psychiatric Rating Scale: Depression Score
Secondary Outcome 2: Phan Vietnamese Psychiatric Rating Scale: Anxiety Score
Secondary Outcome 3: Medical Outcomes Survey Short Form 12
WHO-QOL BREF

Starting date

Not yet recruiting (July 2014)

Contact information

z.steel@unsw.edu.au (Zachary Steel)

Notes

Australian Trial Register Identifier ACTRN12611000946910

Zimmermann 2014
Trial name or title

Effectiveness of a primary care based complex intervention to promote self-management in patients presenting psychiatric symptoms: study protocol of a cluster-randomized controlled trial

Methods

Cluster-randomised controlled trial in primary care

Participants

340 participants will be enrolled in the study, 170 in either arm. Inclusion criteria are: a PHQ ≥ 5 on
the anxiety, depression or somatoform scale, an age of 18-65 years old, German literacy, fully able
to give consent, sufficient auditory and visual capabilities and no current psychotherapeutic treatment

Interventions

Intervention group: a complex, low-threshold intervention by an Advanced Practice Nurse (APN)
using a mixture of case management and counselling techniques to promote self management
Control group: usual care

Outcomes

Primary outcome: self efficacy, measured by the General Self-Efficacy Scale (GSE), here used as a
proxy for self management
Secondary outcomes: PHQ-D symptom load and questionnaires regarding coping with illness and
health related quality of life. Outcome assessments will be applied 8 weeks and 12 months after
the baseline assessment

Starting date

2014

Contact information

t.zimmermann@uke.uni-hamburg.de

Notes

Design paper: Zimmermann T, Puschmann E, Ebersbach M, Daubmann A, Steinmann S, Scherer M.
Effectiveness of a primary care based complex intervention to promote self management in participants presenting psychiatric symptoms: study protocol of a cluster-randomised controlled trial.
BMC Psychiatry 2014;14:2. doi: 10.1186/1471-244X-14-2
Trial registration: Clinicaltrials.gov Identifier: NCT01726387. Results expected: 2015
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DATA AND ANALYSES
Comparison 1. Psychological therapies versus usual care or waiting list
Outcome or subgroup title

No. of
studies

No. of
participants

Statistical method

Effect size

1 Severity of somatic symptoms at end of
treatment

10

1081

Std. Mean Difference (IV, Random,
95% CI)

-0.34 [-0.53,
-0.16]

1.1 Cognitive behavioural therapy versus usual care or waiting list

6

593

Std. Mean Difference (IV, Random,
95% CI)

-0.37 [-0.69,
-0.05]

1.2 Behavioural therapy versus usual care or
waiting list

1

37

Std. Mean Difference (IV, Random,
95% CI)

-0.22 [-0.87,
0.43]

1.3 Third-wave cognitive behavioural therapy
versus usual care or waiting list

1

114

Std. Mean Difference (IV, Random,
95% CI)

-0.31 [-0.68,
0.06]

1.4 Psychodynamic therapy versus usual care
or waiting list

1

252

Std. Mean Difference (IV, Random,
95% CI)

-0.39 [-0.64,
-0.13]

1.5 Integrative therapies versus usual care or
waiting list

1

85

Std. Mean Difference (IV, Random,
95% CI)

-0.15 [-0.69,
0.40]

2 Severity of somatic symptoms within 1 year
after treatment

7

950

Std. Mean Difference (IV, Random,
95% CI)

-0.24 [-0.37,
-0.11]

2.1 Cognitive behavioural therapy versus usual care or waiting list

4

496

Std. Mean Difference (IV, Random,
95% CI)

-0.29 [-0.49,
-0.09]

2.2 Third-wave cognitive behavioural therapy
versus usual care or waiting list

1

107

Std. Mean Difference (IV, Random,
95% CI)

-0.15 [-0.53,
0.23]

2.3 Psychodynamic therapy versus usual care
or waiting list

1

262

Std. Mean Difference (IV, Random,
95% CI)

-0.20 [-0.44,
0.05]

2.4 Integrative therapies versus usual care or
waiting list

1

85

Std. Mean Difference (IV, Random,
95% CI)

-0.15 [-0.69,
0.40]

3 Severity of somatic symptoms > 1 year after
treatment

2

228

Std. Mean Difference (IV, Random,
95% CI)

-0.52 [-0.80,
-0.24]

3.1 Cognitive behavioural therapy versus usual care or waiting list

2

228

Std. Mean Difference (IV, Random,
95% CI)

-0.52 [-0.80,
-0.24]

4 Acceptability

14

1644

Risk Ratio (M-H, Random, 95% CI)

0.93 [0.88, 0.99]

4.1 Cognitive behavioural therapy versus usual care or waiting list

10

1037

Risk Ratio (M-H, Random, 95% CI)

0.93 [0.85, 1.01]

4.2 Behavioural therapy versus usual care or
waiting list

1

48

Risk Ratio (M-H, Random, 95% CI)

0.9 [0.67, 1.21]
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Outcome or subgroup title

No. of
studies

No. of
participants

Statistical method

Effect size

4.3 Third-wave cognitive behavioural therapy
versus usual care or waiting list

1

125

Risk Ratio (M-H, Random, 95% CI)

0.85 [0.72, 1.00]

4.4 Psychodynamic therapy versus usual care
or waiting list

1

328

Risk Ratio (M-H, Random, 95% CI)

0.92 [0.88, 0.96]

4.5 Integrative therapies versus usual care or
waiting list

1

106

Risk Ratio (M-H, Random, 95% CI)

1.06 [0.81, 1.39]

5 Severity of anxiety symptoms at end of
treatment - participant rated

4

270

Std. Mean Difference (IV, Random,
95% CI)

0.06 [-0.20,
0.32]

5.1 Cognitive behavioural therapy versus usual care or waiting list

3

185

Std. Mean Difference (IV, Random,
95% CI)

0.07 [-0.22,
0.37]

5.2 Integrative therapies versus usual care or
waiting list

1

85

Std. Mean Difference (IV, Random,
95% CI)

0.01 [-0.53,
0.56]

6 Severity of anxiety symptoms at end of
treatment - clinician rated

3

320

Std. Mean Difference (IV, Random,
95% CI)

-0.40 [-0.63,
-0.17]

6.1 Cognitive behavioural therapy versus usual care

2

284

Std. Mean Difference (IV, Random,
95% CI)

-0.38 [-0.63,
-0.14]

6.2 Behavioural therapy versus usual care

1

36

Std. Mean Difference (IV, Random,
95% CI)

-0.57 [-1.24,
0.10]

7 Severity of anxiety symptoms within 1 year
after treatment - participant rated

2

134

Std. Mean Difference (IV, Random,
95% CI)

0.18 [-0.22,
0.58]

7.1 Cognitive behavioural therapy versus usual care or waiting list

1

49

Std. Mean Difference (IV, Random,
95% CI)

0.0 [-0.59, 0.59]

7.2 Integrative therapies versus usual care or
waiting list

1

85

Std. Mean Difference (IV, Random,
95% CI)

0.33 [-0.21,
0.88]

8 Severity of anxiety symptoms within 1 year
after treatment - clinician rated

2

251

Std. Mean Difference (IV, Random,
95% CI)

-0.66 [-1.15,
-0.18]

9 Severity of anxiety symptoms > 1 year after
treatment - clinician rated

1

Std. Mean Difference (IV, Random,
95% CI)

Totals not selected

10 Severity of depressive symptoms at end of
treatment - participant rated

6

661

Std. Mean Difference (IV, Random,
95% CI)

-0.03 [-0.22,
0.16]

10.1 Cognitive behavioural therapy versus
usual care or waiting list

4

325

Std. Mean Difference (IV, Random,
95% CI)

0.09 [-0.13,
0.31]

10.2 Psychodynamic therapy versus usual
care or waiting list

1

251

Std. Mean Difference (IV, Random,
95% CI)

-0.30 [-0.55,
-0.04]

10.3 Integrative therapy versus usual care or
waiting list

1

85

Std. Mean Difference (IV, Random,
95% CI)

0.10 [-0.45,
0.64]
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Outcome or subgroup title

No. of
studies

No. of
participants

Statistical method

Effect size

11 Severity of depressive symptoms at end of
treatment - clinician rated

3

316

Std. Mean Difference (IV, Random,
95% CI)

-0.25 [-0.48,
-0.02]

11.1 Cognitive behavioural therapy versus
usual care or waiting list

2

284

Std. Mean Difference (IV, Random,
95% CI)

-0.25 [-0.49,
-0.01]

11.2 Behavioural therapy versus usual care or
waiting list

1

32

Std. Mean Difference (IV, Random,
95% CI)

-0.26 [-0.96,
0.44]

12 Severity of depressive symptoms within 1
year after treatment - participant rated

4

535

Std. Mean Difference (IV, Random,
95% CI)

0.04 [-0.34,
0.42]

12.1 Cognitive behavioural therapy versus
usual care or waiting list

2

189

Std. Mean Difference (IV, Random,
95% CI)

0.21 [-0.07,
0.50]

12.2 Psychodynamic therapy versus usual
care or waiting list

1

261

Std. Mean Difference (IV, Random,
95% CI)

-0.35 [-0.59,
-0.10]

12.3 Integrative therapy versus usual care or
waiting list

1

85

Std. Mean Difference (IV, Random,
95% CI)

0.31 [-0.24,
0.85]

13 Severity of depressive symptoms within 1
year after treatment - clinician rated

2

251

Std. Mean Difference (IV, Random,
95% CI)

-0.55 [-1.17,
0.07]

14 Severity of depressive symptoms > 1 year
after treatment - clinician rated

1

Std. Mean Difference (IV, Random,
95% CI)

Totals not selected

15 Dysfunctional cognitions, emotions and
behaviours at end of treatment

3

440

Std. Mean Difference (IV, Random,
95% CI)

-0.11 [-0.37,
0.16]

15.1 Cognitive behavioural therapy versus
usual care or waiting list

2

189

Std. Mean Difference (IV, Random,
95% CI)

-0.15 [-0.73,
0.44]

15.2 Psychodynamic therapy versus usual
care or waiting list

1

251

Std. Mean Difference (IV, Random,
95% CI)

-0.14 [-0.39,
0.12]

16 Dysfunctional cognitions, emotions, and
behaviours within 1 year after treatment

3

451

Std. Mean Difference (IV, Random,
95% CI)

-0.16 [-0.38,
0.07]

16.1 Cognitive behavioural therapy versus
usual care or waiting list

2

189

Std. Mean Difference (IV, Random,
95% CI)

-0.25 [-0.79,
0.30]

16.2 Psychodynamic therapy versus usual
care or waiting list

1

262

Std. Mean Difference (IV, Random,
95% CI)

-0.13 [-0.38,
0.11]

17 Adverse events

3

445

Risk Ratio (M-H, Random, 95% CI)

1.31 [0.47, 3.66]

18 Treatment response at end of treatment

4

391

Risk Ratio (M-H, Random, 95% CI)

3.30 [2.08, 5.21]

19 Treatment response within 1 year after
treatment

3

332

Risk Ratio (M-H, Random, 95% CI)

2.53 [1.25, 5.10]

20 Treatment response > 1 year after treatment

2

240

Risk Ratio (M-H, Random, 95% CI)

10.31 [2.95,
36.02]
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Outcome or subgroup title

No. of
studies

No. of
participants

Statistical method

Effect size

21 Functional disability and quality of life at
end of treatment

7

730

Std. Mean Difference (IV, Random,
95% CI)

0.17 [0.03, 0.32]

21.1 Cognitive behavioural therapy versus
usual care or waiting list

4

341

Std. Mean Difference (IV, Random,
95% CI)

0.15 [-0.06,
0.37]

21.2 Behavioural therapy versus usual care or
waiting list

1

34

Std. Mean Difference (IV, Random,
95% CI)

0.16 [-0.51,
0.83]

21.3 Third-wave cognitive behavioural therapy versus usual care or waiting list

1

111

Std. Mean Difference (IV, Random,
95% CI)

0.08 [-0.29,
0.46]

21.4 Psychodynamic therapy versus usual
care or waiting list

1

244

Std. Mean Difference (IV, Random,
95% CI)

0.24 [-0.01,
0.50]

22 Functional disability and quality of life
within 1 year after treatment

4

526

Std. Mean Difference (IV, Random,
95% CI)

0.16 [-0.01,
0.33]

22.1 Cognitive behavioural therapy versus
usual care or waiting list

2

168

Std. Mean Difference (IV, Random,
95% CI)

0.22 [-0.08,
0.53]

22.2 Third-wave cognitive behavioural therapy versus usual care or waiting list

1

107

Std. Mean Difference (IV, Random,
95% CI)

-0.10 [-0.48,
0.28]

22.3 Psychodynamic therapy versus usual
care or waiting list

1

251

Std. Mean Difference (IV, Random,
95% CI)

0.23 [-0.02,
0.48]

23 Functional disability and quality of life > 1
year of treatment

1

72

Std. Mean Difference (IV, Random,
95% CI)

0.36 [-0.11,
0.82]

24 Healthcare use at end of treatment

2

117

Std. Mean Difference (IV, Random,
95% CI)

-0.68 [-1.06,
-0.30]

25 Healthcare use within 1 year after treatment

4

532

Std. Mean Difference (IV, Random,
95% CI)

-0.09 [-0.31,
0.12]

25.1 Cognitive behavioural therapy versus
usual care or waiting list

2

189

Std. Mean Difference (IV, Random,
95% CI)

-0.27 [-0.56,
0.02]

25.2 Integrative therapies versus usual care or
waiting list

1

81

Std. Mean Difference (IV, Random,
95% CI)

0.13 [-0.44,
0.69]

25.3 Psychodynamic therapy versus usual
care or waiting list

1

262

Std. Mean Difference (IV, Random,
95% CI)

0.02 [-0.23,
0.26]
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Analysis 1.1. Comparison 1 Psychological therapies versus usual care or
waiting list, Outcome 1 Severity of somatic symptoms at end of treatment.
Study or subgroup

Psychological therapy
N

Usual care/wait list

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

1.1.1 Cognitive behavioural therapy versus usual care or waiting list
Allen 2006

39

38.3 (24.4)

38

48.7 (24.5)

9.42%

-0.42[-0.88,0.03]

Burton 2012

15

11.7 (4.5)

11

12.4 (3.6)

4.44%

-0.16[-0.94,0.62]

Escobar 2007

62

3.5 (1.4)

64

4.2 (1.2)

12.02%

-0.54[-0.9,-0.19]

Martin 2007

70

0.6 (0.6)

70

0.5 (0.5)

12.76%

0.17[-0.16,0.5]

Moreno 2013

108

13 (8.1)

48

19.5 (8.5)

12.16%

-0.78[-1.14,-0.43]

34

13.2 (5.7)

34

15.6 (5.8)

Sumathipala 2000
Subtotal ***

328

265

8.76%

-0.41[-0.9,0.07]

59.55%

-0.37[-0.69,-0.05]

Heterogeneity: Tau2=0.11; Chi2=16.78, df=5(P=0); I2=70.21%
Test for overall effect: Z=2.29(P=0.02)
1.1.2 Behavioural therapy versus usual care or waiting list
Katsamanis 2011

18

Subtotal ***

18

2.8 (4)

19

3.6 (3.6)

19

5.9%

-0.22[-0.87,0.43]

5.9%

-0.22[-0.87,0.43]

Heterogeneity: Not applicable
Test for overall effect: Z=0.66(P=0.51)
1.1.3 Third-wave cognitive behavioural therapy versus usual care or waiting
list
Van Ravesteijn 2013

61

Subtotal ***

61

10.9 (4.9)

53

12.6 (6.1)

53

11.58%

-0.31[-0.68,0.06]

11.58%

-0.31[-0.68,0.06]

Heterogeneity: Not applicable
Test for overall effect: Z=1.63(P=0.1)
1.1.4 Psychodynamic therapy versus usual care or waiting list
Schaefert 2013

147

Subtotal ***

147

9.5 (4.7)

105

11.4 (5.4)

105

15.46%

-0.39[-0.64,-0.13]

15.46%

-0.39[-0.64,-0.13]

Heterogeneity: Not applicable
Test for overall effect: Z=3(P=0)
1.1.5 Integrative therapies versus usual care or waiting list
Kolk 2004

69

7.5%

-0.15[-0.69,0.4]

Subtotal ***

69

21.1 (7.6)

16

16

22.2 (6.9)

7.5%

-0.15[-0.69,0.4]

623

458

100%

-0.34[-0.53,-0.16]

Heterogeneity: Not applicable
Test for overall effect: Z=0.52(P=0.6)
Total ***

Heterogeneity: Tau2=0.04; Chi2=17.66, df=9(P=0.04); I2=49.04%
Test for overall effect: Z=3.64(P=0)
Test for subgroup differences: Chi2=0.82, df=1 (P=0.94), I2=0%
Favours psych therapy
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Analysis 1.2. Comparison 1 Psychological therapies versus usual care or waiting
list, Outcome 2 Severity of somatic symptoms within 1 year after treatment.
Study or subgroup

Psych therapy
N

Usual care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

1.2.1 Cognitive behavioural therapy versus usual care or waiting list
Allen 2006

37

37.8 (28.7)

36

52.8 (28.5)

8.01%

-0.52[-0.99,-0.05]

Escobar 2007

63

9.1 (4.9)

64

10.9 (5)

14.19%

-0.36[-0.72,-0.01]

Martin 2007

70

0.6 (0.6)

70

0.6 (0.6)

15.9%

-0.03[-0.36,0.3]

Moreno 2013

108

16.7 (9)

48

20 (8.9)

14.88%

-0.37[-0.71,-0.03]

Subtotal ***

278

52.98%

-0.29[-0.49,-0.09]

218

Heterogeneity: Tau2=0.01; Chi2=3.63, df=3(P=0.3); I2=17.28%
Test for overall effect: Z=2.87(P=0)
1.2.2 Third-wave cognitive behavioural therapy versus usual care or waiting
list
Van Ravesteijn 2013

57

Subtotal ***

57

11 (5.4)

50

11.8 (5.5)

50

12.07%

-0.15[-0.53,0.23]

12.07%

-0.15[-0.53,0.23]

Heterogeneity: Not applicable
Test for overall effect: Z=0.75(P=0.45)
1.2.3 Psychodynamic therapy versus usual care or waiting list
Schaefert 2013

149

Subtotal ***

149

9.6 (5.1)

113

10.6 (5.1)

113

29.06%

-0.2[-0.44,0.05]

29.06%

-0.2[-0.44,0.05]

Heterogeneity: Not applicable
Test for overall effect: Z=1.59(P=0.11)
1.2.4 Integrative therapies versus usual care or waiting list
Kolk 2004

69

5.89%

-0.15[-0.69,0.4]

Subtotal ***

69

19.9 (7.4)

16

16

21 (7.1)

5.89%

-0.15[-0.69,0.4]

553

397

100%

-0.24[-0.37,-0.11]

Heterogeneity: Not applicable
Test for overall effect: Z=0.53(P=0.59)
Total ***

Heterogeneity: Tau2=0; Chi2=4.36, df=6(P=0.63); I2=0%
Test for overall effect: Z=3.52(P=0)
Test for subgroup differences: Chi2=0.73, df=1 (P=0.87), I2=0%
Favours psych therapy

-2

-1

0

1

2

Favours usual care

Analysis 1.3. Comparison 1 Psychological therapies versus usual care or
waiting list, Outcome 3 Severity of somatic symptoms > 1 year after treatment.
Study or subgroup

CBT
N

Usual care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

1.3.1 Cognitive behavioural therapy versus usual care or waiting list
Allen 2006

35

35 (23)

37

45.4 (23.7)

35.32%

-0.44[-0.91,0.03]

Moreno 2013

108

20.4 (15.5)

48

29 (15)

64.68%

-0.56[-0.91,-0.22]

Subtotal ***

143

100%

-0.52[-0.8,-0.24]

100%

-0.52[-0.8,-0.24]

85

Heterogeneity: Tau2=0; Chi2=0.17, df=1(P=0.68); I2=0%
Test for overall effect: Z=3.65(P=0)
Total ***

143

85
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CBT
N

Usual care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Std. Mean Difference

Random, 95% CI

Random, 95% CI

Heterogeneity: Tau2=0; Chi2=0.17, df=1(P=0.68); I2=0%
Test for overall effect: Z=3.65(P=0)
-1

Favours CBT

-0.5

0

0.5

1

Favours usual care

Analysis 1.4. Comparison 1 Psychological therapies versus usual care or waiting list, Outcome 4 Acceptability.
Study or subgroup

Psych therapy

Usual care

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

1.4.1 Cognitive behavioural therapy versus usual care or waiting list
Allen 2006

39/43

38/41

8.56%

0.98[0.86,1.11]

Burton 2012

13/16

15/16

3.76%

0.87[0.66,1.13]

Escobar 2007

63/87

65/85

6.44%

0.95[0.79,1.13]

Kashner 1995

20/44

26/26

2.81%

0.46[0.34,0.64]

Lidbeck 1997

32/33

17/17

9.74%

0.98[0.88,1.09]

Martin 2007

60/70

59/70

8.03%

1.02[0.88,1.17]

108/120

44/48

9.87%

0.98[0.88,1.09]

Schweickhardt 2007

49/49

42/42

13.01%

1[0.96,1.04]

Sumathipala 2000

22/34

21/34

2.33%

1.05[0.73,1.51]

Zonneveld 2012

65/84

72/78

8.38%

0.84[0.73,0.96]

580

457

72.92%

0.93[0.85,1.01]

Moreno 2013

Subtotal (95% CI)

Total events: 471 (Psych therapy), 399 (Usual care)
Heterogeneity: Tau2=0.01; Chi2=40.96, df=9(P<0.0001); I2=78.03%
Test for overall effect: Z=1.69(P=0.09)
1.4.2 Behavioural therapy versus usual care or waiting list
Katsamanis 2011

18/24

20/24

3.29%

0.9[0.67,1.21]

24

24

3.29%

0.9[0.67,1.21]

Subtotal (95% CI)
Total events: 18 (Psych therapy), 20 (Usual care)
Heterogeneity: Not applicable
Test for overall effect: Z=0.71(P=0.48)

1.4.3 Third-wave cognitive behavioural therapy versus usual care or
waiting list
Van Ravesteijn 2013

49/64

55/61

7.12%

0.85[0.72,1]

64

61

7.12%

0.85[0.72,1]

Subtotal (95% CI)
Total events: 49 (Psych therapy), 55 (Usual care)
Heterogeneity: Not applicable
Test for overall effect: Z=2.02(P=0.04)

1.4.4 Psychodynamic therapy versus usual care or waiting list
Schaefert 2013
Subtotal (95% CI)

168/183

145/145

12.92%

0.92[0.88,0.96]

183

145

12.92%

0.92[0.88,0.96]

Total events: 168 (Psych therapy), 145 (Usual care)
Heterogeneity: Not applicable
Test for overall effect: Z=3.7(P=0)
1.4.5 Integrative therapies versus usual care or waiting list
Kolk 2004
Subtotal (95% CI)

65/83

17/23

3.75%

1.06[0.81,1.39]

83

23

3.75%

1.06[0.81,1.39]
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Psych therapy

Usual care

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

Total events: 65 (Psych therapy), 17 (Usual care)
Heterogeneity: Not applicable
Test for overall effect: Z=0.42(P=0.67)
Total (95% CI)

934

710

100%

0.93[0.88,0.99]

Total events: 771 (Psych therapy), 636 (Usual care)
Heterogeneity: Tau2=0.01; Chi2=43.35, df=13(P<0.0001); I2=70.01%
Test for overall effect: Z=2.32(P=0.02)
Test for subgroup differences: Chi2=2.08, df=1 (P=0.72), I2=0%
0.5

Favours usual care

0.7

1

1.5

2

Favours psych therapy

Analysis 1.5. Comparison 1 Psychological therapies versus usual care or waiting list,
Outcome 5 Severity of anxiety symptoms at end of treatment - participant rated.
Study or subgroup

CBT
N

Usual care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

1.5.1 Cognitive behavioural therapy versus usual care or waiting list
Burton 2012

15

5.9 (5.6)

11

5.2 (4.8)

11.01%

0.13[-0.65,0.91]

Lidbeck 1997

32

10.1 (3.5)

17

10.7 (5.3)

19.26%

-0.14[-0.73,0.45]

61

17.8 (7.7)

49

16.7 (6.9)

Zonneveld 2012
Subtotal ***

108

77

47.13%

0.15[-0.23,0.52]

77.41%

0.07[-0.22,0.37]

Heterogeneity: Tau2=0; Chi2=0.68, df=2(P=0.71); I2=0%
Test for overall effect: Z=0.49(P=0.62)
1.5.2 Integrative therapies versus usual care or waiting list
Kolk 2004

69

22.59%

0.01[-0.53,0.56]

Subtotal ***

69

15.5 (5.4)

16

16

15.4 (5.8)

22.59%

0.01[-0.53,0.56]

177

93

100%

0.06[-0.2,0.32]

Heterogeneity: Not applicable
Test for overall effect: Z=0.05(P=0.96)
Total ***

Heterogeneity: Tau2=0; Chi2=0.71, df=3(P=0.87); I2=0%
Test for overall effect: Z=0.45(P=0.65)
Test for subgroup differences: Chi2=0.04, df=1 (P=0.85), I2=0%
Favours usual care
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Analysis 1.6. Comparison 1 Psychological therapies versus usual care or waiting
list, Outcome 6 Severity of anxiety symptoms at end of treatment - clinician rated.
Study or subgroup

CBT
N

Usual care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

1.6.1 Cognitive behavioural therapy versus usual care
Escobar 2007

63

15.9 (8.6)

65

18.5 (8.6)

43.51%

-0.3[-0.65,0.05]

Moreno 2013

108

9.6 (7.6)

48

13.1 (7.6)

44.68%

-0.46[-0.8,-0.12]

Subtotal ***

171

88.19%

-0.38[-0.63,-0.14]

113

Heterogeneity: Tau2=0; Chi2=0.42, df=1(P=0.52); I2=0%
Test for overall effect: Z=3.05(P=0)
Favours psych therapy
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CBT
N

Usual care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

1.6.2 Behavioural therapy versus usual care
Katsamanis 2011

17

11.81%

-0.57[-1.24,0.1]

Subtotal ***

17

12.1 (7.3)

19

19

16 (6.3)

11.81%

-0.57[-1.24,0.1]

188

132

100%

-0.4[-0.63,-0.17]

Heterogeneity: Not applicable
Test for overall effect: Z=1.66(P=0.1)
Total ***

Heterogeneity: Tau2=0; Chi2=0.69, df=2(P=0.71); I2=0%
Test for overall effect: Z=3.43(P=0)
Test for subgroup differences: Chi2=0.27, df=1 (P=0.61), I2=0%
-1

Favours psych therapy
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Analysis 1.7. Comparison 1 Psychological therapies versus usual care or waiting list,
Outcome 7 Severity of anxiety symptoms within 1 year after treatment - participant rated.
Study or subgroup

CBT
N

Usual care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

1.7.1 Cognitive behavioural therapy versus usual care or waiting list
Lidbeck 1997

32

Subtotal ***

32

9.4 (3.8)

17

9.4 (4.2)

17

46.3%

0[-0.59,0.59]

46.3%

0[-0.59,0.59]

Heterogeneity: Not applicable
Test for overall effect: Not applicable
1.7.2 Integrative therapies versus usual care or waiting list
Kolk 2004

69

53.7%

0.33[-0.21,0.88]

Subtotal ***

69

15.4 (5.7)

16

16

13.6 (4.2)

53.7%

0.33[-0.21,0.88]

101

33

100%

0.18[-0.22,0.58]

Heterogeneity: Not applicable
Test for overall effect: Z=1.19(P=0.23)
Total ***

Heterogeneity: Tau2=0; Chi2=0.66, df=1(P=0.42); I2=0%
Test for overall effect: Z=0.87(P=0.38)
Test for subgroup differences: Chi2=0.66, df=1 (P=0.42), I2=0%
-0.5 -0.25

Favours psych therapy
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Favours usual care

Analysis 1.8. Comparison 1 Psychological therapies versus usual care or waiting list,
Outcome 8 Severity of anxiety symptoms within 1 year after treatment - clinician rated.
Study or subgroup

CBT
N

Usual care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

Escobar 2007

51

14.9 (6.7)

44

17.6 (6.6)

47.84%

-0.41[-0.81,0]

Moreno 2013

108

7.6 (7.5)

48

14.5 (7.9)

52.16%

-0.9[-1.25,-0.54]

Total ***

159

100%

-0.66[-1.15,-0.18]

92

Heterogeneity: Tau2=0.08; Chi2=3.2, df=1(P=0.07); I2=68.76%
Test for overall effect: Z=2.69(P=0.01)
Favours psych therapy
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Analysis 1.9. Comparison 1 Psychological therapies versus usual care or waiting list,
Outcome 9 Severity of anxiety symptoms > 1 year after treatment - clinician rated.
Study or subgroup

CBT
N

Moreno 2013

Usual care

Mean(SD)

108

N

9 (7.8)

Std. Mean Difference

Std. Mean Difference

Random, 95% CI

Random, 95% CI

Mean(SD)

48

16.2 (8.2)

-0.91[-1.26,-0.55]
-2

Favours CBT

-1

0

1

2

Favours usual care

Analysis 1.10. Comparison 1 Psychological therapies versus usual care or waiting list,
Outcome 10 Severity of depressive symptoms at end of treatment - participant rated.
Study or subgroup

CBT
N

Usual care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

1.10.1 Cognitive behavioural therapy versus usual care or waiting list
Burton 2012

15

8.4 (5.1)

11

6.7 (4.9)

5.47%

0.31[-0.47,1.1]

Lidbeck 1997

32

6.7 (3.9)

17

6.2 (3.3)

9.17%

0.13[-0.46,0.72]

Martin 2007

70

13.7 (9.1)

70

12.5 (7.4)

23%

0.14[-0.19,0.48]

Zonneveld 2012

61

29.2 (9.7)

49

29.8 (11.6)

19.17%

-0.06[-0.43,0.32]

56.81%

0.09[-0.13,0.31]

Subtotal ***

178

147

Heterogeneity: Tau2=0; Chi2=1.02, df=3(P=0.8); I2=0%
Test for overall effect: Z=0.78(P=0.44)
1.10.2 Psychodynamic therapy versus usual care or waiting list
Schaefert 2013

146

Subtotal ***

146

6.7 (4.8)

105

8.1 (4.9)

105

32.66%

-0.3[-0.55,-0.04]

32.66%

-0.3[-0.55,-0.04]

Heterogeneity: Not applicable
Test for overall effect: Z=2.3(P=0.02)
1.10.3 Integrative therapy versus usual care or waiting list
Kolk 2004

69

Subtotal ***

69

26.9 (10.2)

10.53%

0.1[-0.45,0.64]

16

16

25.9 (10.8)

10.53%

0.1[-0.45,0.64]

268

100%

-0.03[-0.22,0.16]

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%
Test for overall effect: Z=0.34(P=0.73)
Total ***

393

Heterogeneity: Tau2=0.01; Chi2=6.39, df=5(P=0.27); I2=21.81%
Test for overall effect: Z=0.36(P=0.72)
Test for subgroup differences: Chi2=5.38, df=1 (P=0.07), I2=62.81%
Favours psych therapy

-1

-0.5

0

0.5

1

Favours usual care

Analysis 1.11. Comparison 1 Psychological therapies versus usual care or waiting list,
Outcome 11 Severity of depressive symptoms at end of treatment - clinician rated.
Study or subgroup

CBT
N

Mean(SD)

Usual care
N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

1.11.1 Cognitive behavioural therapy versus usual care or waiting list
Escobar 2007

63

12.9 (6.8)

65

14.6 (6.8)

Favours psych therapy

43.67%
-1

-0.5

0

0.5

1

-0.26[-0.61,0.09]

Favours usual care
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CBT
N

Moreno 2013

108

Subtotal ***

171

Usual care

Mean(SD)

N

9.3 (6.8)

Std. Mean Difference

Mean(SD)

48

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

10.9 (6.6)

113

45.46%

-0.24[-0.58,0.1]

89.13%

-0.25[-0.49,-0.01]

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.95); I2=0%
Test for overall effect: Z=2(P=0.05)
1.11.2 Behavioural therapy versus usual care or waiting list
Katsamanis 2011

17

10.87%

-0.26[-0.96,0.44]

Subtotal ***

17

8.8 (24.8)

15

15

14.5 (16.5)

10.87%

-0.26[-0.96,0.44]

188

128

100%

-0.25[-0.48,-0.02]

Heterogeneity: Not applicable
Test for overall effect: Z=0.73(P=0.46)
Total ***

Heterogeneity: Tau2=0; Chi2=0.01, df=2(P=1); I2=0%
Test for overall effect: Z=2.13(P=0.03)
Test for subgroup differences: Chi2=0, df=1 (P=0.97), I2=0%
-1

Favours psych therapy

-0.5

0

0.5

1

Favours usual care

Analysis 1.12. Comparison 1 Psychological therapies versus usual care or waiting list,
Outcome 12 Severity of depressive symptoms within 1 year after treatment - participant rated.
Study or subgroup

CBT
N

Usual care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

1.12.1 Cognitive behavioural therapy versus usual care or waiting list
Lidbeck 1997

32

6.4 (4)

17

6.2 (3.7)

19.29%

Martin 2007

70

14.2 (9.5)

70

11.9 (7.5)

28.44%

0.27[-0.07,0.6]

Subtotal ***

102

47.73%

0.21[-0.07,0.5]

87

0.05[-0.54,0.64]

Heterogeneity: Tau2=0; Chi2=0.4, df=1(P=0.53); I2=0%
Test for overall effect: Z=1.45(P=0.15)
1.12.2 Psychodynamic therapy versus usual care or waiting list
Schaefert 2013

149

Subtotal ***

149

6.3 (4.6)

112

8 (5.3)

112

31.62%

-0.35[-0.59,-0.1]

31.62%

-0.35[-0.59,-0.1]

Heterogeneity: Not applicable
Test for overall effect: Z=2.74(P=0.01)
1.12.3 Integrative therapy versus usual care or waiting list
Kolk 2004

69

20.65%

0.31[-0.24,0.85]

Subtotal ***

69

25.9 (9.6)

16

16

23.1 (6.4)

20.65%

0.31[-0.24,0.85]

320

215

100%

0.04[-0.34,0.42]

Heterogeneity: Not applicable
Test for overall effect: Z=1.1(P=0.27)
Total ***

Heterogeneity: Tau2=0.1; Chi2=10.7, df=3(P=0.01); I2=71.97%
Test for overall effect: Z=0.21(P=0.84)
Test for subgroup differences: Chi2=10.31, df=1 (P=0.01), I2=80.6%
Favours psych therapy
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-0.5
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Favours usual care
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Analysis 1.13. Comparison 1 Psychological therapies versus usual care or waiting list,
Outcome 13 Severity of depressive symptoms within 1 year after treatment - clinician rated.
Study or subgroup

CBT
N

Usual care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

Escobar 2007

51

12.9 (6.3)

44

14.3 (6.2)

48.74%

-0.22[-0.63,0.18]

Moreno 2013

108

6 (6.1)

48

11.4 (6.4)

51.26%

-0.86[-1.21,-0.5]

Total ***

159

100%

-0.55[-1.17,0.07]

92

Heterogeneity: Tau2=0.16; Chi2=5.33, df=1(P=0.02); I2=81.25%
Test for overall effect: Z=1.73(P=0.08)
-2

Favours CBT

-1

0

1

2

Favours usual care

Analysis 1.14. Comparison 1 Psychological therapies versus usual care or waiting list,
Outcome 14 Severity of depressive symptoms > 1 year after treatment - clinician rated.
Study or subgroup

CBT
N

Moreno 2013

Usual care

Mean(SD)

108

N

7.4 (7.2)

Std. Mean Difference

Std. Mean Difference

Random, 95% CI

Random, 95% CI

Mean(SD)

48

13.4 (7.8)

-0.81[-1.16,-0.46]
-2

Favours psych therapy

-1

0

1

2

Favours usual care

Analysis 1.15. Comparison 1 Psychological therapies versus usual care or waiting list,
Outcome 15 Dysfunctional cognitions, emotions and behaviours at end of treatment.
Study or subgroup

CBT
N

Usual care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

1.15.1 Cognitive behavioural therapy versus usual care or waiting list
Lidbeck 1997

32

4.8 (3.1)

17

6.4 (3.2)

15.84%

-0.5[-1.1,0.1]

Martin 2007

70

5.9 (4.1)

70

5.5 (3.6)

36.24%

0.1[-0.23,0.43]

Subtotal ***

102

52.09%

-0.15[-0.73,0.44]

87

Heterogeneity: Tau2=0.12; Chi2=3.02, df=1(P=0.08); I2=66.85%
Test for overall effect: Z=0.49(P=0.62)
1.15.2 Psychodynamic therapy versus usual care or waiting list
Schaefert 2013

147

47.91%

-0.14[-0.39,0.12]

Subtotal ***

147

7.8 (6.3)

104

104

8.6 (6.2)

47.91%

-0.14[-0.39,0.12]

249

191

100%

-0.11[-0.37,0.16]

Heterogeneity: Not applicable
Test for overall effect: Z=1.06(P=0.29)
Total ***

Heterogeneity: Tau2=0.02; Chi2=3.26, df=2(P=0.2); I2=38.68%
Test for overall effect: Z=0.8(P=0.42)
Test for subgroup differences: Chi2=0, df=1 (P=0.98), I2=0%
Favours psychol therapy
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Analysis 1.16. Comparison 1 Psychological therapies versus usual care or waiting list,
Outcome 16 Dysfunctional cognitions, emotions, and behaviours within 1 year after treatment.
Study or subgroup

CBT
N

Usual care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

1.16.1 Cognitive behavioural therapy versus usual care or waiting list
Lidbeck 1997

32

4.4 (3.4)

17

6.4 (3.2)

13.07%

Martin 2007

70

5.4 (3.3)

70

5.5 (5.2)

34.85%

-0.02[-0.35,0.31]

Subtotal ***

102

47.92%

-0.25[-0.79,0.3]

87

-0.59[-1.19,0.01]

Heterogeneity: Tau2=0.1; Chi2=2.63, df=1(P=0.1); I2=61.97%
Test for overall effect: Z=0.9(P=0.37)
1.16.2 Psychodynamic therapy versus usual care or waiting list
Schaefert 2013

149

52.08%

-0.13[-0.38,0.11]

Subtotal ***

149

7.7 (6.6)

113

113

8.6 (6.9)

52.08%

-0.13[-0.38,0.11]

251

200

100%

-0.16[-0.38,0.07]

Heterogeneity: Not applicable
Test for overall effect: Z=1.08(P=0.28)
Total ***

Heterogeneity: Tau2=0.01; Chi2=2.64, df=2(P=0.27); I2=24.26%
Test for overall effect: Z=1.33(P=0.18)
Test for subgroup differences: Chi2=0.14, df=1 (P=0.71), I2=0%
Favours psych therapy

-2

-1

0

1

2

Favours usual care

Analysis 1.17. Comparison 1 Psychological therapies versus usual care or waiting list, Outcome 17 Adverse events.
Study or subgroup

Experimental

Control

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Martin 2007

Weight

Risk Ratio
M-H, Random, 95% CI

0/70

0/70

12/120

4/48

89.66%

1.2[0.41,3.54]

Zonneveld 2012

1/70

0/67

10.34%

2.87[0.12,69.32]

Total (95% CI)

260

185

100%

1.31[0.47,3.66]

Moreno 2013

Not estimable

Total events: 13 (Experimental), 4 (Control)
Heterogeneity: Tau2=0; Chi2=0.26, df=1(P=0.61); I2=0%
Test for overall effect: Z=0.52(P=0.6)
Favours CBT

0.01

0.1

1

10

100

Favours usual care

Analysis 1.18. Comparison 1 Psychological therapies versus usual care
or waiting list, Outcome 18 Treatment response at end of treatment.
Study or subgroup
Allen 2006

CBT

Usual care

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

17/43

3/41

13.97%

5.4[1.71,17.07]

Burton 2012

7/11

2/15

10.27%

4.77[1.22,18.7]

Escobar 2007

38/63

16/62

52.65%

2.34[1.46,3.73]

Moreno 2013

51/108

5/48

23.12%

4.53[1.93,10.64]

100%

3.3[2.08,5.21]

Total (95% CI)

225

166
Favours usual care
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CBT

Usual care

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

Total events: 113 (CBT), 26 (Usual care)
Heterogeneity: Tau2=0.05; Chi2=3.72, df=3(P=0.29); I2=19.31%
Test for overall effect: Z=5.1(P<0.0001)
0.05

Favours usual care

0.2

1

5

20

Favours CBT

Analysis 1.19. Comparison 1 Psychological therapies versus usual care or
waiting list, Outcome 19 Treatment response within 1 year after treatment.
Study or subgroup

CBT

Usual care

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

Allen 2006

16/43

2/41

17.52%

7.63[1.87,31.13]

Escobar 2007

25/50

13/42

44.11%

1.62[0.95,2.74]

Moreno 2013

46/108

8/48

38.37%

2.56[1.31,4.99]

201

131

100%

2.53[1.25,5.1]

Total (95% CI)
Total events: 87 (CBT), 23 (Usual care)

Heterogeneity: Tau2=0.22; Chi2=4.89, df=2(P=0.09); I2=59.11%
Test for overall effect: Z=2.59(P=0.01)
Favours usual care

0.01

0.1

1

10

100

Favours CBT

Analysis 1.20. Comparison 1 Psychological therapies versus usual care
or waiting list, Outcome 20 Treatment response > 1 year after treatment.
Study or subgroup
Allen 2006
Moreno 2013

CBT

Usual care

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

17/43

2/41

79.68%

8.1[2,32.91]

29/108

0/48

20.32%

26.52[1.65,425.31]

151

89

100%

10.31[2.95,36.02]

Total (95% CI)
Total events: 46 (CBT), 2 (Usual care)

Heterogeneity: Tau2=0; Chi2=0.67, df=1(P=0.41); I2=0%
Test for overall effect: Z=3.66(P=0)
Favours usual care

0.002

0.1

1

10

500

Favours CBT

Analysis 1.21. Comparison 1 Psychological therapies versus usual care or waiting
list, Outcome 21 Functional disability and quality of life at end of treatment.
Study or subgroup

CBT
N

Usual care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

1.21.1 Cognitive behavioural therapy versus usual care or waiting list
Allen 2006

39

63.3 (25.5)

38

56.9 (25.7)

10.67%

0.25[-0.2,0.69]

Burton 2012

15

41.7 (7.3)

11

40.3 (8.4)

3.53%

0.17[-0.61,0.95]

Escobar 2007

63

72.2 (23.4)

65

69.7 (23.8)

17.85%

0.1[-0.24,0.45]

Zonneveld 2012

61

40.1 (12)

49

38.4 (12.4)

15.14%

0.14[-0.24,0.52]

Favours usual care
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CBT
N

Subtotal ***

Usual care

Mean(SD)

178

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

163

47.18%

0.15[-0.06,0.37]

Heterogeneity: Tau2=0; Chi2=0.25, df=3(P=0.97); I2=0%
Test for overall effect: Z=1.4(P=0.16)
1.21.2 Behavioural therapy versus usual care or waiting list
Katsamanis 2011

17

Subtotal ***

17

44.2 (34.6)

17

39 (29.2)

17

4.73%

0.16[-0.51,0.83]

4.73%

0.16[-0.51,0.83]

Heterogeneity: Not applicable
Test for overall effect: Z=0.46(P=0.64)
1.21.3 Third-wave cognitive behavioural therapy versus usual care or waiting
list
Van Ravesteijn 2013

58

Subtotal ***

58

42.8 (12.2)

53

41.8 (11.9)

53

15.46%

0.08[-0.29,0.46]

15.46%

0.08[-0.29,0.46]

Heterogeneity: Not applicable
Test for overall effect: Z=0.43(P=0.66)
1.21.4 Psychodynamic therapy versus usual care or waiting list
Schaefert 2013

145

32.63%

0.24[-0.01,0.5]

Subtotal ***

145

45.1 (9.1)

99

99

42.7 (10.5)

32.63%

0.24[-0.01,0.5]

398

332

100%

0.17[0.03,0.32]

Heterogeneity: Not applicable
Test for overall effect: Z=1.86(P=0.06)
Total ***

Heterogeneity: Tau2=0; Chi2=0.8, df=6(P=0.99); I2=0%
Test for overall effect: Z=2.3(P=0.02)
Test for subgroup differences: Chi2=0.55, df=1 (P=0.91), I2=0%
Favours usual care

-2
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Favours psych therapy

Analysis 1.22. Comparison 1 Psychological therapies versus usual care or waiting
list, Outcome 22 Functional disability and quality of life within 1 year after treatment.
Study or subgroup

CBT
N

Usual care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

1.22.1 Cognitive behavioural therapy versus usual care or waiting list
Allen 2006

37

63.9 (28.5)

36

55 (28.5)

13.94%

Escobar 2007

51

73.2 (24)

44

69.4 (22.9)

18.21%

0.16[-0.24,0.56]

Subtotal ***

88

32.15%

0.22[-0.08,0.53]

80

0.31[-0.15,0.77]

Heterogeneity: Tau2=0; Chi2=0.22, df=1(P=0.64); I2=0%
Test for overall effect: Z=1.45(P=0.15)
1.22.2 Third-wave cognitive behavioural therapy versus usual care or waiting
list
Van Ravesteijn 2013

57

Subtotal ***

57

43.3 (12.7)

50

44.5 (10.5)

50

20.58%

-0.1[-0.48,0.28]

20.58%

-0.1[-0.48,0.28]

47.27%

0.23[-0.02,0.48]

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%
Test for overall effect: Z=0.52(P=0.6)
1.22.3 Psychodynamic therapy versus usual care or waiting list
Schaefert 2013

143

45.6 (10.2)

108

43.1 (10.8)

Favours usual care
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CBT
N

Subtotal ***

Usual care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

143

108

47.27%

0.23[-0.02,0.48]

288

238

100%

0.16[-0.01,0.33]

Heterogeneity: Not applicable
Test for overall effect: Z=1.83(P=0.07)
Total ***

Heterogeneity: Tau2=0; Chi2=2.55, df=3(P=0.47); I2=0%
Test for overall effect: Z=1.84(P=0.07)
Test for subgroup differences: Chi2=2.33, df=1 (P=0.31), I2=14.21%
Favours usual care

-1

-0.5
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1

Favours psych therapy

Analysis 1.23. Comparison 1 Psychological therapies versus usual care or waiting
list, Outcome 23 Functional disability and quality of life > 1 year of treatment.
Study or subgroup

CBT
N

Allen 2006

35

Total ***

35

Usual care

Mean(SD)
68.6 (25.5)

N

Std. Mean Difference

Mean(SD)

37

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

59.2 (26.3)

37

100%

0.36[-0.11,0.82]

100%

0.36[-0.11,0.82]

Heterogeneity: Not applicable
Test for overall effect: Z=1.51(P=0.13)
Favours usual care
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Favours CBT

Analysis 1.24. Comparison 1 Psychological therapies versus usual
care or waiting list, Outcome 24 Healthcare use at end of treatment.
Study or subgroup

CBT
N

Usual care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

Lidbeck 1997

32

2.5 (2.6)

17

4.2 (2.6)

39.85%

-0.64[-1.25,-0.04]

Sumathipala 2000

34

3.1 (6.7)

34

7.9 (6.7)

60.15%

-0.71[-1.2,-0.22]

Total ***

66

100%

-0.68[-1.06,-0.3]

51

Heterogeneity: Tau2=0; Chi2=0.03, df=1(P=0.87); I2=0%
Test for overall effect: Z=3.51(P=0)
Favours CBT
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Favours usual care

Analysis 1.25. Comparison 1 Psychological therapies versus usual care
or waiting list, Outcome 25 Healthcare use within 1 year after treatment.
Study or subgroup

CBT
N

Usual care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

1.25.1 Cognitive behavioural therapy versus usual care or waiting list
Lidbeck 1997

32

2.6 (2.6)

17

4 (2.5)

11.3%

Martin 2007

70

8.5 (9.2)

70

10.2 (8.9)

30.22%

-0.19[-0.52,0.15]

Subtotal ***

102

41.53%

-0.27[-0.56,0.02]

87
Favours psych therapy
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Non-pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

115

Cochrane

Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Cochrane Database of Systematic Reviews

CBT
N

Usual care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

Heterogeneity: Tau2=0; Chi2=1, df=1(P=0.32); I2=0.41%
Test for overall effect: Z=1.81(P=0.07)
1.25.2 Integrative therapies versus usual care or waiting list
Kolk 2004

66

Subtotal ***

66

3.4 (3.9)

15

2.9 (1.8)

15

12.7%

0.13[-0.44,0.69]

12.7%

0.13[-0.44,0.69]

Heterogeneity: Not applicable
Test for overall effect: Z=0.44(P=0.66)
1.25.3 Psychodynamic therapy versus usual care or waiting list
Schaefert 2013

150

45.77%

0.02[-0.23,0.26]

Subtotal ***

150

8 (7.7)

112

112

7.9 (7.9)

45.77%

0.02[-0.23,0.26]

318

214

100%

-0.09[-0.31,0.12]

Heterogeneity: Not applicable
Test for overall effect: Z=0.13(P=0.89)
Total ***

Heterogeneity: Tau2=0.01; Chi2=3.75, df=3(P=0.29); I2=20.02%
Test for overall effect: Z=0.87(P=0.39)
Test for subgroup differences: Chi2=2.74, df=1 (P=0.25), I2=27.05%
Favours psych therapy

-1

-0.5

0

0.5

1

Favours usual care

Comparison 2. Psychological therapies versus enhanced care
Outcome or subgroup title

No. of
studies

No. of
participants

Statistical method

Effect size

1 Severity of somatic symptoms at end of
treatment

5

624

Std. Mean Difference (IV, Random, 95%
CI)

-0.19 [-0.43, 0.04]

1.1 Cognitive behavioural therapy versus
enhanced care

3

307

Std. Mean Difference (IV, Random, 95%
CI)

-0.34 [-0.71, 0.03]

1.2 Third-wave cognitive behavioural therapy versus enhanced care

1

106

Std. Mean Difference (IV, Random, 95%
CI)

0.01 [-0.38, 0.39]

1.3 Psychodynamic therapy versus enhanced care

1

211

Std. Mean Difference (IV, Random, 95%
CI)

-0.04 [-0.31, 0.23]

2 Severity of somatic symptoms within 1
year after treatment

5

593

Std. Mean Difference (IV, Random, 95%
CI)

-0.21 [-0.40,
-0.02]

2.1 Cognitive behavioural therapy versus
enhanced care

3

289

Std. Mean Difference (IV, Random, 95%
CI)

-0.30 [-0.60,
-0.00]

2.2 Third-wave cognitive behavioural therapy versus enhanced care

1

93

Std. Mean Difference (IV, Random, 95%
CI)

0.05 [-0.36, 0.46]

2.3 Psychodynamic therapy versus enhanced care

1

211

Std. Mean Difference (IV, Random, 95%
CI)

-0.20 [-0.47, 0.07]
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Outcome or subgroup title

No. of
studies

No. of
participants

Statistical method

Effect size

3 Severity of somatic symptoms > 1 year after treatment

2

172

Std. Mean Difference (IV, Random, 95%
CI)

-0.32 [-0.73, 0.10]

3.1 Cognitive behavioural therapy versus
enhanced care

1

82

Std. Mean Difference (IV, Random, 95%
CI)

-0.53 [-0.98,
-0.09]

3.2 Third-wave cognitive behavioural therapy versus enhanced care

1

90

Std. Mean Difference (IV, Random, 95%
CI)

-0.11 [-0.53, 0.30]

4 Acceptability

5

679

Risk Ratio (M-H, Random, 95% CI)

0.93 [0.87, 1.00]

4.1 Cognitive behavioural therapy versus
enhanced care

3

349

Risk Ratio (M-H, Random, 95% CI)

0.91 [0.82, 1.02]

4.2 Third-wave cognitive behavioural therapy versus enhanced care

1

119

Risk Ratio (M-H, Random, 95% CI)

0.91 [0.82, 1.01]

4.3 Psychodynamic therapy versus enhanced care

1

211

Risk Ratio (M-H, Random, 95% CI)

1.01 [0.89, 1.14]

5 Severity of anxiety or depressive symptoms (or both) at end of treatment

5

624

Std. Mean Difference (IV, Random, 95%
CI)

-0.14 [-0.30, 0.02]

5.1 Cognitive behavioural therapy versus
enhanced care

3

307

Std. Mean Difference (IV, Random, 95%
CI)

-0.17 [-0.40, 0.05]

5.2 Third-wave cognitive behavioural therapy versus enhanced care

1

106

Std. Mean Difference (IV, Random, 95%
CI)

-0.05 [-0.43, 0.33]

5.3 Psychodynamic therapy versus enhanced care

1

211

Std. Mean Difference (IV, Random, 95%
CI)

-0.13 [-0.40, 0.14]

6 Severity of anxiety or depressive symptoms (or both) within 1 year after treatment

5

593

Std. Mean Difference (IV, Random, 95%
CI)

-0.13 [-0.29, 0.03]

6.1 Cognitive behavioural therapy versus
enhanced care

3

289

Std. Mean Difference (IV, Random, 95%
CI)

-0.17 [-0.40, 0.06]

6.2 Third-wave behavioural therapy versus
enhanced care

1

93

Std. Mean Difference (IV, Random, 95%
CI)

-0.04 [-0.45, 0.36]

6.3 Psychodynamic therapy versus enhanced care

1

211

Std. Mean Difference (IV, Random, 95%
CI)

-0.11 [-0.38, 0.16]

7 Severity of anxiety or depressive symptoms (or both) > 1 year after treatment

2

184

Std. Mean Difference (IV, Random, 95%
CI)

-0.26 [-0.55, 0.03]

7.1 Cognitive behavioural therapy versus
enhanced care

1

94

Std. Mean Difference (IV, Random, 95%
CI)

-0.36 [-0.77, 0.04]

7.2 Third-wave cognitive behavioural therapy versus enhanced care

1

90

Std. Mean Difference (IV, Random, 95%
CI)

-0.15 [-0.56, 0.26]
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Outcome or subgroup title

No. of
studies

No. of
participants

Statistical method

Effect size

8 Dysfunctional cognitions, emotions, and
behaviours at end of treatment

4

499

Std. Mean Difference (IV, Random, 95%
CI)

-0.09 [-0.29, 0.10]

8.1 Cognitive behavioural therapy versus
enhanced care

2

182

Std. Mean Difference (IV, Random, 95%
CI)

-0.28 [-0.57, 0.01]

8.2 Third-wave cognitive behavioural therapy versus enhanced care

1

106

Std. Mean Difference (IV, Random, 95%
CI)

0.06 [-0.32, 0.44]

8.3 Psychodynamic therapy versus enhanced care

1

211

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [-0.27, 0.27]

9 Dysfunctional cognitions, emotions, and
behaviours within 1 year after treatment

4

477

Std. Mean Difference (IV, Random, 95%
CI)

-0.24 [-0.49, 0.00]

9.1 Cognitive behavioural therapy versus
enhanced care

2

173

Std. Mean Difference (IV, Random, 95%
CI)

-0.45 [-0.83,
-0.07]

9.2 Third-wave cognitive behavioural therapy versus enhanced care

1

93

Std. Mean Difference (IV, Random, 95%
CI)

-0.03 [-0.44, 0.38]

9.3 Psychodynamic therapy versus enhanced care

1

211

Std. Mean Difference (IV, Random, 95%
CI)

-0.13 [-0.40, 0.14]

10 Dysfunctional cognitions, emotions, and
behaviours > 1 year after treatment

2

184

Std. Mean Difference (IV, Random, 95%
CI)

-0.58 [-1.27, 0.11]

10.1 Cognitive behavioural therapy versus
enhanced care

1

94

Std. Mean Difference (IV, Random, 95%
CI)

-0.94 [-1.36,
-0.51]

10.2 Third-wave cognitive behavioural
therapy versus enhanced care

1

90

Std. Mean Difference (IV, Random, 95%
CI)

-0.23 [-0.64, 0.19]

11 Functional disability and quality of life
at end of treatment

4

497

Std. Mean Difference (IV, Random, 95%
CI)

0.13 [-0.05, 0.30]

11.1 Cognitive behavioural therapy versus
enhanced care

2

182

Std. Mean Difference (IV, Random, 95%
CI)

0.21 [-0.08, 0.51]

11.2 Third-wave cognitive behavioural
therapy versus enhanced care

1

104

Std. Mean Difference (IV, Random, 95%
CI)

0.07 [-0.31, 0.46]

11.3 Psychodynamic therapy at end of
treatment

1

211

Std. Mean Difference (IV, Random, 95%
CI)

0.08 [-0.19, 0.35]

12 Functional disability and quality of life
within 1 year after treatment

4

476

Std. Mean Difference (IV, Random, 95%
CI)

0.20 [0.02, 0.38]

12.1 Cognitive behavioural therapy versus
enhanced care

2

173

Std. Mean Difference (IV, Random, 95%
CI)

0.30 [0.00, 0.60]

12.2 Third-wave cognitive behavioural
therapy versus enhanced care

1

92

Std. Mean Difference (IV, Random, 95%
CI)

0.10 [-0.31, 0.51]
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Outcome or subgroup title

No. of
studies

No. of
participants

Statistical method

Effect size

12.3 Psychodynamic therapy versus enhanced care

1

211

Std. Mean Difference (IV, Random, 95%
CI)

0.16 [-0.11, 0.43]

13 Functional disability and quality of life >
1 year of treatment

2

184

Std. Mean Difference (IV, Random, 95%
CI)

0.22 [-0.16, 0.60]

13.1 Cognitive behavioural therapy versus
enhanced care

1

94

Std. Mean Difference (IV, Random, 95%
CI)

0.42 [0.01, 0.83]

13.2 Third-wave cognitive behavioural
therapy versus enhanced care

1

90

Std. Mean Difference (IV, Random, 95%
CI)

0.03 [-0.39, 0.44]

14 Healthcare use at end of treatment

2

334

Std. Mean Difference (IV, Random, 95%
CI)

-0.03 [-0.33, 0.28]

14.1 Cognitive behavioural therapy versus
enhanced care

1

123

Std. Mean Difference (IV, Random, 95%
CI)

-0.21 [-0.56, 0.15]

14.2 Psychodynamic therapy versus enhanced care

1

211

Std. Mean Difference (IV, Random, 95%
CI)

0.11 [-0.16, 0.38]

15 Healthcare use within 1 year after treatment

2

319

Std. Mean Difference (IV, Random, 95%
CI)

-0.24 [-0.46,
-0.01]

15.1 Cognitive behavioural therapy versus
enhanced care

1

108

Std. Mean Difference (IV, Random, 95%
CI)

-0.08 [-0.46, 0.30]

15.2 Psychodynamic therapy versus enhanced care

1

211

Std. Mean Difference (IV, Random, 95%
CI)

-0.32 [-0.59,
-0.05]

Analysis 2.1. Comparison 2 Psychological therapies versus enhanced
care, Outcome 1 Severity of somatic symptoms at end of treatment.
Study or subgroup

Psychological intervt.
N

Enhanced care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

2.1.1 Cognitive behavioural therapy versus enhanced care
Schröder 2012

50

1.5 (0.7)

55

1.8 (0.7)

18.77%

-0.51[-0.9,-0.12]

Speckens 1995

39

3.1 (1.7)

38

4.2 (2.1)

15.76%

-0.57[-1.03,-0.11]

65

12.4 (9.6)

60

12.4 (8.9)

Sumathipala 2008
Subtotal ***

154

153

20.75%

0[-0.35,0.35]

55.28%

-0.34[-0.71,0.03]

Heterogeneity: Tau2=0.07; Chi2=5.24, df=2(P=0.07); I2=61.86%
Test for overall effect: Z=1.8(P=0.07)
2.1.2 Third-wave cognitive behavioural therapy versus enhanced care
Fjorback 2013

55

Subtotal ***

55

41.7 (17.4)

51

41.6 (16.4)

51

19.18%

0.01[-0.38,0.39]

19.18%

0.01[-0.38,0.39]

Heterogeneity: Not applicable
Test for overall effect: Z=0.03(P=0.98)
Favours psych therapy

-1

-0.5

0

0.5

1

Favours enhanced care
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Psychological intervt.
N

Enhanced care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

2.1.3 Psychodynamic therapy versus enhanced care
Sattel 2012

107

25.54%

-0.04[-0.31,0.23]

Subtotal ***

107

13.8 (5.3)

104

104

14 (5.3)

25.54%

-0.04[-0.31,0.23]

316

308

100%

-0.19[-0.43,0.04]

Heterogeneity: Not applicable
Test for overall effect: Z=0.27(P=0.78)
Total ***

Heterogeneity: Tau2=0.04; Chi2=8.49, df=4(P=0.08); I2=52.91%
Test for overall effect: Z=1.61(P=0.11)
Test for subgroup differences: Chi2=2.13, df=1 (P=0.35), I2=5.99%
Favours psych therapy

-1

-0.5

0

0.5

1

Favours enhanced care

Analysis 2.2. Comparison 2 Psychological therapies versus enhanced care,
Outcome 2 Severity of somatic symptoms within 1 year after treatment.
Study or subgroup

Psychological intervt.
N

Enhanced care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

2.2.1 Cognitive behavioural therapy versus enhanced care
Schröder 2012

46

1.4 (0.7)

51

1.7 (0.7)

17.38%

-0.5[-0.9,-0.09]

Speckens 1995

37

3.7 (2.2)

39

4.7 (2.4)

14.4%

-0.43[-0.88,0.03]

63

11.7 (9.8)

53

12 (9)

20.34%

-0.03[-0.4,0.33]

52.12%

-0.3[-0.6,-0]

Sumathipala 2008
Subtotal ***

146

143

Heterogeneity: Tau2=0.03; Chi2=3.31, df=2(P=0.19); I2=39.49%
Test for overall effect: Z=1.97(P=0.05)
2.2.2 Third-wave cognitive behavioural therapy versus enhanced care
Fjorback 2013

50

Subtotal ***

50

40.9 (19.8)

43

40 (15.8)

43

17.19%

0.05[-0.36,0.46]

17.19%

0.05[-0.36,0.46]

Heterogeneity: Not applicable
Test for overall effect: Z=0.24(P=0.81)
2.2.3 Psychodynamic therapy versus enhanced care
Sattel 2012

107

30.69%

-0.2[-0.47,0.07]

Subtotal ***

107

12.7 (5.8)

104

104

13.8 (5.3)

30.69%

-0.2[-0.47,0.07]

303

290

100%

-0.21[-0.4,-0.02]

Heterogeneity: Not applicable
Test for overall effect: Z=1.43(P=0.15)
Total ***

Heterogeneity: Tau2=0.01; Chi2=5.32, df=4(P=0.26); I2=24.84%
Test for overall effect: Z=2.13(P=0.03)
Test for subgroup differences: Chi2=1.86, df=1 (P=0.39), I2=0%
Favours psych therapy

-1

-0.5

0

0.5

1

Favours enhanced care

Non-pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

120

Cochrane

Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.3. Comparison 2 Psychological therapies versus enhanced
care, Outcome 3 Severity of somatic symptoms > 1 year after treatment.
Study or subgroup

Psychological intervt.
N

Enhanced care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Std. Mean Difference

Random, 95% CI

Random, 95% CI

2.3.1 Cognitive behavioural therapy versus enhanced care
Schröder 2012

44

Subtotal ***

44

1.3 (0.7)

38

1.7 (0.5)

38

48.21%

-0.53[-0.98,-0.09]

48.21%

-0.53[-0.98,-0.09]

Heterogeneity: Not applicable
Test for overall effect: Z=2.37(P=0.02)
2.3.2 Third-wave cognitive behavioural therapy versus enhanced care
Fjorback 2013

46

51.79%

-0.11[-0.53,0.3]

Subtotal ***

46

38.7 (18.1)

44

44

40.7 (16.7)

51.79%

-0.11[-0.53,0.3]

90

82

100%

-0.32[-0.73,0.1]

Heterogeneity: Not applicable
Test for overall effect: Z=0.54(P=0.59)
Total ***

Heterogeneity: Tau2=0.04; Chi2=1.85, df=1(P=0.17); I2=46.01%
Test for overall effect: Z=1.51(P=0.13)
Test for subgroup differences: Chi2=1.85, df=1 (P=0.17), I2=46.01%
Favours psych therapy

-1

-0.5

0

0.5

1

Favours enhanced care

Analysis 2.4. Comparison 2 Psychological therapies versus enhanced care, Outcome 4 Acceptability.
Study or subgroup

Psychological intervt.

Enhanced care

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

2.4.1 Cognitive behavioural therapy versus enhanced care
Schröder 2012

45/54

66/66

20.21%

0.83[0.74,0.94]

Speckens 1995

34/39

38/40

16.95%

0.92[0.8,1.06]

Sumathipala 2008

64/75

64/75

18.2%

1[0.88,1.14]

Subtotal (95% CI)

168

181

55.36%

0.91[0.82,1.02]

Total events: 143 (Psychological intervt.), 168 (Enhanced care)
Heterogeneity: Tau2=0; Chi2=4, df=2(P=0.14); I2=49.98%
Test for overall effect: Z=1.68(P=0.09)
2.4.2 Third-wave cognitive behavioural therapy versus enhanced care
Fjorback 2013
Subtotal (95% CI)

52/59

58/60

24.41%

0.91[0.82,1.01]

59

60

24.41%

0.91[0.82,1.01]

Total events: 52 (Psychological intervt.), 58 (Enhanced care)
Heterogeneity: Not applicable
Test for overall effect: Z=1.73(P=0.08)
2.4.3 Psychodynamic therapy versus enhanced care
Sattel 2012
Subtotal (95% CI)

89/107

86/104

20.23%

1.01[0.89,1.14]

107

104

20.23%

1.01[0.89,1.14]

Total events: 89 (Psychological intervt.), 86 (Enhanced care)
Heterogeneity: Not applicable
Test for overall effect: Z=0.09(P=0.93)

Favours enhanced care

1

Favours psych therapy
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Psychological intervt.

Enhanced care

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Total (95% CI)

334

Weight

Risk Ratio
M-H, Random, 95% CI

345

100%

0.93[0.87,1]

Total events: 284 (Psychological intervt.), 312 (Enhanced care)
Heterogeneity: Tau2=0; Chi2=6.24, df=4(P=0.18); I2=35.87%
Test for overall effect: Z=2.07(P=0.04)
Test for subgroup differences: Chi2=1.79, df=1 (P=0.41), I2=0%
1

Favours enhanced care

Favours psych therapy

Analysis 2.5. Comparison 2 Psychological therapies versus enhanced care, Outcome
5 Severity of anxiety or depressive symptoms (or both) at end of treatment.
Study or subgroup

Psychological intervt.
N

Enhanced care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Std. Mean Difference

Random, 95% CI

Random, 95% CI

2.5.1 Cognitive behavioural therapy versus enhanced care
Schröder 2012

50

1.2 (1.1)

55

1.4 (0.9)

16.82%

-0.15[-0.54,0.23]

Speckens 1995

39

4.8 (3.5)

38

6.2 (4.1)

12.18%

-0.36[-0.81,0.09]

Sumathipala 2008

65

5.5 (7.7)

60

6.1 (8.3)

20.08%

-0.07[-0.43,0.28]

49.08%

-0.17[-0.4,0.05]

Subtotal ***

154

153

Heterogeneity: Tau2=0; Chi2=1, df=2(P=0.61); I2=0%
Test for overall effect: Z=1.51(P=0.13)
2.5.2 Third-wave cognitive behavioural therapy versus enhanced care
Fjorback 2013

55

Subtotal ***

55

30.2 (20.8)

51

31.3 (22.3)

51

17.04%

-0.05[-0.43,0.33]

17.04%

-0.05[-0.43,0.33]

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%
Test for overall effect: Z=0.26(P=0.79)
2.5.3 Psychodynamic therapy versus enhanced care
Sattel 2012

107

33.89%

-0.13[-0.4,0.14]

Subtotal ***

107

10.3 (6)

104

104

11.1 (6.2)

33.89%

-0.13[-0.4,0.14]

316

308

100%

-0.14[-0.3,0.02]

Heterogeneity: Not applicable
Test for overall effect: Z=0.95(P=0.34)
Total ***

Heterogeneity: Tau2=0; Chi2=1.3, df=4(P=0.86); I2=0%
Test for overall effect: Z=1.72(P=0.09)
Test for subgroup differences: Chi2=0.3, df=1 (P=0.86), I2=0%
Favours psych therapy

-1

-0.5

0

0.5

1

Favours enhanced care

Analysis 2.6. Comparison 2 Psychological therapies versus enhanced care, Outcome
6 Severity of anxiety or depressive symptoms (or both) within 1 year after treatment.
Study or subgroup

Psychological intervt.
N

Enhanced care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

2.6.1 Cognitive behavioural therapy versus enhanced care
Favours psych therapy

-1

-0.5

0

0.5

1

Favours enhanced care
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Psychological intervt.
N

Enhanced care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Std. Mean Difference

Random, 95% CI

Random, 95% CI

Schröder 2013

46

0.8 (1.9)

51

1.3 (0.8)

16.21%

-0.31[-0.71,0.09]

Speckens 1995

37

5.4 (3.8)

39

5.9 (4.1)

12.86%

-0.13[-0.58,0.33]

Sumathipala 2008

63

5.6 (7.9)

53

6.3 (8.2)

19.51%

-0.09[-0.45,0.28]

48.58%

-0.17[-0.4,0.06]

Subtotal ***

146

143

Heterogeneity: Tau2=0; Chi2=0.71, df=2(P=0.7); I2=0%
Test for overall effect: Z=1.45(P=0.15)
2.6.2 Third-wave behavioural therapy versus enhanced care
Fjorback 2013

50

Subtotal ***

50

29.9 (24.7)

43

31 (23.8)

43

15.68%

-0.04[-0.45,0.36]

15.68%

-0.04[-0.45,0.36]

Heterogeneity: Not applicable
Test for overall effect: Z=0.22(P=0.83)
2.6.3 Psychodynamic therapy versus enhanced care
Sattel 2012

107

35.73%

-0.11[-0.38,0.16]

Subtotal ***

107

10.5 (6)

104

104

11.2 (6.5)

35.73%

-0.11[-0.38,0.16]

303

290

100%

-0.13[-0.29,0.03]

Heterogeneity: Not applicable
Test for overall effect: Z=0.81(P=0.42)
Total ***

Heterogeneity: Tau2=0; Chi2=1.02, df=4(P=0.91); I2=0%
Test for overall effect: Z=1.58(P=0.11)
Test for subgroup differences: Chi2=0.31, df=1 (P=0.86), I2=0%
-1

Favours psych therapy

-0.5

0

0.5

1

Favours enhanced care

Analysis 2.7. Comparison 2 Psychological therapies versus enhanced care, Outcome
7 Severity of anxiety or depressive symptoms (or both) > 1 year after treatment.
Study or subgroup

Psychological intervt.
N

Mean(SD)

Enhanced care
N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

2.7.1 Cognitive behavioural therapy versus enhanced care
Schröder 2012

44

Subtotal ***

44

0.8 (2)

50

1.3 (0.9)

50

50.64%

-0.36[-0.77,0.04]

50.64%

-0.36[-0.77,0.04]

Heterogeneity: Not applicable
Test for overall effect: Z=1.75(P=0.08)
2.7.2 Third-wave cognitive behavioural therapy versus enhanced care
Fjorback 2013

46

49.36%

-0.15[-0.56,0.26]

Subtotal ***

46

28.8 (23.5)

44

44

32.3 (22.8)

49.36%

-0.15[-0.56,0.26]

90

94

100%

-0.26[-0.55,0.03]

Heterogeneity: Not applicable
Test for overall effect: Z=0.71(P=0.48)
Total ***

Heterogeneity: Tau2=0; Chi2=0.52, df=1(P=0.47); I2=0%
Test for overall effect: Z=1.74(P=0.08)
Test for subgroup differences: Chi2=0.52, df=1 (P=0.47), I2=0%
Favours CBT

-1

-0.5

0

0.5

1

Favours enhanced care
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Analysis 2.8. Comparison 2 Psychological therapies versus enhanced care,
Outcome 8 Dysfunctional cognitions, emotions, and behaviours at end of treatment.
Study or subgroup

Psychological intervt.
N

Enhanced care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Std. Mean Difference

Random, 95% CI

Random, 95% CI

2.8.1 Cognitive behavioural therapy versus enhanced care
Schröder 2012

50

0.9 (1.4)

55

1.3 (0.9)

21.68%

-0.4[-0.79,-0.01]

Speckens 1995

39

3.3 (2.3)

38

3.6 (2.6)

16.77%

-0.12[-0.57,0.33]

Subtotal ***

89

38.46%

-0.28[-0.57,0.01]

93

Heterogeneity: Tau2=0; Chi2=0.86, df=1(P=0.35); I2=0%
Test for overall effect: Z=1.88(P=0.06)
2.8.2 Third-wave cognitive behavioural therapy versus enhanced care
Fjorback 2013

55

Subtotal ***

55

26.7 (22)

51

25.4 (21.9)

51

22.27%

0.06[-0.32,0.44]

22.27%

0.06[-0.32,0.44]

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%
Test for overall effect: Z=0.3(P=0.76)
2.8.3 Psychodynamic therapy versus enhanced care
Sattel 2012

107

39.28%

0[-0.27,0.27]

Subtotal ***

107

3.5 (2.3)

104

104

3.5 (2.2)

39.28%

0[-0.27,0.27]

251

248

100%

-0.09[-0.29,0.1]

Heterogeneity: Not applicable
Test for overall effect: Not applicable
Total ***

Heterogeneity: Tau2=0.01; Chi2=3.5, df=3(P=0.32); I2=14.3%
Test for overall effect: Z=0.96(P=0.34)
Test for subgroup differences: Chi2=2.64, df=1 (P=0.27), I2=24.38%
Favours psych therapy

-1

-0.5

0

0.5

1

Favours enhanced care

Analysis 2.9. Comparison 2 Psychological therapies versus enhanced care, Outcome
9 Dysfunctional cognitions, emotions, and behaviours within 1 year after treatment.
Study or subgroup

Psychological intervt.
N

Enhanced care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

2.9.1 Cognitive behavioural therapy versus enhanced care
Schröder 2012

46

0.5 (1.5)

51

1.3 (0.8)

22.64%

Speckens 1995

37

2.9 (2.4)

39

3.5 (2.5)

19.93%

-0.24[-0.69,0.21]

Subtotal ***

83

42.57%

-0.45[-0.83,-0.07]

90

-0.63[-1.04,-0.23]

Heterogeneity: Tau2=0.03; Chi2=1.59, df=1(P=0.21); I2=37.07%
Test for overall effect: Z=2.3(P=0.02)
2.9.2 Third-wave cognitive behavioural therapy versus enhanced care
Fjorback 2013

50

Subtotal ***

50

23.1 (21.8)

43

23.7 (17.9)

43

22.72%

-0.03[-0.44,0.38]

22.72%

-0.03[-0.44,0.38]

Heterogeneity: Not applicable
Test for overall effect: Z=0.14(P=0.89)
2.9.3 Psychodynamic therapy versus enhanced care
Favours psych therapy

-1

-0.5

0

0.5

1

Favours enhanced care
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Psychological intervt.
N

Enhanced care

Mean(SD)

Sattel 2012

107

Subtotal ***

107

240

N

3.1 (2.3)

Std. Mean Difference

Mean(SD)

104

Weight

Std. Mean Difference

Random, 95% CI

Random, 95% CI

3.4 (2.3)

34.71%

-0.13[-0.4,0.14]

104

34.71%

-0.13[-0.4,0.14]

237

100%

-0.24[-0.49,0]

Heterogeneity: Not applicable
Test for overall effect: Z=0.94(P=0.35)
Total ***

Heterogeneity: Tau2=0.03; Chi2=5.21, df=3(P=0.16); I2=42.39%
Test for overall effect: Z=1.93(P=0.05)
Test for subgroup differences: Chi2=2.56, df=1 (P=0.28), I2=21.79%
Favours psych therapy

-1

-0.5

0

0.5

1

Favours enhanced care

Analysis 2.10. Comparison 2 Psychological therapies versus enhanced care, Outcome
10 Dysfunctional cognitions, emotions, and behaviours > 1 year after treatment.
Study or subgroup

Psychological intervt.
N

Enhanced care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

2.10.1 Cognitive behavioural therapy versus enhanced care
Schröder 2012

44

Subtotal ***

44

0.2 (1.5)

50

1.3 (0.7)

50

49.72%

-0.94[-1.36,-0.51]

49.72%

-0.94[-1.36,-0.51]

Heterogeneity: Not applicable
Test for overall effect: Z=4.29(P<0.0001)
2.10.2 Third-wave cognitive behavioural therapy versus enhanced care
Fjorback 2013

46

Subtotal ***

46

20.6 (17.3)

50.28%

-0.23[-0.64,0.19]

44

44

25.3 (23.2)

50.28%

-0.23[-0.64,0.19]

94

100%

-0.58[-1.27,0.11]

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%
Test for overall effect: Z=1.08(P=0.28)
Total ***

90

Heterogeneity: Tau2=0.2; Chi2=5.43, df=1(P=0.02); I2=81.6%
Test for overall effect: Z=1.64(P=0.1)
Test for subgroup differences: Chi2=5.43, df=1 (P=0.02), I2=81.6%
Favours CBT

-2

-1

0

1

2

Favours enhanced care

Analysis 2.11. Comparison 2 Psychological therapies versus enhanced care,
Outcome 11 Functional disability and quality of life at end of treatment.
Study or subgroup

CBT
N

Enhanced care

Mean(SD)

N

Mean(SD)

Std. Mean Difference

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

2.11.1 Cognitive behavioural therapy versus enhanced care
Schröder 2012

50

49.4 (19.9)

55

45.6 (20.3)

21.06%

Speckens 1995

39

-3.6 (2.3)

38

-4.2 (2.4)

15.41%

0.25[-0.2,0.7]

Subtotal ***

89

36.47%

0.21[-0.08,0.51]

93

0.19[-0.2,0.57]

Heterogeneity: Tau2=0; Chi2=0.05, df=1(P=0.82); I2=0%
Test for overall effect: Z=1.44(P=0.15)
Favours enhanced care

-0.5 -0.25

0

0.25 0.5

Favours psych therapy
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CBT
N

Enhanced care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

2.11.2 Third-wave cognitive behavioural therapy versus enhanced care
Fjorback 2013

53

Subtotal ***

53

38.7 (12.2)

51

37.8 (13.1)

51

20.98%

0.07[-0.31,0.46]

20.98%

0.07[-0.31,0.46]

Heterogeneity: Not applicable
Test for overall effect: Z=0.36(P=0.72)
2.11.3 Psychodynamic therapy at end of treatment
Sattel 2012

107

42.55%

0.08[-0.19,0.35]

Subtotal ***

107

36.6 (11.5)

104

104

35.6 (12.5)

42.55%

0.08[-0.19,0.35]

249

248

100%

0.13[-0.05,0.3]

Heterogeneity: Not applicable
Test for overall effect: Z=0.6(P=0.55)
Total ***

Heterogeneity: Tau2=0; Chi2=0.57, df=3(P=0.9); I2=0%
Test for overall effect: Z=1.43(P=0.15)
Test for subgroup differences: Chi2=0.52, df=1 (P=0.77), I2=0%
-0.5 -0.25

Favours enhanced care

0

0.25 0.5

Favours psych therapy

Analysis 2.12. Comparison 2 Psychological therapies versus enhanced care,
Outcome 12 Functional disability and quality of life within 1 year after treatment.
Study or subgroup

CBT
N

Enhanced care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

2.12.1 Cognitive behavioural therapy versus enhanced care
Schröder 2012

46

54.2 (23.3)

51

45.4 (21.1)

20.08%

0.39[-0.01,0.8]

Speckens 1995

37

-3.9 (2.5)

39

-4.4 (2.7)

16.01%

0.19[-0.26,0.64]

Subtotal ***

83

36.09%

0.3[0,0.6]

90

Heterogeneity: Tau2=0; Chi2=0.44, df=1(P=0.51); I2=0%
Test for overall effect: Z=1.98(P=0.05)
2.12.2 Third-wave cognitive behavioural therapy versus enhanced care
Fjorback 2013

49

Subtotal ***

49

39.6 (12.7)

43

38.2 (15.5)

43

19.38%

0.1[-0.31,0.51]

19.38%

0.1[-0.31,0.51]

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%
Test for overall effect: Z=0.47(P=0.64)
2.12.3 Psychodynamic therapy versus enhanced care
Sattel 2012

107

44.53%

0.16[-0.11,0.43]

Subtotal ***

107

37.2 (11.8)

104

104

35.4 (11.7)

44.53%

0.16[-0.11,0.43]

239

237

100%

0.2[0.02,0.38]

Heterogeneity: Not applicable
Test for overall effect: Z=1.14(P=0.26)
Total ***

Heterogeneity: Tau2=0; Chi2=1.22, df=3(P=0.75); I2=0%
Test for overall effect: Z=2.16(P=0.03)
Test for subgroup differences: Chi2=0.79, df=1 (P=0.67), I2=0%
Favours enhanced care

-1

-0.5

0

0.5

1

Favours psych therapy
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Analysis 2.13. Comparison 2 Psychological therapies versus enhanced care,
Outcome 13 Functional disability and quality of life > 1 year of treatment.
Study or subgroup

CBT
N

Enhanced care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

2.13.1 Cognitive behavioural therapy versus enhanced care
Schröder 2012

44

Subtotal ***

44

54.4 (22.4)

50

45.2 (21.4)

50

50.25%

0.42[0.01,0.83]

50.25%

0.42[0.01,0.83]

Heterogeneity: Not applicable
Test for overall effect: Z=2(P=0.05)
2.13.2 Third-wave cognitive behavioural therapy versus enhanced care
Fjorback 2013

45

49.75%

0.03[-0.39,0.44]

Subtotal ***

45

39.8 (13.4)

45

45

39.5 (11.2)

49.75%

0.03[-0.39,0.44]

89

95

100%

0.22[-0.16,0.6]

Heterogeneity: Not applicable
Test for overall effect: Z=0.13(P=0.89)
Total ***

Heterogeneity: Tau2=0.03; Chi2=1.72, df=1(P=0.19); I2=41.77%
Test for overall effect: Z=1.15(P=0.25)
Test for subgroup differences: Chi2=1.72, df=1 (P=0.19), I2=41.77%
-0.5 -0.25

Favours enhanced care

0

0.25 0.5

Favours CBT

Analysis 2.14. Comparison 2 Psychological therapies versus
enhanced care, Outcome 14 Healthcare use at end of treatment.
Study or subgroup

Psychological intervt.
N

Enhanced care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

2.14.1 Cognitive behavioural therapy versus enhanced care
Sumathipala 2008

63

Subtotal ***

63

1.1 (1.7)

60

1.6 (3)

60

43.11%

-0.21[-0.56,0.15]

43.11%

-0.21[-0.56,0.15]

Heterogeneity: Not applicable
Test for overall effect: Z=1.13(P=0.26)
2.14.2 Psychodynamic therapy versus enhanced care
Sattel 2012

107

Subtotal ***

107

3.9 (5.1)

56.89%

0.11[-0.16,0.38]

104

104

3.4 (3.8)

56.89%

0.11[-0.16,0.38]

164

100%

-0.03[-0.33,0.28]

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%
Test for overall effect: Z=0.8(P=0.42)
Total ***

170

Heterogeneity: Tau2=0.02; Chi2=1.93, df=1(P=0.17); I2=48.11%
Test for overall effect: Z=0.16(P=0.87)
Test for subgroup differences: Chi2=1.93, df=1 (P=0.17), I2=48.11%
Favours psych therapy

-0.5

-0.25

0

0.25

0.5

Favours enhanced care
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Analysis 2.15. Comparison 2 Psychological therapies versus enhanced
care, Outcome 15 Healthcare use within 1 year after treatment.
Study or subgroup

Psychological intervt.
N

Enhanced care

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Std. Mean Difference

Random, 95% CI

Random, 95% CI

2.15.1 Cognitive behavioural therapy versus enhanced care
Sumathipala 2008

57

Subtotal ***

57

1.8 (2.6)

51

2 (2.5)

51

34.43%

-0.08[-0.46,0.3]

34.43%

-0.08[-0.46,0.3]

Heterogeneity: Not applicable
Test for overall effect: Z=0.4(P=0.69)
2.15.2 Psychodynamic therapy versus enhanced care
Sattel 2012

107

65.57%

-0.32[-0.59,-0.05]

Subtotal ***

107

2.5 (2.6)

104

104

3.5 (3.6)

65.57%

-0.32[-0.59,-0.05]

164

155

100%

-0.24[-0.46,-0.01]

Heterogeneity: Not applicable
Test for overall effect: Z=2.29(P=0.02)
Total ***

Heterogeneity: Tau2=0; Chi2=1.02, df=1(P=0.31); I2=2.32%
Test for overall effect: Z=2.06(P=0.04)
Test for subgroup differences: Chi2=1.02, df=1 (P=0.31), I2=2.32%
Favours psych therapy

-0.5

-0.25

0

0.25

0.5

Favours enhanced care

Comparison 3. Cognitive behavioural therapy versus behavioural therapy
Outcome or subgroup title

No. of
studies

1 Severity of somatic symptoms at end of
treatment

No. of
participants

Statistical method

Effect size

1

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals
only

2 Acceptability

1

Risk Ratio (M-H, Random, 95% CI)

Subtotals
only

3 Severity of anxiety or depressive symptoms
(or both) at end of treatment

1

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals
only

4 Functional disability and quality of life at
end of treatment

1

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals
only

Analysis 3.1. Comparison 3 Cognitive behavioural therapy versus behavioural
therapy, Outcome 1 Severity of somatic symptoms at end of treatment.
Study or subgroup

Experimental
N

Schröder 2013

47

Mean(SD)
24.6 (20.5)

Control
N
37

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Random, 95% CI

22.5 (19.4)
Favours CBT

0%
-1

-0.5

0

0.5

Std. Mean Difference

1

0.1[-0.33,0.53]

Favours BT
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Analysis 3.2. Comparison 3 Cognitive behavioural therapy versus behavioural therapy, Outcome 2 Acceptability.
Study or subgroup

Experimental

Control

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Schröder 2013

42/49

Weight

Risk Ratio
M-H, Random, 95% CI

36/41

0%
1

Favours BT

0.98[0.83,1.15]

Favours CBT

Analysis 3.3. Comparison 3 Cognitive behavioural therapy versus behavioural therapy,
Outcome 3 Severity of anxiety or depressive symptoms (or both) at end of treatment.
Study or subgroup

Experimental
N

Schröder 2013

47

Mean(SD)
8.2 (4.7)

Control
N

Std. Mean Difference

Mean(SD)

37

Weight

Random, 95% CI

Random, 95% CI

8.2 (3.5)
Favours CBT

Std. Mean Difference

0%
-1

-0.5

0

0.5

1

0.01[-0.42,0.44]

Favours BT

Analysis 3.4. Comparison 3 Cognitive behavioural therapy versus behavioural
therapy, Outcome 4 Functional disability and quality of life at end of treatment.
Study or subgroup

Experimental
N

Schröder 2013

47

Mean(SD)
43.1 (10.7)

Control
N
37

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Random, 95% CI

40.2 (9.9)
Favours BT

Std. Mean Difference

0%
-1

-0.5

0

0.5

1

0.28[-0.15,0.71]

Favours CBT

ADDITIONAL TABLES
Table 1. Diagnostic categories of somatoform disorders and medically unexplained physical symptoms and their
eligibility for the current review
Eligible for this review?
DSM-IV

ICD-10

YES

NO

Somatisation disorder

Somatisation disorder

x

-

Undifferentiated somatoform disorder (duration > 6 months)

Undifferentiated somatoform disorder (duration > 6 months)

x

-

-

Somatoform autonomic dysfunction

x

-

Pain disorder

Persistent somatoform pain disorder

x

-

Somatoform disorders, unspecified

Somatoform disorders unspecified

x

-

Hypochondriasis

Hypochondriacal disorder

-

x

-

Other somatoform disorders

-

x
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Table 1. Diagnostic categories of somatoform disorders and medically unexplained physical symptoms and their
eligibility for the current review (Continued)
Body dysmorphic disorder

Body dysmorphic disorder

-

x

Conversion disorder

Dissociative and conversion disorders

-

x

YES

NO

Alternative somatoform diagnoses (such as abridged somatisation disorder or multisomatoform disorder)

x

-

Chronic MUPS (duration ≥ 6 months)

x

-

Functional somatic syndromes

-

x

Specific functional somatic symptoms

-

x

DSM: Diagnostic and Statistical Manual of Mental Disorders; ICD: International Classification of Diseases.
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Number of
sessions

Therapist

Comparison

duration of
follow-up

Martin
2007

CBT

group

once

1

psychologist and psychotherapeutic specialist

usual care

6 months

Burton
2012

psychological therapy in
symptoms clinic

alone

3 months

4

experienced specialised GP

usual care

3 months

Schweickhardt 2007

psychotherapy

alone

2 weeks

5

psychotherapists

psychoeducational
reading material

6 months

Sumathipala 2000

CBT

alone

3 months

6

research psychiatrist

usual care

3 months

Sumathipala 2008

CBT

alone

3 months

6

trained primary care physician

enhanced treatment
as usual

12 months

Schröder
2013

CBT

group

2 months

8

psychotherapist

progressive muscle
relaxation

6 months

Van
Ravensteijn 2013

mindfullness-based cognitive
therapy

group

2 months

8

experienced mindfullness
trainer

enhanced treatment
as usual

9 months

Fjorback
2013

mindfullness

group

3 months

8

experienced psychiatrist

enhanced treatment
as usual

15 months

Kashner
1995

group psychological intervention + CL

group

4 months

8

master level clinician

consultation letter

12 months

Lidbeck
1997

CBT

group

3 months

9

trained physician

waiting list

9 months

Schroder
2012

stress intervention (psychotherapy + letter etc)

group + alone

4 months

9

consultant or senior resident
psychiatry

enhanced treatment
as usual

16 months

Katsamanis 2011

psychophysiologic treatment
+ psychiatric consultation

alone

10 weeks

10

psychologist or biofeedback
clinician

psychiatric consultation

10 weeks

Moreno
2013

CBT + Letter (1) CBT + Letter
(2)

alone (1)
group (2)

10 weeks

10

psychologist

usual care + letter

12 months

Cochrane

Duration
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Group/alone

Trusted evidence.
Informed decisions.
Better health.

Intervention

Library
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(Continued)

alone

3 months

10

trained and experienced psychologist

psychiatric consultation

15 months

Escobar
2007

CBT + psychiatric consultation letter

alone

3 months

10

therapist

usual care + PCL

9 moths

Sattel
2012

psychodynamic interpersonal
psychotherapy

alone

3 months

12

psychologist or physician
with psychotherapy experience

enhanced treatment
as usual

9 months

Schaefert
2013

GP training in MUPS + interpersonal psychodynamically
based therapy

group

9 months

12

psychosomatic specialist

GP training in MUPS

12 months

Zonneveld
2012

CBT

group

13 weeks

13

psychologist

waiting list

13 weeks

Schilte
2001

disclosure intervention

alone

unclear

unclear

trained disclosure doctor

usual care

24 months

Speckens
1995

CBT

alone

6 months

6-16

trained physician and behavioural therapist

enhanced treatment
as usual

12 months

Kolk 2004

psychological intervention
(varied)

alone

max 6 months

max 12

trained therapist

usual care

12 months

Cochrane

CBT + psychiatric consultation

Trusted evidence.
Informed decisions.
Better health.

Allen 2006

Library

CBT: cognitive behavioural therapy; GP: general practitioner; max: maximum; MUPS: medically unexplained physical symptoms.
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Cochrane

Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

APPENDICES
Appendix 1. Additional search strategies: CENTRAL (all years)
The Cochrane Central Register of Controlled Trials (CENTRAL) was searched using the following terms:
#1 MeSH descriptor: [Somatoform Disorders] explode all trees
#2 MeSH descriptor: [Psychophysiologic Disorders] this term only
#3 somatization or somatisation or somatoform or somatizer* or multisomatoform or (somatic NEAR/2 (symptom* or syndrom*))
#4 MUPS or "medical* unexplained" or "unexplained medical*" or (unexplained near/2 symptom*)
#5 neurastheni*
#6 (#1 or #2 or #3 or #4 or #5)
#7 SR-DEPRESSN or HS-DEPRESSN
#8 (#6 not #7)
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DIFFERENCES BETWEEN PROTOCOL AND REVIEW
Although the protocol was thought through very thoroughly, we had to make a few post-hoc changes to procedures, to improve the quality
of the review. First, in the included studies, we found almost no information regarding previous treatments for MUPS. Therefore, we did
not include this item in the 'Characteristics of included studies' table.
A second post-hoc change also regarded the 'Characteristics of included studies' table. In all included studies, therapists had received a
certain form of training before they performed the interventions. There was a great variation in background, experience, and intensity
and duration of extra training. We found it problematic to define criteria to assess the amount of training. Therefore, we decided not to
categorise the therapists based on experience, but to describe their extent of experience narratively in the 'Characteristics of included
studies' table.
Although not specifically addressed in the protocol, for brevity's sake we chose to combine anxiety and depression outcomes for three of
five comparisons: Fjorback 2013; Schröder 2012; Sumathipala 2008. We decided to do this, as different outcome instruments were used
in these studies, some measuring anxiety and depression separately, some measuring them altogether reporting one combination score.
By combining all scores, we made it possible to make study results more comparable. For the same reason, we chose to combine SF-36
subscales (mainly physical component scores and mental component scores), in order to be able to pool these with other scales measuring
function or quality of life.
We had not anticipated that several studies used consultation letters, in both study arms, in addition to an intervention or usual care. We
categorised these studies under the main comparison (CBT versus usual care or waiting list conditions), as the consultation letter only
concerned a co-intervention. We did not conduct a sensitivity analysis.
Finally, several studies compared a psychological therapy with some form of enhanced or structured care, a comparison we had not
foreseen at the protocol stage. Therefore, we added this comparison.

INDEX TERMS
Medical Subject Headings (MeSH)
Cognitive Behavioral Therapy; Psychotherapy [*methods]; Randomized Controlled Trials as Topic; Somatoform Disorders [*therapy];
Waiting Lists

MeSH check words
Adult; Humans
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